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Pulmonary exacerbations cause significant morbidity in people with cystic fibrosis, 
but their treatment with extended courses of intravenous antibiotics may result in 
important systemic side-effects, adverse reactions and complications. Treatment 
through the inhaled route, where the lungs are targeted directly with less systemic 
exposure may be more appropriate, however little is known about the clinical and 
microbiological utility of using inhaled antibiotics in the acute setting. A recent 
expansion in available inhaled antibiotics licensed for the chronic suppression of P. 
aeruginosa means some may now also be repurposed in the acute setting. This thesis 
examined the clinical and microbiological outcomes of using inhaled aztreonam 
lysine (AZLI) in the treatment of acute pulmonary exacerbations of cystic fibrosis.  
 
Methods 
Adults with CF were recruited to an open-label pilot randomised crossover study at 
a regional adult centre in the UK (AZTEC-CF Study, ClinicalTrials.gov: NCT02894684). 
Inclusion criteria included age > 16 years, P. aeruginosa infection and no prior use of 
AZLI. Exclusion criteria included Burkholderia cepacia complex infection and solid-
organ transplant. During two consecutive exacerbations requiring hospitalisation for 
intravenous antibiotics, subjects received 14 days AZLI plus intravenous 
colistimethate (AZLI+IV) or standard dual intravenous antibiotics (IV+IV). Primary 
outcome was change in % predicted FEV1 (ppFEV1) at 14 days. Key secondary 
outcomes included health-related quality of life outcomes, sputum bacterial load 
and 16S rRNA sequenced microbiome dynamics associated with each treatment. 
 
Results 
Sixteen people with CF were consented and randomised, and 28/32 (87.5%) 
exacerbations were completed. At 14 days, improvement in ppFEV1 was greater in 
the AZLI +IV compared to the IV+IV arm (mean 13.5% versus 8.8%; paired differences 




CFQ-R Respiratory Domain was achieved more frequently in exacerbations treated 
with AZLI+IV (83.3% vs. 43.8%, p=0.04). No significant differences were found 
between treatments for changes in sputum bacterial load, systemic inflammation, 
antimicrobial resistance or adverse events. IV+IV and AZLI+IV exerted different 
effects on the lung microbiome, where IV+IV reduced the abundance of the 
anaerobes Prevotella melaninogenica and Veillonella dispar.  Comparatively, AZLI+IV 
was associated with little change in either structure or composition of the 
microbiome. Neither treatment consistently reduced the abundance of P. 
aeruginosa but where reductions were seen they were associated with improved 
quality of life. 
 
Conclusion: 
AZLI is effective and well tolerated in the treatment of acute pulmonary 
exacerbations of CF. Superior improvements in lung function and quality of life 
outcomes alongside a potentially advantageous microbiological profile suggest AZLI 
may represent a new treatment approach for acute pulmonary exacerbations and 
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Chapter 1:  Introduction and Review of the Literature 
 Genetics of cystic fibrosis 
Cystic fibrosis (CF) is the most common life limiting genetic condition in the United 
Kingdom (UK) with over 10000 people currently living with the disease. [1] CF is 
caused by mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene located on the long arm of chromosome 7. [2] This gene codes for the 
CFTR protein, a symmetrical 1480 amino acid structure which functions 
predominantly as an anion channel and belongs to the ATP-Binding Cassette (ABC) 
Transporters family of membrane-spanning proteins. [3]  
 
Over 2000 CFTR mutations have been identified with missense and frameshift 
mutations the most prevalent (39.3% and 15.7% respectively). [4] Mutations can be 
classed according to the specific mechanism by which they interrupt the synthesis or 
function of the CFTR protein, see Table 1.2.1. In Europe, approximately 87% of 
people with CF carry at least one Class II mutation, 17% Class I, 3.9% Class III, 3.3% 
class IV and 3.0% class V. [5] Geographical variation exists for each mutation class, 
for example Israel has a higher prevalence of Class I mutations (45%) and people with 
CF in the UK and Ireland have higher prevalence of Class III mutations (6.2% and 
13.9% respectively). [5] The most common mutation is Phe508Del (c. 
1521_1523delCTT) with prevalence in the UK CF population of 91% (50.2% 
homozygous), and only 9 other mutations have a prevalence of >1%, see Table 1.2.2. 
[1] The F508D mutation is a Class II mutation, causing CFTR protein misfolding 
resulting in failure of the protein to be localised to the cell membrane. [6] 
 
CF displays autosomal recessive inheritance thereby requiring both parents to carry 
at least one pathogenic CF allele and the child to receive both in order for the disease 
to manifest itself. The fact that until relatively recently CF was a lethal condition in 
early childhood has led to the postulate that carrier status must convey an 
evolutionary selective advantage to allow CFTR mutations to maintain their 




mutated CFTR allele may be less susceptible to secretory diarrhoeas such as seen in 
Vibrio cholerae (cholera) and Salmonella typhi infections. [7,8] In the case of cholera, 
a reduction in anion secretion in response to the cholera toxin with subsequent 
reduction in colonic fluid loss has been seen in murine carriers of a single pathogenic 
mutation, however this has not been replicated in humans. [9] Salmonella typhi is 
purported to enter cells via open CFTR channels and CFTR mutations may therefore 
reduce susceptibility to typhoid fever. [7] Interestingly, the incidence of 
Mycobacterium tuberculosis (TB) has also been reported to be lower in CF carriers 
and the European TB pandemic of the 17th century may have provided enough 
historical selective pressure to account for the incidences of CFTR mutations seen 
today. [10,11] 
 Epidemiology 
The carrier rate for a CFTR gene is approximately 1 in 25, and while live-birth rates 
vary from country to country the UK incidence is 1 in 2400 live births. [12] Since the 
advent of a UK-wide new-born screening programme, over 95% of CF diagnoses are 
now made in the first year of life. [1] 
 
CF was first distinguished from coeliac disease in 1938, when mucous plugging of the 
pancreas was noted at autopsies of malnourished young children. [13] Life-
expectancy for a new-born with CF at that time was often no more than six months 
but since then increased recognition of the disease, understanding of its genetic 
basis and advances in disease management have heralded dramatic increases in 






Table 1.2.1 Traditional classification of CFTR mutations. Adapted from De Beck 
and Amaral [14]   
Class I II III IV V VI 

































Table 1.2.2: CFTR mutations in the UK CF population with prevalence >1%. 
Adapted from UK CF Registry Report 2016 [15] 
 
  
Mutation Name N % 
F508D 9035 89.7 
G551D 581 5.8 
R117H 587 5.8 
G542X 356 3.5 
621+G->T 258 2.6 
N1303K 159 1.6 
1717-1G->A 157 1.6 





1.3.1 Ion transport defects associated with cystic fibrosis 
 
CFTR functions as an anion channel and is expressed in many epithelial cells, in 
multiple organ systems throughout the body and regulates the conductance of both 
chloride (Cl-) and bicarbonate (HCO3-) anions out of the cell. ABC proteins can also 
often function as local regulators and CFTR has been shown to regulate neighbouring 
epithelial Na+ channels (ENaC). [16,17] CFTR dysfunction therefore results not only 
in deficient Cl- and bicarbonate (HCO3-) secretion but also drives excess absorption 
of sodium, thus dramatically perturbing the normal osmotic conditions at the 
epithelial surfaces. [17,18] The abnormally dehydrated epithelial environment is the 
underlying aetiology for the majority of clinical sequelae in CF. 
1.3.2 Clinical manifestations of CF 
 
The expression of CFTR across a wide range of epithelial cells results in CF being a 
truly multi-organ disease. Dehydrated epithelial surfaces trigger a milieu of stasis, 
infection and inflammation which manifest most obviously in the lungs with chronic 
suppurative lung disease but can affect almost any system in the body.  
One of the most common extra-pulmonary manifestations of disease is in the 
reproductive system where ~98% of males are infertile and subfertility is also well 
recognised in women. [19] In males, infertility is usually secondary to aberrant 
development of the vas deferens resulting in congenital bilateral absence of the vas 
deferens (CBAVD), although semen abnormalities including azospermia, reduced 
semen volume and abnormal semen pH have also been reported. [19,20] In women 
with CF, mucus plugs may act as mechanical barriers to conception but the 
reproductive tract is otherwise structurally normal. [21] 
 
The pancreas is another commonly affected organ and the term “cystic fibrosis” was 
originally a description of pancreatic lesions seen during autopsy. [22] Bicarbonate 




digestive acids but in the CF pancreas a lack of epithelial bicarbonate contributes to 
pancreatic injury as viscid unbuffered acidic secretions do not flow to the bowel and 
instead cause localised pancreatic damage. [23] Progressive local injury leads to 
pancreatic fibrosis with subsequent exocrine and endocrine insufficiency. Exocrine 
abnormalities are characterised by malabsorption of fat and also fat-soluble vitamins 
resulting in malnutrition. Endocrine dysfunction develops when damaged, 
dysregulated Beta-cells struggle to release insulin adequately and cystic fibrosis 
related diabetes (CFRD) ensues. [24] CFRD is not only associated with aberrant 
glycaemia, but also carries with it significant morbidity and a three-fold increase in 
mortality. [25] 
 
Elsewhere, stasis of hyperviscous bile can accumulate in the biliary tree causing focal 
inflammation and fibrosis. In this setting persistent hepatocyte injury can lead to CF 
related liver disease, the most serious consequence of which is decompensated 
cirrhosis, the third most common cause of death in children and adolescents with CF. 
[26,27]Other common co-morbidities include polyposis and chronic sinusitis in the 
upper respiratory tract, low bone mineral density, gastro-oesophageal reflux and 
renal disease. [28–31] 
1.3.3 Mucociliary consequences of impaired CFTR function 
Despite the prevalence of co-morbidities in multiple other systems, the single biggest 
impact on morbidity and mortality in people with CF is lung disease, which develops 
and progresses as a direct pathophysiological consequence of a  dehydrated airway 
surface liquid (ASL), see  Figure 1.3.1. [32] The ion transport defects outlined in 
section 1.3.1 disrupt the osmotic composition of the periciliary layer (PCL), which 
becomes progressively compressed and increasingly viscous such that the ciliary 
clearance mechanisms slow down and eventually stop. [33] Mucus stasis ensues 
creating a niche for infection and inflammation. [34] 
 
Further compounding the local environmental disturbance is reduced HCO3- which 
appears to be important for the release and efficient expansion of mucins within the 




more recently been implicated as playing a similar role in the airways where 
abnormally acidic pH was found in cultured CF human bronchoepithelial cells as well 
as CF pigs. [37,38] The reduced pH noted in CF pigs was associated with reduced 
bacterial killing by the innate antimicrobial peptides usually resident in the ASL. Thus, 







Figure 1.3.1: Airway surface liquid in normal and CF airways 
NORMAL AIRWAY SURFACE 
LIQUID 







Contains large mucins which form a gel to trap inhaled particles which are 
subsequently removed by the mucociliary clearance mechanisms 
Periciliary layer (PCL): 
Lies underneath the mucous layer and surrounds the cilia and is in direct contact 




1.3.4 Impaired innate immune defence in CF 
The lungs have many protective mechanisms against the constant exposure to 
inhaled environmental pathogens and irritants. One such mechanism is an array of 
antimicrobial peptides found in the ASL that are able to rapidly kill or inactivate 
inhaled bacteria.[39,40] These negatively charged cationic peptides disrupt bacterial 
membranes and are found in the ASL where they are active against a wide range of 
bacteria including the CF pathogens Staphylococcus aureus and Pseudomonas 
aeruginosa. [39,41] However, attachment and subsequent disruption of the bacterial 
membrane is dependent on an alkaline pH and the acidified CF ASL impairs their 
activity. [38,39,42] 
 
Alongside the innate antimicrobial properties of the ASL, another powerful defence 
mechanism is the recruitment of white blood cells (e.g. neutrophils) into the airways. 
Neutrophils migrate into the lungs via the post-capillary venules in response to 
complex signalling from cytokines and chemoattractants. [43] Once in the airways, 
bacterial phagocytosis occurs accompanied by the release of proteases to degrade 
by-products of phagocytosis. Excess accumulation of proteases results in an 
imbalance of innate inhibitors e.g. alpha1-anti-trypsin, such that proteolytic activity 
is exerted on the CF airway itself, degrading structural proteins e.g. collagen and 
elastin. This results in prolonged and sustained inflammatory airway damage. [44,45] 
The most well-characterised of the proteases is neutrophil elastase (NE), 
concentrations of which are higher in the airway of people with CF compared to 
those with non-CF bronchiectasis and also healthy controls. [46] In CF, increased NE 
has been associated with poorer clinical outcomes including increased 
bronchiectasis and airway inflammation in childhood, and accelerated lung function 
decline in adulthood. [47,48] Bacterial burden is high in the CF airways, but even 
allowing for that, neutrophil recruitment is exaggerated and disproportionately 
prolonged. [49,50]  
 
The exaggerated accumulation of neutrophils in the CF airway has been suggested 




expression has been confirmed on the membranes of neutrophils and reduced 
expression is noted in CF. [52] CFTR defective neutrophils appear to have reduced 
bacterial killing properties but also delayed death, perhaps explaining the observed 
accumulation in the airways. [53] Also, recent evidence suggests that the CF 
neutrophils are more likely to form neutrophil extracellular traps (NETs), web-like 
traps formed by dying neutrophils. NETs have the ability to immobilise and kill 
bacteria but can conversely induce excess inflammation, particularly when 
pathogens such as P. aeruginosa are able to adapt to resist NET-mediated killing. 
[53–55] 
1.3.5 Pulmonary infection in CF 
 
The defective mucociliary clearance and impaired innate immunity discussed earlier 
result in a pulmonary microenvironment that is susceptible to chronic infection and 
subsequent progressive irreversible lung damage which remains the leading cause 
of morbidity and mortality in CF. [32] 
 
The original description of CF identified tubular bronchiectasis with purulent 
bronchitis and bronchopneumonias on autopsy and also reported S. aureus was the 
most common organism cultured. [22] S. aureus remains the most commonly 
isolated organism in younger patients with CF, but as age increases the microbiology 
of CF changes and by adulthood P. aeruginosa is the most prevalent pathogen. 
[56,57] Other well recognised CF pathogens include species of the Burkholderia 
cepacia complex (BCC), some of which are associated with accelerated pulmonary 
decline. [58] More recently other microbes such as Stenotrophomonas maltophilia, 
Achromobacter xylosoxidans and non-tuberculous Mycobacteria (NTM) have been 
termed “emerging pathogens” due of their increasing prevalence, although the 
pathogenicity of some remains controversial. [59–62] 
 
P. aeruginosa, a Gram-negative facultative anaerobe found ubiquitously in the 
environment, remains the major pathogen associated with CF with a prevalence of 




cause of hospital acquired pneumonia, often in immunocompromised hosts, 
accounting for 8% of all health-care associated infections in the US. [63] P. 
aeruginosa has the potential to be resistant to multiple antibiotics and the World 
Health Organisation recently designated it as one of only three “Critical” pathogens 
requiring urgent research and high-priority development of new antibiotic 
approaches. [64]  
 
In CF, P. aeruginosa infection is associated with accelerated pulmonary function 
decline and is the leading cause of morbidity and mortality. [1,32,65] P. aeruginosa 
is most commonly acquired from the environment but transmission of “epidemic” 
strains of P. aeruginosa between people with CF is also well documented. [66] 
Transmissible strains were first identified based on molecular analysis in the 1990s 
and some strains such as the Liverpool Epidemic Strain (LES) have been associated 
with even poorer prognosis. [67] 
 
Despite the changes to the CF lung environment discussed earlier, the lung is still a 
hostile and challenging environment for microbes due to factors such as osmotic 
gradients, oxidative stress, the presence of other bacteria and an exaggerated host 
response. [68] A large genome allows P. aeruginosa to undergo a number of 
adaptations and this versatility is a trait that allows it to overcome the challenges of 
colonising CF lung.  
 
Although the precise sequence of events that take place between inhalation of P. 
aeruginosa and infection being established is not known, an initial step is likely to be 
adhering to a surface in the lungs. Healthy lungs have a functioning mucociliary 
escalator to help clear any inhaled pathogens/irritants but the static, viscid 
secretions in CF airways are full of mucins to which P. aeruginosa can bind and 
become enveloped within. [69] Despite adequate ventilation of the airways 
themselves, hypoxic zones exist within the large aggregations of luminal mucous and 
eventually P. aeruginosa is enveloped within these oxygen-deplete aggregations and 




The overproduction of alginate is the hallmark of an adaption from a free-swimming 
planktonic phenotype to the “mucoid” phenotype. Alginate, a cationic 
exopolysaccharide, provides a structure for a biofilm matrix allowing microbial cells 
to be held together in an organised community, thereby providing physical 
protection from stressors such as antibiotics and host immune cell phagocytosis. [68] 
The mucoid phenotype and biofilm growth are associated with greater pathogenicity 
in CF, probably at least in part due to reduced ability of the innate immune system 
and antibiotics to penetrate and overcome the infection. For example, transition to 
mucoid phenotype has been associated with immediate pulmonary consequences 
including reduced lung function, increased symptoms and changes on chest 
radiography. [72] In the longer term, a mucoid phenotype is associated with 
increased bronchiectasis, accelerated pulmonary function decline and increased 
mortality. [73,74] Mucoid phenotype and biofilm formation are therefore 
considered evidence of a transition from acute to chronic P. aeruginosa infection in 
CF.  
 
Other phenotypic adaptions include increasing antibiotic resistance, [75,76] loss of 
motility, [77] the adoption of a hypermutator role, [78] DNA repair, [76] and iron 
acquisition. [79,80] Together these traits are termed pathoadaptations. [68] 
Pathoadaptations occur as a result of mutations in genes for key regulatory proteins 
and are often evidence of selective pressure from the lung environment. Some 
mutations acquired in key regulatory genes are consistently found in different 
patients suggesting parallel evolution during the process of adaptation, however this 
is not always the case and there may be different trajectories of evolution between 
individuals. [68,70,81,82] More recently dissection studies of explanted lungs have 
confirmed that even within the same patient, genetically and phenotypically distinct 
populations are found in different geographic regions of the lung perhaps as a result 
of the different regional environmental conditions and subsequent distinct 





 Pulmonary exacerbations 
1.4.1 Definition 
One of the hallmarks of CF pulmonary disease is episodic acute worsening of 
symptoms and lung function. These events are termed pulmonary exacerbations. 
Although the definition of an exacerbation not universally agreed, there are two 
broad approaches to defining these important events: 
1. A requirement for treatment with acute antibiotic therapy 
2. A cluster of symptoms or signs that indicate a recent deterioration. 
The first approach has often been used in clinical studies however there exists 
considerable inter-clinician, inter-centre and inter-country variation in the 
thresholds for initiating antibiotics. For example, some centres only utilise IV 
antibiotics in acute deteriorations whereas others have adopted a strategy of giving 
IV antibiotics at regular intervals, e.g. 3-4 monthly regardless of clinical status. [84–
86] 
 
Given the heterogeneity in the first approach, attempts have been made to 
standardize the definition into a scoring system or a set of minimal criteria. [87,88] 
Fuchs defined exacerbations as a clinical need for IV antibiotics in the presence of at 
least 4 out of 12 possible signs or symptoms. [87]A EuroCareCF working group 
simplified this approach and defined an exacerbation as the clinical need for acute 
treatment in the presence of two of the following symptoms/signs. 
• Change in sputum volume or colour 
• Increased cough 
• Increased malaise, fatigue or lethargy 
• Anorexia or weight loss 
• Decrease in pulmonary function by 10% or more / Radiographic changes 








Despite the clinical significance of acute pulmonary exacerbations, their 
pathogenesis remains incompletely understood. A number of different aetiologies 
and mechanisms have been suggested to be responsible including bacterial 
infection, viral triggers, fungal infection, inhaled pollutants and even proton pump 
inhibitors. [89–93] With regards to microbiology, acute pulmonary exacerbations do 
not tend to be associated with the acquisition of new bacterial species or even new 
clones of an already present species. [94] Sputum bacterial load does not appear to 
increase prior to acute pulmonary exacerbations, leading to speculation that acute 
pulmonary exacerbations may represent spread of already present infection to 
previously undiseased areas of the lung. [91,95,96] The triggers for spread to new 
areas may be multifactorial. For example, viruses such as Respiratory Synctial Virus 
(RSV) have been demonstrated to promote adherence of P. aeruginosa to epithelial 
cells and hence an initial viral insult to an uninfected area of lung could result in 
adherence of P. aeruginosa and subsequent infection in that area. [97] Equally, an 
imbalance in an established regional population of bacteria within the lung may 
result in a more active sub-population, which could in-turn drive a spread of 
planktonic bacteria to new areas of lung. The resulting host response would elicit the 
symptoms and signs of an acute pulmonary exacerbation and the newly migrated 
planktonic population would be more sensitive to antibiotics, hence explaining the 
response to antibiotics. [95] 
 
An alternative hypothesis to the spread of existing infection is the concept that 
changes occur within the already established infection and these changes drive an 
increased localised immune response. An example of this would be the phenotypic 
shift towards an increase in pyocyanin overproduced observed at exacerbation. [98] 
Any within-population phenotypic shifts as a result of selective pressures in the local 
environment would result in a similar sputum bacterial load but a resultant change 
in metabolites, virulence factors or alginate production could trigger increased 




development of the symptoms and signs of an exacerbation with resultant lung 
injury. Much of the research investigating exacerbations has to-date focussed on 
single bacteria or host-bacteria interactions. More recently, there has been 
increasing understanding of the polymicrobial nature of CF lung infections, much of 
which has been garnered by novel culture-independent techniques such as next 




Whilst there has been debate regarding the definition and pathogenesis of 
exacerbations, there is consensus when it comes to the clinical significance of these 
acute events. Acute pulmonary exacerbations are an important driver of morbidity 
in CF and have been associated with reduced quality of life outcomes, sleep 
disturbances and impaired neurobehavioural function. [99,100] Moreover, severe 
exacerbations requiring IV antibiotics are themselves a risk factor for further 
exacerbations as well an independent risk factor for mortality. [101,102] A number 
of studies have demonstrated lung function frequently does not return to baseline 
after exacerbations and progressive loss of lung function from sequential 
exacerbations can account for half of the lung function deterioration seen in people 
with CF. [103–105] The healthcare impact is also considerable with a US study 






 The Lung Microbiota in Cystic Fibrosis 
Traditional culture techniques rely on growing bacteria on media in laboratory 
conditions often optimised for growth of specific organisms to allow subsequent 
identification. In the last 20 years, novel techniques utilising NGS to identify bacteria 
have become available, enabling detection and description of bacterial communities 
without the need for conventional culture.  These technologies have allowed a 
greater understanding of bacterial communities throughout the human body and 
have revealed functional roles in both health and disease.  
 
A healthy human gut for example is home to a highly diverse community of 
microorganisms, which has symbiotic functions including metabolism of otherwise 
indigestible compounds and defence against opportunistic pathogens. [107,108] 
Furthermore, bacteria in the gut influence the stimulation and development of the 
innate mucosal immune system.  In addition to the roles in health, there has been 
significant interest in the relationship between microbiomes and diseases such as 
obesity, inflammatory bowel disease and diabetes mellitus. [109–111]  
 
In the lungs, studies utilising culture-independent techniques have identified the 
presence of bacterial communities much more complex than previously appreciated. 
The lungs were long considered to be an inherently sterile environment, in part due 
to the fact that conventional culture techniques often yielded negative results during 
health and it was only during disease that pathogens were detected.[112,113] 
However, the advent of culture-independent techniques has demonstrated that 
multiple organisms comprise a community in the lungs regardless of health status. 
[114–116] [250-252] This community is termed the lung “microbiota”, a term which 
is often used interchangeably with “microbiome” although the two terms are subtly 
different, see Table 1.5.1. In this section I discuss the techniques employed and 











Microbiome The collection of genomes from all the microrganisms in a 
particular environment 
Microbiota The microorganisms found in a particular environment 
16S rRNA gene A gene which codes for a ribosomal subunit. Present in all 
prokaryotes and has variable regions, which differ slightly 
between bacterial species  
 
Alpha diversity Within-sample diversity 
Commonly used alpha diversity metrics 
Richness A measure of the number of species in a community 
Evenness A measure of similarity of the relative abundance for each 
species in a community. I.e. Does one species dominate or 




Combination of richness and evenness.se 
 




Clusters of similar sequences assumed to represent a 





Inferred DNA sequence representing a true taxonomic unit 




1.5.1 16S rRNA gene sequencing 
 
The 16S rRNA gene codes for a ribosomal subunit present in nearly all bacteria. The 
gene itself is approximately 1.5kb long and consists of conserved regions, similar in 
nearly all microorganisms, and nine variable regions labelled V1-V9, which are 
practically specific to each microorganism, see Figure 1.5.1 . [117] The identification 
of the precise DNA sequence of a bacteria’s 16S rRNA gene therefore allows 
inference of its identity in a similar way that a unique fingerprint allows identification 
in humans. 
Figure 1.5.1: Schematic illustration of structure of the 16S rRNA gene  
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In order to deduce the 16S rRNA gene sequence, DNA is extracted from a sample, 
e.g. sputum, and the 16S rRNA gene is amplified using polymerase chain reaction 
(PCR).  Next generation sequencing of the amplified sequences allows elucidation of 
the precise gene sequences and estimation of their relative abundance. Online 
reference databases can then be used to match each sequence to an organism to 
allow identification of each member of the polymicrobioal community. However, it 
is important to note that sequencing of the 16S rRNA gene has limited resolution and 
often cannot distinguish between individual species with similar 16S rRNA gene 
sequences. Instead of distinct species, sequences are referenced against and 
assigned into operational taxonomic units or more recently amplicon sequence 
variants. 
1.5.2 Amplicon sequence variants vs. operational taxonomic units 
 
As described above, 16S rRNA gene sequencing often cannot distinguish between 
individual species because many very similar species share similar 16S rRNA gene 
sequences. Intrinsic errors in the amplification or sequencing process can result in 
amplified sequences differing from each other very slightly making species 
differentiation even more challenging. [118,119] To date most studies have 
overcome this by clustering very similar sequences together into operational 
taxonomic units (OTU). An arbitrary threshold of 97% is commonly used for 
clustering such that sequences differing from each other by less than 3% are 
considered to be the same OTU. OTUs can then be matched against known OTUs in 
reference database to provide taxonomic information, often providing resolution to 
the genus level. 
 
More recently, a new approach to taxonomically resolve sequences has been 
developed which attempts to limit the variation caused by intrinsic amplification or 
sequencing errors. This approach infers the biological sequences within a sample 
using a model which relies on input read abundances (true reads are likely to be more 
abundant) and distances (less abundant reads only a few base-differences away from 




technique are termed ‘amplicon sequence variants’ (ASV) and replace OTUs.  
[118,120] ASVs hold a number of advantages over OTUs; firstly, by eliminating 
amplification/sequencing error, more sequences can be accurately resolved to the 
species level which has clear benefits for microbiome research. Secondly, an ASV is 
a fixed, defined sequence and can therefore be consistently labelled allowing 
comparison between studies. Again, this holds obvious advantages to microbiome 
researchers. With these advantages in mind there have been calls for ASVs to replace 
OTUs as the basic unit in 16S rRNA gene sequencing studies. [120] Most CF 
microbiome research to date predates these calls and therefore OTUs form the basis 
of most studies described in this chapter. 
1.5.3 Ecology of the microbiome 
 
Given the large number of species identified even in healthy lungs, ecological theory 
and analyses are often employed to understand community dynamics. According to 
ecological principles the composition of the lung microbiome is determined by three 
factors:  
 
1. Immigration of organisms into the lung 
2. Elimination of microbes from the airways 
3. Regional growth factors [113] 
The lung microbiota in healthy individuals is dictated largely by immigration and 
elimination and hence generally consists predominantly of those Gram-negative 
anaerobes also resident in the oral flora such as Prevotella spp. and Veillonella spp. 
[113] In disease, the regional growth conditions are altered and niches for other 
species to thrive are created. In CF, viscous secretions, altered pH, nutrient 
availability and architectural disturbance may all help select for a community of 
altered composition to that of healthy individuals.  
 
Ecological diversity analyses are frequently used to describe and quantify changes 




diversity, whereas diversity between samples is known as beta-diversity. [121] A 
description of frequently used diversity metrics are included in Table 1.5.1. 
Longitudinal changes in diversity over time, and in response to the intensive 
antibiotic treatment that people with CF are exposed to, has been the subject of 
much interest in the last decade. 
 
1.5.4 CF respiratory microbiota in early life 
 
Understanding the development of the CF respiratory microbiota in early life has 
attracted interest in order to appreciate the driving factors behind the distinct 
microbiota seen later in life and also to identify potential opportunities for 
intervention. Neonates and infants cannot expectorate sputum independently and 
bronchoalveolar lavage (BAL) is only used sparingly; hence, upper respiratory tract 
samples are often used as surrogates. This approach is imperfect given discordance 
between BAL samples and upper respiratory tract (URT) samples has been observed 
for some taxa. [122] Nevertheless, concordance is high for some important taxa such 
as Moraxella and Staphylococcus, and in the absence of less invasive techniques URT 
sampling enables early estimation of the neonatal lower respiratory tract.  
 
The composition of CF nasopharyngeal microbiota diverges from that of non-CF 
infants as early as the first few months of life. [122,123] Newborn healthy infants 
appear to have nasopharyngeal microbiota dominated by Moraxella spp., 
Corynebacetrium spp. and Haemophilus spp., a community structure that persists for 
at least the first 6 months of life. Conversely the CF nasopharynx microbiome is 
initially dominated by S. aureus before a gradual increase in Streptococcus spp. and 
Moraxellaceae at 3 months of age. [123] Despite the increased S.aureus seen in CF, 
there were no decreases in measures of richness or diversity indicating that changes 
are due to differing microenvironment rather than inter-species competition. [124] 
 
The divergence observed in the first few months of life precedes antibiotic 




changes in the microbiota, but as CF infants grow older exposure to antibiotics, 
either via acute treatment for respiratory illnesses or prophylaxis against classic CF 
pathogens, becomes inevitable. Mika et al. investigated the relationship between 
antibiotics and the nasal microbiota by following 30 newborn infants with CF and 
performing fortnightly sampling for the first 12 months of life. [125] Antibiotic 
administration was associated with an increase in the Shannon diversity measure (a 
measure of the richness and evenness of a community) but this was judged to be 
most likely secondary to an increase in transient colonisers. Interestingly, antibiotic 
therapy was staphylococcal directed but decreases in Staphylococcus OTUs were not 
seen. Instead significant reductions in Moraxellaceae were observed and when 
oligotyping was used to better evaluate changes in Staphylococcus at the species 
level, mild reductions in S. aureus were offset by increases in S. epidermidis, leading 
the authors to suggest that S. epidermidis may act as a reservoir of resistance. These 
findings were supported by Prevaes et al. who conducted a similar study in a slightly 
older population (mean age 2yrs old). [123] There, antibiotic treatment was 
associated with reductions in Moraxellaceae and S. aureus OTUs, with increases in 
other staphylococcal OTUs, although more specific oligotyping was not performed.  
 
As children grow older, sampling from the lower airways becomes more common 
and comparisons between the lower and upper airways become feasible. Given the 
close proximity and inter-related spaces of the nose, throat and lungs, it could be 
expected that they share similar community structures, however the reality is that 
the nasal community appears different from that of the throat and lung, which are 
much more closely aligned. Boutin et al. found differences in the community 
structure of the nasal cavity compared to throat and sputum samples in that 
diversity, richness and evenness were significantly higher in nasal samples, and up to 
21 of the 76 most abundant nasal OTUs were not present in the throat or sputum 
samples. [126] Interestingly, the authors also found that people with CF could be 
broadly defined into one of two ecotypes based on the presence or absence of 
Pseudomonas OTUs, and the similarities between throat and sputum samples began 




findings in a recently published study, which for the first time included routine 
sequential BAL sampling in young children as part of the large AREST-CF study cohort 
in Australia and USA. [127] There, lower airway cultures mirrored those of the oral 
cavity until approximately age 2 years, when increasing predominance of known CF 
pathogens was observed and communities subsequently diverged. This has a 
number of clinical implications in that firstly, throat swabs can provide adequate 
representation of the lower airways in very young children, and secondly prevention 
or delay of this transition point by manipulation of the microbiota could theoretically 
be a strategy to improve outcomes later in life. 
1.5.5 Progressive loss of diversity 
Once the lungs are colonised with CF pathogens a pattern of progressively uneven 
community structures ensues. Cox et al. examined bio-banked sputum samples from 
a cohort of 63 clinically stable people with CF of ages ranging from 9 months to 72 
years. [115]This cross-sectional approach identified loss of community richness, 
evenness and diversity as age increased. Pseudomonas and Burkholderia OTUs began 
to progressively dominate in older people with CF, and the changes in community 
structure were inversely associated with pulmonary function. In a similar study 
design with 269 patients, Coburn et al. also found sample diversity inversely 
correlated with age and disease stage. Progressive loss of diversity was particularly 
correlated with Pseudomonas and Burkholderia abundance, which notably increased 
after the age of 25 years. [128] 
 
Zhao et al. were the first to confirm these findings longitudinally when they followed 
6 patients over a 9-year period with serial sputum collections. [129] It was observed 
that the 3 patients with what was termed as more “progressive” disease had 
significant decreases in community diversity over the course of several years.  This 
study was soon followed by Fodor et al. who focussed more on changes in the 
microbiota associated with acute changes in clinical status, but did observe a strong 
correlation between low species richness and poor lung function. [130] Stokell et al. 
followed a single patient up over 3 years and observed increasing total bacterial load 





Contrastingly, Whelan et al. published a study of 6 patients who submitted thrice-
weekly sputum samples for a year.  [132] No overall changes in community structure 
were observed over the course of the year and the authors concluded that the 
respiratory microbiome is unique to each patient and the previously reported 
associations between community structure and clinical parameters may be true on 
a cohort/population level but not at an individual level. However, it is worth noting 
that the 6 patients in the study appeared relatively stable with a median of only 1 
exacerbation in the 12-month study period and it is likely that the follow up period 
was not long enough to capture the indolent changes likely to be present in those 
patients. A much longer study period was adopted by Acosta et al., who analysed 
samples from patients with bio-banked sputum samples in three discrete historic 
cohorts spanning 20 years at a single-centre. [133] Across the cohorts, clinical status 
was better in the more recent cohorts, and this was associated with a decrease in 
the proportion of Pseudomonas-dominated communities and increased overall 
diversity, further supporting a relationship between community structure and 
clinical outcomes.  
 
The association reported in most studies between community structure and clinical 
outcomes has inevitably led to the question of whether a less diverse, less rich or 
less even microbiome is simply a marker of increased pulmonary disease or is itself 
a driver in disease pathogenesis. [134] If the latter were true, efforts to promote a 
more diverse community could have the potential to slow pulmonary disease 
progression. An Italian group has led efforts to find patterns or signatures in the 
microbiome that may predispose patients to accelerated lung function decline, 
however no causal association has been elucidated. [135–137] Instead, Zhao et al. 
found that the relationship between age, lung function and community diversity 
disappeared once controlled for antibiotic use, suggesting antibiotic therapy is the 
predominant driver of reducing community diversity. [129] The same group later 
developed a statistical approach to more precisely correct for antibiotic exposure 




approach was applied to 478 sputum samples and confirmed antibiotic use is an 
independent predictor for decreased diversity. [138] 
 
Accurately recording antibiotic use is troublesome in longitudinal CF studies due to 
the widespread use of long-term antibiotics for which compliance may be 
heterogeneous and also frequent episodic use of acute antibiotics in CF (which can 
often be self-directed). [139] Furthermore, the majority of CF microbiome studies to 
date have been retrospective in nature, which brings added challenges for 
establishing concurrent antibiotic use when not accurately recorded at the time. 
 
Pittman et al. were able to prospectively perform bronchoscopy and record 
antibiotic exposure for 32 children with CF as part of the AREST-CF study. In that 
study community diversity was found to be much lower in the BAL of those patients 
receiving antibiotics despite all participants being young children with mild lung 
disease. [140] Thus it appears likely that the strong association between community 
structure and degree of lung disease is related to the inevitable prolonged and 
aggressive use of antibiotics in CF, rather than direct pathogenesis from a less diverse 
microbiome. 
1.5.6 Changes associated with chronic suppressive antibiotics 
Inhaled antibiotics such as colistimethate, tobramycin, AZLI and levofloxacin 
preparations are all licenced in the UK for the treatment of chronic P. aeruginosa 
infections and have, to varying degrees, demonstrated improvements in lung 
function and exacerbation rates as well as sputum density of P. aeruginosa. [141–
144] However, despite the widespread use of these inhaled anti-pseudomonals in 
CF, the effect of these treatments on the microbiome remains poorly defined. 
Furthermore, many patients receive chronic macrolide therapy over many years, at 
least in part for its immunomodulatory effects, yet similarly little is known about the 
effects of this potential persistent selective pressure on the microbiota.  
 
When considering inhaled antibiotics there is contrasting evidence as to their 




between inhaled antibiotic treatments and bacterial community structure (although 
it is unclear which agents patients were using in that study), whereas a more recent 
study found chronic alternating inhaled antibiotic therapy to be associated with less 
diverse microbiomes. [145,146] Acosta et al. utilised a prospectively collected 
Canadian sputum biobank and primarily investigated changes in CF cohort 
microbiota over time, but also assessed whether different long-term antibiotics were 
associated with distinct microbiota. [133] 82 samples from 42 patients were 
sequenced and beta-diversity differed in those receiving long-term inhaled 
tobramycin and colistimethate, but interestingly no differences were seen in people 
receiving AZLI. The authors also assessed the impact of long-term oral azithromycin 
and nebulised dornase-alfa but these agents were not associated with any 
differences in lung microbiota composition or structure. 
 
Perhaps intrigued by the lack of effect seen for AZLI given its established clinical 
benefits, the same group has investigated its effects in more detail. The same 
Canadian biobank was used to identify and sequence 80 samples from 24 people 
with CF and naive to AZLI followed by 82 samples from the same patients following 
initiation of AZLI. [147] Overall no differences were observed in alpha or beta 
diversity measures, but lower relative abundances of Prevotella were seen following 
AZLI initiation. The authors then sub-classified study participants into AZLI 
“responders” and “non-responders” based on clinical outcomes and found “non-
responders” to have lower abundance of Pseudomonas and higher abundance of 
Staphylococcus OTUs.  
 
The same study group recently reported results from a multi-centre observational 
study of long-term AZLI use where sputum samples were taken before, during and 
after a 28-day AZLI treatment period. [146]  In keeping with their previous findings, 
AZLI was not associated with consistent changes in the microbiota; however changes 
were present at an individual level. Again, participants were classed as responders 
or non-responders and a higher relative abundance of Staphylococcus and 




validating some of the findings of the retrospective study. These findings raise the 
prospect of signatures in an individual’s microbiota acting as a biomarker for 
response to antibiotics. 
1.5.7 Changes associated with acute pulmonary exacerbations 
Despite the importance of exacerbations on long-term outcomes of people with CF, 
the pathophysiology of these events remains undefined.[99,148] Clinically, 
exacerbations are frequent and are characterised by changes in symptoms beyond 
day to day variation and can include increase in sputum volume or purulence, 
shortness of breath and fatigue. The precise mechanisms underlying these important 
events remain elusive and studies looking for answers using culture-independent 
techniques have not found consistent answers. For example, one may expect to find 
evidence of increases in known pathogens at the time of exacerbations yet there is 
no consistent evidence of this. [95] In fact, a number of studies have found the CF 
microbiota to be extremely stable over time and resilient to change at exacerbation 
and also following subsequent treatment. [129,130,149,150]  
 
However, when the community structure as a whole is considered, a number of 
larger studies have found reduced diversity or richness at the times of exacerbation 
compared to clinical stability. Coburn et al. found small decreases in Shannon 
diversity in exacerbation samples compared to baseline in their study of 269 people 
with CF and similarly, Filkins et al. found that samples taken during exacerbations 
had significantly lower diversity than samples taken when patients were stable. 
[128,151] Perhaps most convincingly Li et al. collated data from 18 previous studies 
to analyse over 700 sputum samples and found significant reductions in community 
richness at exacerbation. [152]  
 
In terms of changes in individual taxa at the time of exacerbation, Carmody et al. 
followed 4 patients for 3 months with daily sputum sampling and observed daily 
stability between exacerbations but increased P. aeruginosa abundance at the time 
of exacerbation in some patients and increases in Prevotella OTUs in others. [153] 




exacerbations to appear similar phenotypically but have different underlying 
aetiology with only some being due to changes that can be observed in the 
microbiota, and secondly that previously overlooked anaerobes may play a 
pathogenic role.   
 
The first concept is supported by Whelan et al. who found in longitudinal sampling 
of 6 patients that some but not all exacerbations were associated with changes in 
the microbiota.  [132] In exacerbations of chronic obstructive pulmonary disease 
(COPD), four distinct aetiological clusters have been identified: Bacterial, viral, 
eosinophilic predominant and “paucinflammatory”. Even if these clusters are not 
mirrored in CF, it is plausible that not all exacerbation clusters would be associated 
with changes apparent in either individual taxa or overall bacterial community 
structure. [154] Changes in the metabolic activity of specific taxa or the community 
as a whole triggering an exacerbation could be another explanation for an apparent 
lack of change in the community structure seen in some studies. The metabolites 
lactate and putrescine were found by Twomey et al. to be increased during 
exacerbation in the absence of clear changes in the community structure.[155] 
Quinn et al. used ecological functional networking to identify the non-melavonate 
pathway of isoprenoid synthesis as a “keystone” pathway in CF infections. 
Intriguingly fosmidomycin, an anti-malarial agent, is known to be effective at 
targeting this pathway. [156] 
 
The second concept to emerge from the study of Carmody et al. relates to the 
changes in Prevotella abundance at the time of exacerbation and raises the prospect 
that species not considered conventional CF pathogens may play a role in 
exacerbations. [153] Anaerobic species are easily overlooked in conventional 
selective culturing due to the requirement for anoxic culture yet are frequently 
identified in culture-independent analyses of the CF lower airways. In addition to 
Prevotella, Gemella and the Streptococci anginosus (millieri) group have both been 
found to have associations with clinical instability. [151,153,157] Anaerobes have 




polymicrobial setting; hence even if not directly pathogenic, they may still play a 
contributory role to the pathogenesis of some exacerbations. [158,159] 
 
To summarise, the aetiologies underpinning the transition from a stable state to an 
acute exacerbation are not well understood. It seems likely there are multiple 
aetiological clusters only some of which may be associated with changes in 
community structure.  
1.5.8 Changes associated with treatment for acute pulmonary 
exacerbations 
 
Traditional dogma would dictate that intensive, targeted antimicrobial therapy with 
dual anti-pseudomonal agents will result in significant reductions in abundance of P. 
aeruginosa; however, in a similar vein to the findings from studies of the onset of 
exacerbations, microbiota responses to treatment for acute pulmonary 
exacerbations in CF have not aligned with this conventional understanding of acute 
infections in CF.  
 
One of the predominant themes that has emerged from studies of the effect of acute 
antibiotics on the lung microbiota is that P. aeruginosa is not impacted to the same 
degree as other members of the community. For example, Daniels et al. studied 12 
adult with CF across the cycle of an exacerbation, and found that following initiation 
of anti-pseudomonal antimicrobials, the relative abundance of P. aeruginosa actually 
increased, alongside a reduction in the total number of species detected. [160] 
Cuthbertson et al. also found no evidence of reduced P. aeruginosa abundance in a 
study of 12 CF patients receiving treatment for pulmonary exacerbations. Instead, 
reductions in Streptococcus sanguinis, Prevotella and Porphyromonas OTUs were 
observed. [150] Similarly, Li et al., in their analysis of over 700 sputum samples, 
found that antibiotic treatment had no effect on Pseudomonas abundance, but did 
have significant effects on Gemella, Staphylococcus, Acitnomyces, Moraxllaceae and 
Fusobacterium. [152] Further, Fodor et al. again found that dominant taxa such as 




and end of an exacerbation, but the relative abundances of Gemella, Streptococcus 
and a small number of other less abundant OTUs were all reduced. [130] 
In contrast, two studies have found reductions in P. aeruginosa following treatment. 
Firstly, Zemanick et al. investigated the association between inflammation and 
changes to the airway microbiota during treatment for exacerbations and found that 
although bacterial load did not change, the relative abundance of P. aeruginosa was 
observed to decrease, and that these changes correlated with improved lung 
function. [161] A reduction in P. aeruginosa abundance following treatment was also 
reported by Smith et al., who noted rapid decreases in P. aeruginosa abundance and 
an associated increase in diversity following the initiation of intravenous antibiotic 
treatment for pulmonary exacerbations in CF, although these changes were transient 
and returned to baseline following the completion of treatment. [162] 
1.5.9 Limitations to CF Microbiome research to date 
 
There are a number of factors that may explain the differences between the studies 
described in this section and many of them apply to studies of the CF microbiome in 
general. The most obvious is the heterogeneous study designs, which are mostly 
retrospective and/or observational in nature and include a wide range of antibiotic 
regimens. For example, some studies included exacerbations treated with oral 
antibiotics as well as those requiring intravenous therapy. [150,160] Milder 
exacerbations are often treated with oral antibiotics and hence associated changes 
in the microbiota may also be expected to be more subtle. Even in those studies 
where only intravenous regimens were used, the antibiotic regimens or doses given 
are often not listed. The frequent lack of a control or comparator group further 
exacerbates the difficulty in interpreting results. A further consideration is the 
sampling timeframes in each study, where again there exists considerable variation 
that may have implications for interpreting results, particularly given that Smith et 
al. reported significant but transient reductions in P. aeruginosa abundance in the 





Variation also exists within and between patients in-terms of P. aeruginosa 
populations, where high levels of phenotypic diversity are typically exhibited. [68] 
Differing antimicrobial resistance, virulence and biofilm formation abilities could all 
feasibly impact on clinical outcomes of those infected with P. aeruginosa, however 
these changes would not be detected by sequencing of the 16S rRNA gene. 
 
Given the heterogeneous nature of CF as a disease and also its associated 
microbiome, one strategy is to utilise a cross-over design which has been employed 
to good effect in a recent phase III clinical trial of a new CFTR modulator. [163] Cross-
over studies allow each patient to act as their own control, minimising inter-
individual variation as a confounder and improving the statistical efficiency of a 
study. To our knowledge only one cross-over study has been performed in the CF 
microbiome setting when Peleg et al. conducted a double-blind, placebo-controlled, 
cross-over study of 28 days ivacaftor treatment. [164] Sputum was collected at the 
start and end of each 28-day treatment period and 16S rRNA gene sequencing was 
performed. No significant differences were observed for either total bacterial load 
or P. aeruginosa abundance following ivacaftor therapy, and no significant difference 
in the microbiota composition (based on 16S rRNA microbiome analysis) was 
observed between the placebo and treatment samples. However, the authors noted 
that when they adjusted for consistent or changing antibiotic exposure within the 
28-day study period, ivacaftor was associated with a significant reduction in P. 
aeruginosa abundance, that is to say, changes in the microbiota induced by acute 
changes in antibiotic administration during the 28-day treatment periods may have 
masked the effect induced by ivacaftor. It is important to note that, in clinical 
practice, CFTR modulators may affect the ability to collect good quality sputum 
samples and without confirmation of good quality samples, there are limitations as 
to the conclusions which can be drawn. 
 
Bias can be introduced into sequencing results at practically any stage from sample 
collection, where multiple freeze-thaw cycles have been demonstrated to affect the 




where different sequencing platforms can also produce different profiles. [165,166] 
There is no universally standardised protocol for the extraction of DNA from 
respiratory samples and hence methods are often inconsistent between study 
groups, for example the lysis of bacterial cells, which is a required initial step in order 
to release DNA before purification, can be performed mechanically with bead 
beading or enzymatically and each method can vary in their efficacy against Gram-
negative and Gram-positive bacteria resulting in subsequent downstream bias. 
[167,168] 
 
DNA extraction can be standardised and efficiently performed using commercial kits, 
however contaminating DNA is seen commonly in such kits and hence negative 
controls are recommended to help identify potential contamination. [169] Another 
striking methodological inconsistency is the use of propidium monoazide (PMA), a 
chemical compound that binds DNA in cells with damaged membranes and hence 
allows exclusion of non-viable DNA from sequencing. Excluding non-viable DNA has 
been suggested to be important for accurately identifying which members of the 
community are active at times of exacerbation, and help to avoid overestimation of 
viable microorganisms following treatment with antibiotics, but it is not utilised by 
all groups. [170,171] There are concerns that PMA may incompletely penetrate 
sputum, hence only identifying a portion of non-viable cells.  PMA is also known to 
stain viable cells of some species and not stain dead cells in others. [172] In CF 
exacerbations, PMA treatment was not found to significantly alter the community as 
a whole, and only changes in low abundance “satellite” taxa were apparent. [170]  
 
Overall, there is certainly evidence some that acute antibiotic administration alters 
the respiratory microbiota, however in the absence of prospective controlled trials 
it is difficult to interpret these results given the confounders mentioned above. 
Indeed, there have been calls for future clinical trials in CF to include biobanking of 
samples to allow more rigorous scrutiny of the effect of antibiotic agents on the 





 Management of infection in CF 
1.6.1 Early life 
The management of chronic infection in CF is targeted towards the suppression of 
purported pathogenic colonisers with the synchronous aim of preventing 
exacerbations. Strategies usually include the administration of long-term antibiotics 
by either inhaled and/or oral route. Some countries adopt a pre-emptive approach 
to chronic infection and start long-term oral prophylaxis at an early age, for example 
until recently UK guidelines recommended oral anti-staphylococcal prophylaxis in all 
infants and this strategy was historically widely adopted in the UK and Australasia. 
[173–175] This approach has been associated with reductions in S. aureus positive 
respiratory cultures however, a number of reviews including a Cochrane meta-
analysis have found little evidence that these reductions translated into 
improvements in clinical outcomes and worryingly a trend towards increased P. 
aeruginosa growths has been observed. [176–178] To address this concern, a large 
multi-centre randomised control trial, CF START (EudraCT No: 2016-002578-11), is 
currently underway in the UK.   
1.6.2 Eradication of P. aeruginosa 
Given the prognostic implications of chronic P. aeruginosa infection, all guidelines 
recommend an attempt at eradication after a first P. aeruginosa-positive respiratory 
culture. [176,179–182] Nebulised antibiotics alone or in combination with oral 
antibiotics have been found to be superior at achieving eradication however as of 
yet no specific agent or regime has emerged as superior. [183] Historically, some 
patients were admitted to hospital for intravenous antibiotics in addition to inhaled 
antibiotics for targeted eradication, however the recent TORPEDO-CF study 
demonstrated intravenous antibiotics were not superior to oral antibiotics in terms 
of sustained eradication but were associated with increased treatment burden and 
healthcare costs.[184] Success rates of eradication vary depending on the timeframe 
chosen to evaluate success: At one month, eradication improves sputum-culture 
negativity by 90%, but by six months success rates of 30-50% are reported. 




eradicated by eradication treatment, or whether its bacterial load is merely 
suppressed such that it cannot be detected by conventional culture methods. 
Supporting this, some studies have shown that P. aeruginosa recurrence following 
eradication is often by an isolate that shares an identical genotype to the isolate that 
triggered eradication in the first place. [187] 
 
Once eradication has failed, focus shifts from eradication to suppression in the form 
of long-term nebulised antibiotics. Failure of eradication therapy to induce sputum-
culture negativity is considered to represent the onset of chronic infection and failed 
eradication is seen more frequently in those whose baseline P. aeruginosa growths 
already had features of pathoadaptation. [188] Clinically, there are a number of 
criteria to define chronic infection with perhaps the most common being the Leeds 
criteria and the European consensus criteria (ECC). [182,189] The ECC categorise 
infection as chronic when three samples over 6 months with at least a month 
between them are positive for P. aeruginosa. [182] The Leeds criteria define chronic 
infection when >50% of cultures in the last 12 months are positive. [189] Once 
chronic P. aeruginosa infection is established it is associated with increased 
healthcare utilisation, morbidity and mortality in CF and hence much effort is 
targeted towards suppression in the form of long-term nebulised antibiotics. 
[190,191] 
 
1.6.3 Anti-pseudomonal antibiotics in CF 
 
Common antibiotic agents utilised against P. aeruginosa in CF include some 
aminoglycosides e.g. tobramycin, penicillin/beta-lactam combinations e.g. 
piperacillin/tazobactam, 3rd generation cephalosporins e.g. ceftazidime, 
monobactams e.g. aztreonam and polymyxins e.g. colistimethate. The mechanism of 
action and spectrum of activity for each of these classes are set out in Table 1.6.1.  
 
In general, antibiotic choice in CF is largely empirical given results of susceptibility 




194] This is initially counter-intuitive, but it must be kept in mind that the culture 
conditions during susceptibility testing are drastically unrepresentative of the CF 
lung. For example, the anaerobic conditions within aggregates of sputum discussed 
earlier are not replicated by routine aerobic bacterial culture. Susceptibility testing 
is also performed in a monospecies environment, yet the CF lung is a multi-species 
environment and inter-species interactions appear to alter susceptibility to 
antibiotics. [195] Furthermore, within a sputum sample or even within a colony of P. 
aeruginosa, different phenotypes co-exist and each may have different antimicrobial 
susceptibility. Susceptibility testing relies on selection and growth of a small number 
of isolates which may not represent the population as a whole. 
 
Given some of the limitations in conventional antibiotic susceptibility testing 
described above, much effort has been put into deriving new methods. Different 
susceptibility techniques including biofilm susceptibility testing and multiple 
combination antibiotic susceptibility testing (also called “synergy” testing) have been 
developed in attempts to improve and inform antibiotic selection. However, despite 
these methods being designed to more closely replicate the in-vivo lung 
environment, prospective clinical trials utilising these approached have to date, 
failed to demonstrate improved patient outcomes. [196–198] 
 
1.6.4 Inhaled antibiotics and the management of chronic infection 
 
Chronic infection with P. aeruginosa cannot usually be eradicated and hence 
treatment is targeted towards suppression of bacterial load in an attempt to prevent 
exacerbations and pulmonary function decline. The inhaled route offers the chance 
to deliver antibiotics directly to the site of infection and aerosol delivery of 
antibiotics has taken place since the 1940s. [199] Early attempts tended to include 
the aerosolisation of IV formulations, however these often contain preservatives or 





 Table 1.6.1: Mechanism of action and coverage of commonly used anti-
pseudomonal antibiotics in cystic fibrosis 
  
Class of Drug Mechanism of action 







Inhibits bacterial protein 
synthesis by binding 
irreversibly to 30S ribosomal 
subunit 
+ +/- - 
Penicillin/Beta-lactam 
e.g. Piperacillin/tazobactam 
Disrupts cell wall 
synthesis/repair by binding to 
penicillin binding proteins 
1b,2a,2b,3 to disrupt 
peptidoglycan synthesis 
+ + + 
Monobactams 
e.g. Aztreonam 
Disrupts cell wall 
synthesis/repair by binding to 
penicillin binding protein 3 to 
disrupt peptidoglycan 
synthesis 
+ - - 
3rd-generation cephalosporins 
e.g. Ceftazidime 
Disrupts cell wall 
synthesis/repair by binding to 
penicillin binding protein 
1a,1b,2,3 to disrupt 
peptidoglycan synthesis 
+ +/- +/- 
Polymyxins 
e.g. Colistimethate 
Binds to phospholipids in the 
outer membrane of Gram-
negative bacteria, displaces 
cations thereby disrupting 
the outer membrane allowing 
leakage of intracellular 
contents and cell death. 
+ - - 
Carbapenems 
e.g. Meropenem 
Disrupts cell wall 
synthesis/repair by binding to 
penicillin binding protein 
2,3,4 to disrupt peptidoglycan 
synthesis 





Aerosols deposit themselves via different processes e.g. impaction or sedimentation, 
dependent on their physical properties and specific preparations of antibiotic agents 
have been developed to optimise deposition in the lung, Table 1.6.2.  Impaction 
occurs when large particles, travelling at speed, undergo turbulence or changes in 
direction, whereas sedimentation is a time-dependent deposition of particles under 
the influence of gravity in the context of low flow. Impaction tends to occur in the 
upper/central airways, whereas sedimentation is a small airways/alveolar process.  
Particle size also helps dictate which process occurs, with larger particles (>8µm) 
tending to deposit via impaction, smaller particles (1-8µm) tending to undergo 
gravitational sedimentation and very small particles (<1µm) may not deposit at all. 
[199,202,203] The main attraction to the inhaled route of antibiotic administration 
is the possibility for delivering large concentrations of antibiotic directly to the site 
of infection with substantially less systemic exposure than oral or IV administration. 
Pharmacokinetic studies have demonstrated that IV administration of tobramycin 
(10mg/kg/day) achieved maximum concentrations (Cmax) of 29.4µg/ml and 3.9µg/g 
in serum and sputum respectively, whereas inhalation of 300mg tobramycin 
achieved corresponding Cmax of 1 µg/ml and 1200 µg/g respectively. [204,205]  
Similarly, aztreonam lysine for inhalation (AZLI) achieved  sputum Cmax of 324-
677µg/g , yet serum Cmax was 0.4µg/ml, whereas IV aztreonam achieves a sputum 
Cmax of 18.7ug/ml and a serum Cmax of 228ug/ml.  [206–209]  
 
The available inhaled anti-pseudomonals in the UK are presented in Table 1.6.2. 
Nebulised colistimethate is considered first-line in the UK and approximately 25% of 
people with CF are currently prescribed it. [1] Colistimethate has a relatively small 
evidence base but has been shown to be superior to placebo in terms of clinical 
symptom scores. [207]  Despite use for many years in Europe, the absence of robust 
placebo-controlled randomised trials meant it has never been approved for use in 
the USA where tobramycin (TNS) is first-line. In the UK, TNS is a second-line agent 
with AZLI a third-line agent, and their efficacy is supported by evidence from a 





The benefits of TNS were first demonstrated nearly 20 years ago in a 6 months trial 
of TNS (alternating 28 days on 28 days off) vs. placebo. An alternating regimen was 
selected based on the rationale that “drug holidays” allowed susceptible pathogens 
to repopulate the airways, preventing the build-up of resistance. [210,211] TNS was 
associated with increased lung function, reduced sputum density of P. aeruginosa 
and comparative studies against colistimethate have demonstrated superiority of 
TNS in terms of lung function improvement and reduced exacerbation rate. 
[141,212,213] 
 
AZLI is an aerosolized lysine salt formulation of the monobactam aztreonam and has 
been licensed in the UK for approximately 5 years. [214] Aztreonam binds to 
penicillin-binding proteins of susceptible pathogens including P. aeruginosa and 
other Gram-negative pathogens. [215] IV preparations of aztreonam are formulated 
with arginine, which is associated with deleterious clinical outcomes when inhaled. 
[200] New preparations were sought for a formulation of aztreonam that could be 
safely used to target pulmonary infection in CF leading to development of AZLI. 
Evidence for AZLI use in the chronic setting comes from the two clinical trials AIR-CF1 
and AIR-CF2 and their open label extension AIR-CF3 [216–218]. AIR CF1 was a 
placebo-controlled trial of a 28-day course of AZLI that found AZLI given three times 
a day was associated with improved lung function, reduced P. aeruginosa sputum 
density and improved quality of life. [216] AIR-CF2 compared an alternating regimen 
of AZLI and TNS to placebo and TNS over 3 months and found improved P. aeruginosa 
sputum density, quality of life and exacerbation frequency in the AZLI arm. [217] AIR-
CF3 was an 18-month open-label extension which demonstrated sustained 
responses in lung function and quality of life. A persistent suppressive effect on P. 
aeruginosa was also seen and no increases in antibiotic resistance were reported. 
[218] Recently, the results of these trials were corroborated by an effectiveness 
study investigating the outcomes of AZLI use in a real-world population. [219] There, 
AZLI was found to be associated with significant improvements in lung function, 





As well as the development of specific antibiotic preparations for inhalation, there 
has also been development of nebulisers designed to provide optimum delivery. 
Modern nebulisers such as the eFlow (Pari Medical, West Byfleet, UK) and Ineb 
(Profile Pharma, Zambon, Chichester, UK) utilise vibrating meshes enabling them to 
be much smaller than traditional nebuliser devices. The mesh is precision engineered 
with thousands of taper holes and as the antibiotic preparation is forced through the 
holes the mesh vibrates at ~116kHz to generate 2.5µm aerosolised particles. [220]   
 
Recently, dry-powder preparations have also become available, see Table 1.6.2. 
These preparations have been shown to be non-inferior to nebulised treatments and 
are quicker and more convenient to take, however their use can be associated with 










Table 1.6.2: Inhaled antibiotics currently available in the UK 
  
Drug Brand name   Dose  Device 
            
Colistimethate      
 Colistin*  2 million units BD Any 
 Promixin  1 million units BD Ineb 
 Colobreathe#  1.6million units BD Turbospin 
      
Tobramycin      
 Bramitob  300mg BD Any 
 Tymbrineb  300mg BD PARI LC PLUS 
 TOBI  300mg BD Any 
 TobiPod#  28mg BD Podhaler 
      
Aztreonam      
 Cayston  75mg TDS eFlow 
      
Levofloxacin      
  Quinsair   240mg BD eFlow 
*IV preparation used for inhalation.  
#Dry power preparation     




1.6.5 Management of acute pulmonary exacerbations 
 
As previously described acute pulmonary exacerbations are associated with 
considerable morbidity and mortality, however in contrast to the huge research 
efforts targeted towards CFTR modulators and chronic suppressive antimicrobial 
therapy, there is a relative lack of evidence underpinning the management of 
exacerbations. This is a result of a combination of factors including heterogeneity of 
exacerbations themselves, lack of clear definitions, gaps in our understanding of the 
pathophysiology and also ethical challenges in testing alternative approaches given 
the importance of recovery of exacerbations. Recommended practice from 
guidelines is often based on expert consensus and founded in practices which have 
been established over many years by anecdotal and observational evidence, but few 
prospective trials. Probably as a consequence of the lack of robust evidence there 
exists variation between clinicians, centres and countries in antibiotic strategies and 
use of adjunct therapies. [86,223] Nevertheless, goals of therapy are broadly agreed 
in that management is targeted towards improving lung function and relieving 
symptoms. [224] 
 
When deciding whether to instigate treatment, clinicians must weigh up the 
constellation of symptoms, signs and lung function to establish whether there is 
indeed evidence of an exacerbation but also the degree of severity.  Milder 
exacerbations, which account for over 70% of all exacerbations, can often be treated 
with oral antibiotics. [225] In chronic P. aeruginosa infection, ciprofloxacin is the first 
line oral agent and has been shown to be useful in this setting. [226,227] Other 
antibiotics such as chloramphenicol, tetracyclines and co-trimoxazole all have some 
activity against P. aeruginosa and are considered second-line. [179]  
 
In more severe exacerbations or where there is lack of response to oral antibiotics, 
IV antibiotics are recommended. [173,176] IV antibiotics used commonly are 
presented in Table 1.6.3. Guidelines recommend the use of two IV antibiotics based 




resistance to monotherapy may result in treatment failure and further clinical 
decline. [228,229] A recent Cochrane review found combination therapy of two IV 
antibiotics was associated with significantly greater improvements in lung function 
compared to a single antibiotic approach, although overall quality of evidence 
supporting this approach was low. [230] The authors of the review found no 
evidence to support superiority of a specific antibiotic, and in practice antibiotic 














Table 1.6.3: Anti-pseudomonal IV antibiotics available for use in the UK.  
   
  Drug   Dose Frequency 
Group 1: Beta-lactams/Monobactams/Carbapenems 
 Piperacillin/Tazobactam  4.5g 3 to 4 daily 
 Meropenem  1 to 2g 3 daily 
 Aztreonam  2g 3 daily 
 Ceftazidime  3g 3 daily 
 Ceftazidime/Avibactam  2g 3 daily 
 Ceftolozane/Tazobactam  1g 3 daily 
Group 2: Aminoglycosides/Polymyxins/Phosphonic acids  
 Tobramycin  3mg/kg 3 daily 
 Fosfomycin  4g 3 daily 
 Colistimethate  2 million units 3 daily 




People with CF have a different volume of distribution, eliminate antibiotics quicker 
than healthy controls and therefore often require higher doses of antibiotics. 
[231,232] In addition, the complex nature of infection in CF requires longer 
treatment durations. Typically, 10-14 days is recommended as a minimum and in the 
US, average duration of IV treatment is 16 days in adults and 14 days in children. 
[224] Longer courses can be beneficial if lung function has not returned to baseline 
at 14 days. [233] In addition to the high doses and extended durations of antibiotic 
courses used in CF, there is also evidence that the best performing CF centres are 
those that use the most IV antibiotics and this has been used to support an approach 
of treating infection early and aggressively. [234–236] 
 
However, the benefits of IV antibiotics must be weighed against the risks. In CF, high 
doses and long durations result in incredibly high cumulative exposures to antibiotics 
and subsequently side-effects, adverse effects and long-term complications are 
increasingly reported. [120] Aminoglycosides in particular are nephrotoxic and 
ototoxic and the incidence of acute kidney injury has been reported to be as much 
as 100 times greater in people with CF than the general population. [237,238] It is 
therefore unsurprising that in the long-term, cumulative IV antibiotic courses have 
been inversely associated with renal function. [31] Beta-lactams do not carry the 
same risk of nephrotoxicity but are associated with adverse reactions ranging from 
mild rash to severe angioedema or anaphylaxis. Lifetime cumulative IV beta-lactam 
exposure is associated with an increased risk of allergic reaction which can result in 
severely limited antibiotic options in certain patients. [239] 
 
IV antibiotics require venous access and hence repeated venepuncture and cannula 
insertions. Repeated venous access attempts can lead to increasingly difficult 
cannulation which is problematic for patients. Totally implantable venous access 
devices (TIVAD) are therefore considered in individuals requiring repeated courses 
of IV antibiotics or who have difficult venous access. TIVAD are more convenient for 
patients but serious complications including blockage, thrombosis and infection can 




 Inhaled antibiotics for the treatment of acute chest infections – A 
new approach? 
The increasing life-expectancy of people with CF brings new challenges including 
increasing burden on beds/resources and also increased lifetime systemic antibiotic 
exposure with subsequent implications for morbidity associated to toxicity and 
allergic reactions. Hence, other treatment approaches must be considered and in the 
last five years two new inhaled antibiotics (AZLI and LIS) have become available and 
a number of other products including an inhaled tobramycin/fosfomycin 
preparation, inhaled liposomal amikacin and inhaled ciprofloxacin are in various 
stages of development. [241–244] Inhaled antibiotics have traditionally been 
reserved to suppress chronic infection, however the recent expansion of available 
preparations means they could now be considered for use in acute exacerbations.  
Many of the properties that make inhaled antibiotics useful for the treatment of 
chronic infection e.g. delivery of high concentration of drug to the site of infection 
and minimal systemic exposure also make them attractive for the treatment of acute 
pulmonary exacerbations. Furthermore, they may represent another treatment 
option for individuals with difficult venous access.  
 
There have been concerns that areas of the lung most affected by acute infection 
may also have reduced ventilation, and hence inhaled antibiotics would sub-
optimally deliver drugs to that area. For example, a computational fluid dynamics 
model predicted that in a scenario where airway liquid was thick, e.g. during an 
exacerbation, smaller airways would have significantly lower concentrations of AZLI 
than larger airways. [245] However, a recent imaging study using magnetic 
resonance imaging (MRI) found perfusion was also significantly decreased in areas 
of infection at the time of exacerbation, thus suggesting IV antibiotics may not hold 
superiority over inhaled antibiotics in that regard. [246] 
 
The use of nebulised antibiotics for acute pulmonary exacerbations is not a novel 
idea. Nebulising IV preparations of tobramycin was reported in 1983, carbenicillin in 




preparations, e.g. aztreonam arginine, include lung irritants and the results of studies 
in the 1980s were, perhaps unsurprisingly, mixed. A Cochrane review in 2012 found 
only four small randomised control trials and insufficient information for meta-
analyses. [250] More recently, a randomised cross-over study confirmed the benefits 
of TNS vs. IV tobramycin in the treatment of acute exacerbations. This was the first 
study to utilise a preparation optimised for inhalation and 14 days of TNS was 
associated with a 16% improvement in FEV1, which was similar to IV tobramycin, but 
TNS use resulted in renal sparing and a significantly prolonged time to next 
exacerbation. [251] 
 
A recent systematic review of evidence-gaps in CF highlighted the management of 
acute pulmonary exacerbations as an area in need of further research. [252] 
Inhalation of antibiotic agents optimised for pulmonary delivery warrants further 
investigation and further trials are needed.  
1.7.1 Inhaled antibiotics in non-CF bronchiectasis 
 
Similarly to CF, P. aeruginosa is the most common pathogenic coloniser found in 
people with non-CF bronchiectasis (NCFB) and mortality is higher in NCFB when P. 
aeruginosa is cultured in sputum. [253,254] Three months of treatment with 
nebulised colistin has been reported to extend time to next exacerbation compared 
to placebo in people with chronic P. aeruginosa infection and inhaled ciprofloxacin 
has had some success, although recent phase 3 clinical trials were conflicting. 
[243,255,256]  Long-term inhaled aztreonam was not found to be beneficial with 
NCFB, although post-hoc analysis revealed clinical improvements were seen in the 
sub-group with high sputum bacterial load at baseline. [257,258] Other evaluated 
agents include gentamicin, where in a study of 65 adults with NCFB, 12 months of 
nebulised gentamicin reduced exacerbation rate compared to placebo in people with 
H. influenza or P. aeruginosa infection. Recent guidelines therefore recommend 






In the acute setting, relatively little is known about the feasibility of inhaled 
antibiotics for treatment of exacerbations of NCFB as only two studies have been 
conducted. The first was a multi-centre study comparing the addition of nebulised 
tobramycin or placebo to oral ciprofloxacin for treatment of exacerbations in people 
with NCFB and P. aeruginosa. [262] The study recruited 53 patients and although 
there was significantly greater microbiological efficacy seen in the nebulised arm, no 
corresponding clinical improvements were noted.  More recently, a Chinese study 
explored the efficacy and safety of the addition of nebulised amikacin to standard IV 
antibiotic therapy for treatment of exacerbations in adults with NCFB and reported 
similar clinical outcomes between groups, but significantly greater sputum bacterial 
eradication rates with nebulised amikacin. [263] In both studies, nebulised 
antibiotics were tolerated well, although wheeze (a recognised side-effect of 
nebulised tobramycin preparations) was reported to be higher in those receiving 
tobramycin in the earlier study.   
1.7.2 Inhaled antibiotics in ventilator-associated pneumonia 
 
Ventilator-associated pneumonia (VAP) occurs in 10-27% of intubated critically ill 
patients and accounts for up to 50% of antibiotic use in intensive care units. [264]  
The use of aerosolised antibiotics has been advocated in this population given the 
high rates of multi-drug resistant pathogens (including P. aeruginosa) and the 
theoretical ability to deliver high concentrations of the drug to the site of action. A 
number of different antibiotic agents, preparations and delivery devices have been 
investigated including those previously studied in CF e.g. colistimethate, tobramycin, 
and amikacin. [265–267] Additionally, novel preparations e.g. an amikacin-
fosfomycin combination nebulised therapy have also been studied. [268] Results 
from these studies are mixed, probably reflecting the wide range of preparations 
used and challenges delivering aerosols to mechanically ventilated patients. [269] 
Nevertheless, in studies with preparations and delivery optimised for intubated 
patients, positive effects on bacterial load, antibiotic resistance, time to intubation 





One systematic review and meta-analysis of a heterogenous range of study designs, 
interventions and comparators found nebulised antibiotics were associated with 
improved short-term clinical outcomes but no microbiological cure or mortality 
benefit. [266] A further review only considered the role of colistimethate and found 
improved clinical response, microbiological eradication and  reduced infection-
related mortality  when nebulised colistimethate was added to standard IV therapy. 
[271] Subsequently, in 2016 the American Thoracic Society recommended the use of 
nebulised antibiotics for VAP in certain circumstances, namely when the causative 
organism was a Gram-negative bacilli exhibiting some degree of antimicrobial 
resistance. [266,272] More recently, a European meta-analysis found evidence of 
improved clinical cure rate and reduced mechanical ventilation duration but no 
effect on overall mortality for nebulised antibiotics used as either an adjunct to, or 
substitute for, IV antibiotics. [273] Nephrotoxicity was reduced when nebulised 
antibiotics were used, but there was a 9% increase in respiratory complications, 
which appeared to particularly affect those with severe acute respiratory distress 
syndrome, and a European consensus statement therefore suggested more research 
was required before nebulised antibiotics could be routinely recommended .  
[273,274] 
1.7.3 Inhaled antibiotics in chronic obstructive pulmonary disease 
 
To date, only gentamicin has been evaluated in the acute COPD exacerbation setting, 
although nebulised tobramycin was associated with reduced sputum inflammation 
in stable COPD patients. [275,276]The gentamicin study was an Iranian double-
blinded placebo-controlled clinical trial in hospitalised patients with an acute 
exacerbation of COPD. 86 participants were randomly assigned to the addition of 
nebulised gentamicin or placebo (0.9% sodium chloride) to oral antibiotics for five 
days. Both treatments improved dyspnoea scores and the nebulised gentamicin 






1.7.4 Current use of inhaled antibiotics for acute pulmonary exacerbations 
in CF  
 
Observational studies report 10-24% of patients treated for an exacerbation received 
inhaled antibiotics; however it is not clear from these studies whether these were 
short courses for exacerbation treatment or the continuation of long-term 
suppression. [223–225,277] Given the lack of evidence for or against their use in this 
setting there have been calls for further studies to address the evidence gap for the 
approach. [223,278]   
 Conclusion 
CF pulmonary disease is characterised by progressive chronic infection, punctuated 
by periods of acute deterioration termed exacerbations. Exacerbations are 
associated with significant morbidity and increased mortality and currently require 
aggressive management in the form of two IV antibiotics for extended periods. Such 
treatment can be associated with complications, side-effects and increased 
antimicrobial resistance, therefore new strategies are required. Inhaled antibiotics, 
a well-established weapon in the management of chronic CF lung infection, may 
represent a new treatment strategy in the management of acute infections and 






 Aim of this thesis 
 
Aim 1:  Establish the current usage of inhaled antibiotics in the acute setting 
amongst CF clinicians in the UK. 
 
Aim 2:  To investigate the clinical utility of AZLI plus IV colistin against dual IV 
antibiotics for the treatment of acute pulmonary exacerbations of 
cystic fibrosis. 
 








Chapter 2: What is Current Practice? A Nationwide Survey of 
the Use of Inhaled Antibiotics for Acute Pulmonary 
Exacerbations of CF 
 Introduction 
The recent expansion of available preparations of inhaled antibiotics has led to the 
consideration of using inhaled antibiotics in place of intravenous antibiotics for some 
pulmonary exacerbations. [279] Inhaled antibiotics may hold benefits over 
intravenous antibiotics given they deliver a higher dose directly to the lung, with 
associated reduced systemic exposure (with potential for reduced allergies, 
intolerance and off target sequelae) as well as reduced need for intravenous access. 
In the USA, observational studies report 10-24% of patients treated for an 
exacerbation received inhaled antibiotics yet it is not clear whether these were new 
acute treatment courses or continuation of long-term suppression. [223–225] The 
most recent clinical trial in this area was conducted in the UK and there is anecdotal 
reporting of their use. [251,280] However, UK guidelines make no comment 
regarding the use of inhaled antibiotics in the acute setting and the extent to which 
inhaled antibiotics are being employed in the acute setting in CF in the UK is 
unknown. The aim of this study was therefore to explore, understand and 
benchmark usage of inhaled antibiotics for the treatment of acute pulmonary 
exacerbations of CF in the UK. 
 Methods: 
An online platform (SurveyMonkey Inc, USA) was used to create a survey for national 
distribution amongst clinicians involved in the care of people with CF. The survey 
consisted of three main sections; ‘Demographics’, ‘Usage’ and ‘Barriers’. These 
sections aimed to establish firstly which CF centre and in which setting (adult or 
paediatric) the respondent worked. Secondly, information regarding their use of 
inhaled antibiotics in the acute setting and the final section sought to elucidate 




(Table 2.2.1), and was circulated via the UK Cystic Fibrosis Medical Association 
(UKCFMA) and also the UK CF Network. The UKCFMA is made up of physicians with 
specialist interest in CF from both the adult and paediatric setting. The UK CF 
Network is an online forum for professional discussion between UK CF clinicians. The 
UK has adult 28 adult CF centres (16 with greater than 200 patients)  and 31 
paediatric CF centres (6 greater than 200 patients). [15] The survey was open 
between February and March 2019. In addition to analysis of overall trends, sub-
group analyses were performed based on adult/paediatric setting, size of centre and 
prior training of the respondent. Differences were compared using Fisher’s exact test 
or Mann-Whitney’s test for categorical and continuous data respectively. All 
statistical analyses were conducted in RStudio (v1.0.136, R Studio Inc). A p-value of 











Which CF centre do you work at? Open question 
Adults or paediatric? Open question 
How many patients at your centre? Open question 
Have you undertaken a period of CF training 
abroad? 
Yes/No 
Have you used inhaled antibiotics in place of 
intravenous antibiotics for the treatment of an 
acute pulmonary exacerbation of CF? 
Multiple choice: 
Never/Rarely/Often 
Which inhaled antibiotics have you used? 
Tickbox from a list of 
antibiotics 
What is your overall experience in using inhaled 
antibiotics for the treatment of acute pulmonary 
exacerbations in CF? 
Five-point Likert scale 
What do you feel are the main barriers to 
increased use of inhaled antibiotics in the acute 
setting? 
Tickbox from a list of 
possible barriers with 
freehand option 
How do you foresee your use of inhaled 









The survey was accessed by 35 respondents and completed by 34 (97% completion 
rate). Respondents represented 25 different CF specialist centres across the United 
Kingdom (see Figure 2.3.1) providing care for 6850 people with CF (two-thirds of the 
UK CF population). [1]  Overall, 21 (62%) respondents were primarily involved in the 
care of adults with CF, representing 15/28 (53.6%) of all adult specialist CF centres in 
the UK. 13 respondents were primarily involved in the care of children with CF, 
representing 13/31 (42%) of all paediatric specialist CF centres. 
2.3.1 Use of inhaled antibiotics 
 
Twenty-five respondents (74%) reported previous use of inhaled antibiotics to treat 
acute pulmonary exacerbations of cystic fibrosis and there was no significant 
difference in practice between adult or paediatric clinicians (17/21, 81% vs. 8/13, 
62% respectively, p=0.25), see Figure 2.3.2. Four respondents reported a period of 
CF training abroad and all four (100%) reported the use of inhaled antibiotics in the 
acute setting compared to 21/30 (70.0%) of those with no period of training abroad, 
however this numerical difference was not statistically significant (p=0.29). As 
regards frequency, only 3 /25 (12.0%) reported use often.  
 
Overall experience was evaluated using a 5-point Likert scale. Only 2/25 (8%) 
respondents reported their experience using inhaled antibiotics was negative with 
the majority describing neutral experience and 10/25 (40%) describing positive or 
very positive experience, see Figure 3. Where usage was reported, colistimethate, 

















Figure 2.3.2: Percentage of respondents reporting any use of inhaled antibiotics in 
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Figure 2.3.3: Likert scale responses to the question “What is your overall 
experience in using inhaled antibiotics for the treatment of acute pulmonary 
exacerbations in CF?” 
 







Figure 2.3.4: Percentage of respondents (n=24) with prior use of inhaled 






2.3.2 Perceived barriers 
The next section explored respondents’ perceptions of potential barriers against the 
use of inhaled antibiotics in the acute setting. “Inadequate delivery of drug to the 
site of action” was identified by 14/33 (42%) of respondents and was the most 
frequently identified barrier. Other frequently identified barriers included “side-
effects e.g. coughing”: 9/33 (27%), unlikely clinical benefit: 10/33 (30%) and patient 
choice 6/33 (18.2%), see Table 2.3.1 
 
2.3.3 Future use 
Finally, respondents were asked how they expected their use of inhaled antibiotics 
would change in the next few years. No respondents expected use to decline. All 
clinicians reporting they had never used inhaled antibiotics in the acute setting 
expected their practice to remain unchanged. Conversely, those who had used 
inhaled antibiotics were significantly more likely to increase their use in the next few 
years (12/25 prior users reported they were likely to increase use compared to 0/9 






Table 2.3.1: Perceived barriers to the use of inhaled antibiotics in the treatment 






Inadequate delivery to the site of action, e.g. reduced 
ventilation in area of acute infection 
14 42.4 
Unlikely clinical benefit 10 30.3 
Side-effects, e.g. coughing 9 27.3 
Patient choice 6 18.2 
Limited available agents/preparations 5 15.2 
Cost 3 9.1 
Selected others (all n=1)   
“Lack of evidence base”   
“Technicalities of giving these drugs on a ward, 
storage in pts rooms, fridge size. Drug interactions.”   
“Difficult to do in acute setting with physio provision”   
“Unlikely to aide systemic effects of infection“   
“Good in mild exacerbations not proven in more 
severe and patients can be too unwell to tolerate 





This study explored the current nationwide usage of inhaled antibiotics for the 
treatment of acute pulmonary exacerbations of CF. Our findings demonstrate that 
the majority of CF centres have used inhaled antibiotics in the acute setting, however 
there is variation in practice and only a minority of centres/clinicians routinely use 
this approach. 
 
In the US, guidelines for the management of young children with CF recommend the 
use of inhaled antibiotics as part of the management of pulmonary exacerbations. 
[279] However, we found no significant difference between usage in the adult and 
paediatric settings in the UK and if anything, a trend towards less use in paediatrics. 
These findings may be explained by the challenges in administering nebulisers to 
young children, who may not be able to follow instructions adequately to achieve 
optimal delivery of the antibiotic into the lung. Furthermore, most antibiotics 
optimised for inhalation are targeted towards P. aeruginosa which is found in fewer 
children than adults and hence it is unsurprising that paediatric use of inhaled 
antibiotics remains low. 
 
Data from previously published studies suggest that in healthcare settings outside 
the UK, the rates of use of inhaled antibiotics during acute pulmonary exacerbations 
may be as high as 24%. [225] Accordingly, all three clinicians (from three centres, one 
paediatric and two adults CF clinicians) who had completed a period of CF training 
outside the UK had used inhaled antibiotics in the acute settings, compared to two-
thirds of those trained exclusively in the UK.  
 
Although UK guidelines make no recommendations for or against the use of inhaled 
antibiotics in the acute setting, the most recent study in this area was conducted in 
the UK and found substituting nebulised tobramycin for intravenous tobramycin was 
effective in treating exacerbations and was superior in terms of time to next 
exacerbation. [251] As such it is perhaps of no surprise that tobramycin was the most 





This study explored perceived barriers/concerns for the use of inhaled antibiotics in 
the acute setting and the most frequent concern related to inadequate delivery of 
drug to the site of action. This was an unexpected finding given that inhaled 
antibiotics deliver a significantly greater dose of antibiotic to the lung. One 
interpretation of this finding is that clinicians may perceive that although a greater 
dose of antibiotic is delivered to the lung itself, the site of infection may be plugged 
with excess mucus and therefore not ventilated adequately. The aerosolised drug 
would instead be deposited in higher concentrations in areas of increased 
ventilation, i.e. healthy lung, and hence concentrations at the site of infection may 
be sub-inhibitory. In such scenarios intravenous antibiotic delivery may be perceived 
as superior, however a recent study using MRI perfusion imaging found areas of 
airway obstruction are associated with local pulmonary vasoconstriction and 
subsequent perfusion deficits. [246] This mechanism is a physiological compensatory 
response to reduced ventilation and helps direct blood to areas better ventilated 
areas of the lung. Thus, intravenous administration may not actually hold superiority 
in terms of delivery of drugs to the site of infection. 
 
Another interpretation of clinicians’ perception that inhaled antibiotics are 
inadequate in terms of delivery to the site of action is they feel that some degree of 
systemic antibiotic exposure is necessary for optimal treatment of acute pulmonary 
exacerbations. The relationship between systemic inflammation and pulmonary 
exacerbations in CF is complex, for example C-reactive protein (CRP), does not 
appear to be related to exacerbation severity,  but a very elevated admission CRP is 
highly specific for a poor treatment response. [281,282] Clinicians may therefore 
have fears that the reduced systemic exposure of inhaled antibiotics may not 
sufficiently treat the systemic component of an acute pulmonary exacerbation of CF. 
Downey et al. demonstrated IV antibiotic treatment of pulmonary exacerbations was 
associated with reduced circulating CD11b stained neutrophils, a marker of systemic 
inflammation. [283] However, the same study found IV antibiotics were not 




modulating the local inflammatory process in the lungs would alter exacerbation 
outcomes.  
 
Our findings suggest that the use of inhaled antibiotics in the acute setting will 
increase in the coming years given no respondents felt their use would decrease and 
over a third felt their use would increase. The lack of evidence in this area was 
recently highlighted in two systematic reviews and since use is likely to increase, 
studies are needed to allow optimisation and standardisation of practice. [252,284]  
 
The limited availability of antibiotic agents optimised for inhalation has historically 
been a barrier to the use of nebulised antibiotics in the acute setting, available 
preparations being used predominantly for chronic suppression of P. aeruginosa. 
The use of various intravenous preparations via the inhaled route has been tested in 
the past, but this can be associated with lung irritation and is therefore inappropriate 
during exacerbations. [200,249] Although in our study some clinicians highlighted 
that the lack of available preparations still remains a barrier today, the number of 
licensed agents has increased in the last ten years. A number of other agents are also 
undergoing clinical trials, e.g. fosfomycin/tobramycin combination, liposomal 
amikacin,  and dry-powder ciprofloxacin, all in the non-acute setting and 
predominantly targeted towards chronic suppression of P. aeruginosa in a clinically 
stable population. [242–244] Repurposing of these drugs towards the acute setting 
could potentially yield an increase in treatment options for acute pulmonary 
exacerbations of CF and further studies are needed. 
 
Limitations to this study lie mainly in recall bias associated with all studies of this kind 
and the fact that responses were not received from all CF centres in the UK. The 
survey was distributed amongst the UKCFMA and UK CF Network and a potential 
selection bias could be that clinicians engaged in these forums are more likely to 
adopt or try new practices and the use of inhaled antibiotics in the acute setting 
would therefore be overestimated. Additionally, practice may vary within centres, 




did not ask respondents whether they had used inhaled antibiotics as a primary 
treatment strategy or as secondary/salvage therapy once other treatments had 
failed and are therefore unable to comment on inhaled antibiotic utility in those 
distinct settings. Nevertheless, the strengths of the study lie in the coverage of over 
two-thirds of the UK CF population and over 70% of adult CF centres in the UK. This 
is the only study, to our knowledge, exploring current practices and perceptions 
regarding the use of inhaled antibiotics for acute pulmonary exacerbations and can 
inform future research directions in order to standardise and optimise this treatment 
strategy. 
 
In conclusion, the majority of CF clinicians in the UK have used inhaled antibiotics to 
treat acute pulmonary exacerbations. Very few reported negative outcomes and 
usage appears set to increase in the coming years. Research defining the appropriate 





Chapter 3: AZTEC-CF Methods and Study Design 
 Introduction  
AZTEC-CF (Aztreonam lysine for inhalation for the treatment of exacerbations of 
cystic fibrosis) is an open-label, pilot single centre (Liverpool Heart & Chest Hospital 
NHS Foundation Trust), randomised cross-over pilot trial designed to investigate the 
efficacy of AZLI in the treatment of acute pulmonary exacerbation of CF. Study 
documents are deposited on the github.com repository available at  
https://github.com/Ffrost2/AZTEC-CF. 
3.1.1 Study rationale 
Inhaled antibiotics deliver an extremely high concentration of drug to the lung, which 
can be in the order of 300 times greater than IV antibiotics, with significantly less 
systemic exposure. With this in mind, using inhaled antibiotics in the acute setting 
may treat acute lung infection more effectively while also reducing some of the 
complications associated with repeated prolonged systemic antibiotic exposure. The 
recent expansion of available preparations optimised for inhalation means there are 
now more options available for consideration of use in the acute setting, however, 
there are concerns inhaled antibiotics may not treat the systemic component of 
exacerbations or may not reach the area of infection due to reduced ventilation. This 
study aims to further our understanding of the efficacy, safety and microbiological 
implications of using inhaled antibiotics to treat acute exacerbations.  
3.1.2 How does this study meet the research needs of the CF community?  
A recent priority setting partnership, facilitated by the James Lind Alliance, helped 
define the top 10 list of priority clinical research questions in CF. [285] The process 
included elicitation and prioritisation surveys of patient and clinical communities. 
Investigating the use of inhaled antibiotics in the acute setting addresses three of the 
research priorities set out by the JLA process.  Additionally, a recent systematic 
review of areas which lack evidence for treatment decisions in CF highlighted a gap 
in the evidence for exacerbation management and determining most effective route 




supported by the recent Cochrane review of inhaled antibiotics for the treatment of 




 Study objectives 
 
Primary objective 
• To investigate whether there is immediate clinical benefit in the use 
of AZLI in acute exacerbations of CF. 
Secondary objectives 
• To investigate what effects AZLI+IV has on lung microbiology 
compared to IV+IV 
 
 Study design 
3.3.1 AZTEC-CF design 
 
AZTEC-CF was a single centre pilot study at Liverpool Heart and Chest Hospital NHS 
Foundation Trust (LHCH). LHCH is a regional CF centre in the north-west of England, 
the fifth largest centre in the country, delivering care to over 300 adults with CF. The 
study design was a randomised cross-over study comparing AZLI plus IV 
colistimethate (AZLI+IV) against standard care of two intravenous antibiotics (IV+IV). 
Each participant received both treatments in a random sequence across two 
separate acute exacerbations. AZLI+IV rather than dual inhaled antimicrobials was 
chosen given concerns the inhaled route alone may not treat any potential systemic 
component of an acute pulmonary exacerbation. Colistimethate was selected over  
tobramycin for a number of reasons. Firstly, colistimethate remains first-line 
treatment in the LES cohort at LHCH. The prevalence of LES is high at LHCH and 
overall colistimethate resistance remains low in this population. [286] Secondly, UK 
guidelines recommend a standardised dosing regimen for colistimethate of 2 MU 
TDS in adults with CF. [173] This negates the need for extra venepuncture and dose 
adjustments as compared to Tobramycin. It was felt by the study team that, given 




for prolonged courses would introduce an intolerable new risk of bias into study 
results and colistimethate was therefore considered preferential. Finally, the impact 
of each agent on lung microbiology was considered given the stated aims of the 
study. In order to be able to be able draw conclusions about the effects of AZLI+IV 
against IV+IV it was important to have some understanding of the likely effect of the 
IV agent used in both arms. Neither colistimethate nor tobramycin has been 
particularly well characterised in terms of their effects on the lung microbiota but 
colistimethate use has been rigorously tested in a sheep CF model. [287] 
Colistimethate was again felt to hold superiority over tobramycin in that regard and 
on those bases, it was included as the IV agent in both arms. 
 
The cross-over design, see Figure 3.3.1, was chosen in an attempt to mitigate some 
of the heterogeneity of CF exacerbations. Cross-over designs are not suitable in all 
circumstances but have been suggested to be particularly useful in evaluating 
interventions with a temporary effect in chronic but symptomatic conditions and it 
was therefore felt to be appropriate to apply this design to the treatment of 
pulmonary exacerbations of CF. [288,289] Furthermore, cross-over studies improve 
the statistical power of a study thereby requiring smaller samples sizes and 
improving the efficiency of the study. 
 
3.3.2 Funding 
AZTEC-CF was funded by an investigator supported research grant from Gilead 
Sciences (IN-UK-205-4065).  The funder had no role in the study conduct, data 




Figure 3.3.1:  AZTEC-CF study schem



























3.3.3 Eligibility criteria 
 
Inclusion criteria 
1. Confirmed diagnosis of CF  
2. Patients aged 16 - 65 years of age who can give informed consent 
3. FEV1 >25% or <75% predicted 
4. Receive inpatient treatment for acute pulmonary exacerbations of CF at LHCH 
5. Presence of P. aeruginosa in lower respiratory tract cultures in the 6 months 
prior to screening 
 
Exclusion criteria 
1. Documented allergy to beta-lactam antibiotics or IV colistimethate 
2. Growth of Burkholderia cepacia Complex (BCC) within 1 year 
3. Pregnancy 
4. Previous organ transplant 
5. Receiving other clinical trial medication 
6. Already prescribed regular AZLI 
7. Hypersensitivity reaction to AZLI excipient 
8. Hypersensitivity reaction to polymyxin B 
9. Patients with myasthenia gravis 





3.3.4 Study approvals 
Local approvals 
The study was approved locally by the Liverpool Heart and Chest Hospital Research 
and Innovation Committee following internal review and discussion at committee 
meeting (2016AZLIDN001/1124). The study concept, protocol and documents were 
also discussed and approved by the local patient group, the SURE group.  
Regulatory approvals 
Ethical approval was provided by the North West -Haydock Research Ethics 
Committee (16/NW/0741) in November 2016. MHRA clinical trial authorisation (CTA) 
was also received in November 2016 (21422/0007/001-0001). Health Research 
Authority approval was obtained in December 2016. The study was registered with 
EudraCT (2016-002832-34) and ClinicalTrials.org (NCT02894684). 
 Participant identification, recruitment and randomisation 
Participants were recruited from the outpatient clinic at the adult CF centre at 
Liverpool Heart and Chest Hospital NHS Foundation Trust. All potential participants 
were identified from the local registry using lung function and microbiology eligibility 
criteria. This approach identified 65 individuals and recruitment was by one of two 
approaches. Firstly, a patient information sheet (PIS) was posted to all potential 
participants individually to inform them of the study. Potential participants were 
asked, if interested, to contact a member of the research team. The second approach 
to recruitment was to approach potential participants directly in the outpatient 
department. In practice participants were recruited from both approaches, with 6/1 
recruited directly via the first approach and 10/16 via the second. More details are 
provided in Figure 4.3.1. 
3.4.1 Consent 
All participants interested in enrolling were seen by a member of the study team who 
explained the study in more detail, confirmed inclusion and exclusion criteria and 
obtained fully informed written consent. In practice this was performed in an 
85 
 
outpatient clinic appointment. Participants were only randomised to treatment at 
the time of their first admission, see 3.4.4. 
3.4.2 Baseline investigations 
At the time of consent, all patients received a unique identifier and baseline clinical 
characteristics (age, sex, genotype, lung function, body mass index, recent sputum 
microbiology, annual intravenous antibiotic days), past medical history and 
medication history were all recorded.  
3.4.3 AZLI test dose 
A test dose of AZLI was administered by a CF specialist physiotherapist in order to 
assess for side-effects or evidence of an exaggerated bronchoconstriction response. 
Severe wheeze or a post-dose drop in FEV1 of 10% was considered an exclusion to 
continuation within the study. 
3.4.4 Randomisation 
Block randomisation in groups of four was carried out prospectively using 
Statsdirect® (Statsdirect Ltd. 2013). A randomisation scheme was generated 
indicating the treatment arm each participant would initiate at the point of their first 
exacerbation. This was performed prospectively, and the randomisation scheme was 
referred to only at the point of randomisation. Point of randomisation was the point 
at which participants were admitted to Liverpool Heart and Chest Hospital for 
treatment of a protocol defined pulmonary exacerbation. 
3.4.5 Blinding 
Neither study investigators nor participants were blinded to the treatment during 
each admission. The different modalities of the respective interventions meant 
blinding would have required dummy or sham nebulisations and infusions. The 
logistical impediments this would have on the day to day running of the study were 
felt to make them practically infeasible. In an effort to minimise bias, outcomes were 
selected such that all measurements were objective and either measured or 




3.4.6 Definition of pulmonary exacerbation 
A pulmonary exacerbation was defined as per the modified Fuch’s criteria set out by 
the EuroCareCF working group in 2011:  
 Two or more of the following: 
• Change in sputum volume or colour 
• Increased cough 
• Increased malaise, fatigue or lethargy 
• Anorexia or weight loss 
• Decrease in predicted FEV1 or 10% or more 




 Study procedures 
3.5.1 Study interventions 
Over the course of two exacerbations, participants sequentially received 14 days of 
the two treatments detailed below. For IV+IV, antibiotic selection was at the 
discretion of the admitting clinician. 
Treatment A (AZLI+IV): 
AZLI 75mg TDS via nebuliser 
PLUS 
Colistimethate 2MU TDS intravenously 
 
Treatment B (IV+IV): 
Colistimethate 2MU TDS intravenously 
PLUS ONE OF: 
Meropenem 1g TDS intravenously, 
Piperacillin/tazobactam 4.5g TDS intravenously, 
Ceftazidime 3g TDS intravenously 
Aztreonam 2g TDS intravenously 
Fosfomycin 4g TDS intravenously 
 
A research prescription was supplied by the hospital pharmacy and included 14 days 
of stock for all components of the respective treatment. AZLI was administered via 
an eFlow® rapid nebuliser system (PARI Respiratory, Germany). The eFlow ® device 
is an electronic nebuliser which generates aerosols as liquid passes through a 
vibrating stainless-steel membrane. All late phase clinical trials of AZLI have used the 
eFlow® device and AZLI is therefore only licensed for use via this device. Instruction 
on the use of the device was provided to participants by specialist CF physiotherapist.  
3.5.1.1 Completion of 14 days treatment 
AZLI+IV and IV+IV were both continued for 14 days at which point participants could 
be discharged home, as long as the clinical team were satisfied with resolution of 
pulmonary exacerbation. If after 14 days of treatment the clinical team felt that the 
pulmonary exacerbation was not suitably resolved, then participants were switched 
to regular stock antimicrobial therapy consisting of two intravenous antibiotics 
selected in line with local formulary by the clinical team. The requirement for more 
than 14 days of antibiotics was recorded as an adverse event. 
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3.5.1.2 Early termination of treatment 
If the clinical team felt at any point that the allocated study treatment was failing to 
sufficiently improve clinical status and continuing was no longer in a participant’s 
best interests, then with the agreement of the participant, study treatments were 
discontinued and standard antimicrobial therapy selected from local formulary was 
commenced. Participants continued in the study and all routine assessments were 
performed as normal at day 7 and day 14 but early terminations of treatment was 
recorded by the study team and if associated with clear clinical deterioration the 
relevant adverse event reporting forms were completed.  
3.5.1.3 Concomitant medications and adjunctive therapies 
In order to ensure the study was pragmatically integrated with standard clinical care, 
there were no restrictions on concomitant medications or adjunctive therapies. 
Initiation and/or changes in both concomitant medications and adjunctive therapies 
were recorded at day 7 and day 14. 
 
3.5.2 Study Assessments 
Study assessments were conducted on day 1, 7 & 14 as set out in the schedule of 
events below. A tolerance of +/- 1 day was allowed. 
3.5.2.1 Day 1 
Participants were seen by a member of the study team who confirmed ongoing 
consent to participation and any remaining questions were answered. Spirometry (if 
not performed in the previous 24 hours) was performed and blood was collected for 
routine haematology and biochemistry. A quality of life questionnaire was 
completed by the participant and a fresh expectorated sputum sample was collected. 
3.5.2.2 Day 7 
On day 7, spirometry was performed, and participants were seen by a member of 
the study team who assessed any adverse events and recorded any changes in 




3.5.2.3 Day 14 
On day 14, the final day of treatment, participants were again seen by a member of 
the study team. Adverse events and changes in concomitant medications were 
recorded. Blood was collected for routine haematology and biochemistry. 
Spirometry was performed, a quality of life questionnaire was completed, and 
expectorated sputum collected. Participants were thanked for their on-going 
participation. 
 
3.5.2.4 Study completion 
Participants were considered to have completed the study at the point of their third 
admission with acute pulmonary exacerbation, such that days to next exacerbation 
from the second admission were recorded.  
3.5.2.5 Spirometry 
Spirometry was performed prior to study drug initiation on day 1, and then in the 
morning on day 7 and 14 of admission. If a participant had performed spirometry as 
part of an outpatient clinic <24 hours prior to admission, then this was deemed 
acceptable in lieu of a repeat day 1 spirometry. All spirometry was performed in the 
pulmonary function laboratory at Liverpool Heart & Chest Hospital by an accredited 
respiratory physiologist blinded to treatment allocation. Spirometry was performed 
in Spirostik™ (Geratherm Respiratory GmBH, Germany), Of primary interest was the 
forced expiratory volume in 1 second (FEV1), as percentage of predicted values. All 
predicted reference ranges were calculated using the Global Lung Initiative reference 
equations. [290] 
3.5.2.6 Blood sample collection 
Blood was collected on day 1, 7 and 14 in S-Monovette® blood collection tubes 








Table 3.5.1: Schedule of assessments for AZTEC-CF Study 
 
  
  Day 1 Day 7 Day 14 
Confirm consent x x x 
Medication history x x x 
Physical examination x x x 
Bloods x x x 
Spirometry x x x 
CFQ-R x   x 
Sputum sample x   x 
Assess for Adverse Events x x x 
Record adjunctive medication/therapies x x x 
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3.5.2.7 Health related quality of life 
Participants were asked to complete a CFQ-R questionnaire on day 1 and day 14. The 
CFQ-R is a validated disease specific health-related quality of life (HRQoL) tool. The 
questionnaire addresses a number of generic and disease specific domains including 
‘Physical’, ‘Vitality’, ‘Emotion’, ‘Eating’, ‘Treatment burden’, ‘Health Perceptions’, 
‘Social’, ‘Body Image’, ‘Role’, ‘Weight’, ‘Respiratory’ and ‘Digest’. The CFQ-R consists 
of 50 scaled questions which are weighted to give a score on a 0-100 scale for each 
domain, where a higher score indicates better HRQoL. CFQ-R domain scores were 
generated by the data input tool provided by the questionnaire developers 
(https://cfqr.github.io). 
3.5.2.8 Sputum collection 
Sputum was collected on day 1 and day 14. Participants were asked to expectorate 
into a sterile specimen collection pot which was immediately sealed and placed in a 
4oC fridge. Within 24 hours, samples were subsequently separated into three 2ml 
aliquots and flash frozen in liquid nitrogen prior to storage at -80oC.  
3.5.3 Concomitant medications and adjunctive therapies 
No restrictions were placed on participants with regards to concomitant medications 
or adjunctive therapies. All non-IMP related management decisions were left to the 
medical team looking after each participant. The use of concomitant medication and 
adjunctive therapies was recorded for comparisons between groups.  
3.5.4 Safety assessments 
Adverse events were assessed at Day 1, 7 and 14 and recorded in accordance with 
GCP and local trust policy. Operational definitions are presented in Table 3.5.2. 
Operational definitions for (S)AEs  
Adverse events were recorded in the CRF. If there was suspicion that the 
participants’ disease has progressed faster due to the administration of an IMP, then 
it was recorded and reported as an unexpected adverse event. Clinically significant 
derangements in the results of objective tests (e.g. bloods, spirometry) were 
recorded as adverse events. Any requirement for a prolonged course of antibiotics 
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beyond 14 days was recorded as an AE. All adverse events were recorded with clinical 
symptoms and accompanied with a simple, brief description of the event, including 
dates as appropriate via the Liverpool Heart and Chest Hospital local AE form. All 
adverse events were recorded until the day of completion of each trial arm.  
Recording and reporting of SAEs AND SUSARs  
All SAEs/SUSARs occurring from the time of start of trial treatment until 1-day post 
cessation of trial treatment were recorded and delivered to the Sponsor within 24 





Table 3.5.2: Operational definition for adverse events and adverse reactions in 





Adverse Event (AE) Any untoward medical occurrence in a participant to whom 
a medicinal product has been administered, including 
occurrences which are not necessarily caused by or related 




An untoward and unintended response in a participant to 
an investigational medicinal product which is related to any 
dose administered to that participant. 
The phrase "response to an investigational medicinal 
product" means that a causal relationship between a trial 
medication and an AE is at least a reasonable possibility, i.e. 
the relationship cannot be ruled out. 
All cases judged by either the reporting medically qualified 
professional or the Sponsor as having a reasonable 
suspected causal relationship to the trial medication qualify 
as adverse reactions. 
Serious Adverse 
Event (SAE) 
A serious adverse event is any untoward medical 
occurrence that: 
• results in death 
• is life-threatening 
• requires inpatient hospitalisation or prolongation of existing 
hospitalisation 
• results in persistent or significant disability/incapacity 
• consists of a congenital anomaly or birth defect 
Other ‘important medical events’ may also be considered 
serious if they jeopardise the participant or require an 
intervention to prevent one of the above consequences. 
Serious Adverse 
Reaction (SAR) 
An adverse event that is both serious and, in the opinion of 
the reporting Investigator, believed with reasonable 
probability to be due to one of the trial treatments, based 





A serious adverse reaction, the nature and severity of which 
is not consistent with the information about the medicinal 
product in question set out: 
• in the case of a product with a marketing authorisation, in 
the summary of product characteristics (SmPC) for that 
product 
• in the case of any other investigational medicinal product, in 





3.6.1 Primary endpoint 
1. Change in absolute % predicted FEV1 from Day 1 to Day 14 
3.6.2 Secondary endpoints 
1. Days to next protocol-defined pulmonary exacerbation   
-Defined as the need for intravenous antibiotics in the presence of 2 
or more criteria, see Section 3.4.6.  
2. Change in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory 
domain 
3. Change in sputum bacterial load from Day 1 to Day 14 
4. Change in serum inflammatory markers from Day 1 to Day 14 
5. Changes in aztreonam resistance from Day 1 to Day 14 
6. Changes in lung microbiota from Day 1 to Day 14 
 Protocol amendments 
Non-substantial amendment 1 
Initially the protocol excluded those people with CF under the age of 18 years. Non-
substantial amendment 1 changed the lower age limit from 18 to 16 years old to 
reflect the fact people with CF transition to the adult clinic at LHCH from the age of 
16 years onwards and are able to give fully informed consent. Excluding those 16-18 
years of age was therefore deemed inappropriate and the amendment was approved 
by the HRA on 9th June 2017. 
Non substantial amendment 2 
The second amendment to the protocol removed a day 28 outcome assessment. 
Participants enrolled early in the study reported coming back to hospital so soon 
after a 14-day inpatient stay was unappealing and often not feasible. A number of 
protocol deviations were logged in response to non-attendance at day 28 visit. Given 
day 28 spirometry is neither part of routine clinical practice nor a frequently reported 
as an exacerbation outcome measure, removal of this visit was felt unlikely to impact 
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the scientific merit, clinical relevance or safety of the trial. The amendment was 
approved by the HRA on 30th January 2018.  
 
 Statistical considerations 
Statistical analyses were conducted in RStudio (v1.0.136, R Studio Inc). After 
normality testing using the Shapiro-Wilk test, only lung function data was found to 
be distributed normally. Lung function is therefore presented as mean ± SD 
throughout, and all other outcomes are presented as median [IQR]. Between-
treatment comparisons e.g. comparison of change in lung function over 14 days 
between IV+IV and AZLI+IV, were conducted as intention to treat analyses and 
presented as mean or median difference [95% confidence interval] depending on 
normality of the outcome variable. Unpaired between-group comparisons were 
made using t-test or Mann-Whitney U test depending on normality. Paired data were 
compared using Wilcoxon signed-rank test. Unadjusted p-values are presented 






Chapter 4: Aztreonam Lysine for the Treatment of 
Exacerbations of CF: An Open-Label Pilot Randomised 
Crossover Study (AZTEC-CF) 
 
 Introduction 
The AZTEC-CF protocol is described in detail in Chapter 3. The Health Research 
Authority approved AZTEC-CF in December 2016 and the study opened for 
recruitment in January 2017. Three participants were withdrawn from the study 
prior to randomisation, see Figure 4.2.1. One participant withdrew consent, one 
participant no longer met the inclusion/exclusion criteria as they were commenced 
on chronic AZLI therapy prior to randomisation and one participant failed to attend 
for AZLI test dose and was therefore withdrawn from the study by the PI. A timeline 
of exacerbations and designated treatments is set out in Figure 4.2.2. 
 Results 
4.2.1 Study completion 
All 16 randomised participants successfully completed the first study arm.  Two 
participants withdrew prior to their second exacerbation and a further two did not 
exacerbate for a second time before study censorship in February 2019. Thus, 28 of 
a possible 32 exacerbations (87.5%) were completed and included for analysis. Of 
these, 24 exacerbations (12 pairs from participants who completed both treatment 
arms) were available for all statistical calculations. 
4.2.2 IV+IV arm antibiotics 
During the IV+IV arm, participants received intravenous colistimethate 2 Megaunits 
three times a day (TDS) along with another IV antibiotic selected on clinical grounds 








Antibiotic Dose Used, n (%) 
Meropenem 1g TDS 9 (56) 
Ceftazidime 3g TDS 6 (38) 
Piperacillin/Tazobactam 4.5g TDS 1 (6) 
TDS= Thrice daily dosing 
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4.2.3 Study participants 
Baseline demographics and clinical characteristics are presented in Table 4.2.2. 
Briefly, the median [IQR] age was 29.5 years [24.5 to 32.5], mean ± SD FEV1 was 52.4 
% ± 14.7, median BMI was 22.1 kg/m2 [19.2 to 23.6] and participants had received a 
median 26 days [13.8 to 45.8] of intravenous antibiotics in the preceding 12 months. 
No participants had ever received CFTR modulators. 10/16 (62.5%) were infected 
with the transmissible Liverpool Epidemic Strain of P. aeruginosa, 4/16 (25.0%) were 
co-infected with S. aureus and 3/16 (18.8%) co-infected with Aspergillus spp.  Despite 
males and females being distributed evenly within the LHCH clinics from which 
participants were recruited, only one female study participant was recruited and 
consented meaning the study cohort was predominantly male. At enrolment, 15/16 
(93.7%) participants were receiving an inhaled anti-pseudomonal antibiotic regimen: 
10/16 (62.5%) continuous inhaled colistimethate preparations, 4/16 (25.0%) 
monthly alternating inhaled colistimethate and tobramycin preparations, and 1/16 
(6.3%) alternate month tobramycin monotherapy alone. Chronic oral macrolide 
therapy was prescribed in 16/16 (100.0%). To allow comparison of clinical 
parameters between exacerbations, participant level data from day 1 of each 
exacerbation is presented in Table 4.2.3. Overall, there were no meaningful 
differences in median day 1 parameters across exacerbations and on an individual 
level there was evidence that inflammatory markers were similar across 
exacerbations given 75% of those with raised CRP at exacerbation 1, also had a raised 
CRP at exacerbation 2. Similarly, 87.5% of those with normal CRP at exacerbation 1 





































Table 4.2.2: Clinical characteristics of participants in the AZTEC-CF study, with 
comparison by allocated sequence.  
Data presented as n (%), median [IQR] or mean ± SD. 
 
    AZLI+IV/IV+IV IV+IV/AZLI+IV All 
Demographics       
 Age 28.9 [25.4, 30.3] 29.7 [22.4, 33.1] 29.5 [24.5, 32.5] 
   Sex, male 7 (87.5) 8 (100) 15 (93.8) 
   Phe508del homozygous 8 (100) 3 (7.5) 11 (68.8) 
   Phe508del heterozygous 0 (0.0) 5 (62.5) 5 (31.2) 
   FEV1, % predicted  47.9 ± 14.4 56.9 ± 14.5 52.4 ± 14.7 
   BMI, kg/m2 22.6 [21.2, 25.0] 20.0 [19.1, 22.3] 22.1 [19.2, 23.6] 
   Annualised IV days 26.0 [20.0, 35.3] 20.50 [6.8, 45.8] 26.0 [13.8, 45.8] 
   Pancreatic insufficiency 6 (75.0) 8 (100.0) 14 (87.5) 
   GORD 5 (62.5) 6 (75.0) 11 (68.8) 
   CFRD 6 (75.0) 5 (62.5) 11 (68.8) 
Microbiology    
   P. aeruginosa 8 (100.0) 8 (100.0) 16 (100.0) 
   Liverpool Epidemic Strain 5 (62.5) 5 (62.5) 10 (62.5) 
   S. aureus 4 (50.0) 0 (0.0) 4 (25.0) 
 NTM    
   M. avium complex 0 (0.0) 1 (12.5) 1 (6.2) 
   M. abscessus complex 1 (12.5) 2 (25.0) 3 (18.8) 
   Aspergillus spp. 2 (25.0) 1 (12.5) 3 (18.8) 
Long-term oral medication    
   Macrolide 8 (100.0) 7 (87.5) 15 (93.8) 
   Proton pump inhibitor 8 (100.0) 4 (57.1) 12 (80.0) 
   Ursodeoxycholic acid 6 (75.0) 4 (50.0) 10 (62.5) 
   Dornase Alfa 6 (75.0) 6 (75.0) 12 (75.0) 
Nebulised therapies       
 Colistimethate 6 (75.0) 4 (50.0) 10 (62.5) 
 Tobramycin  1 (12.5) 0 (0.0) 1 (12.5) 
  Both   0 (0.0) 4 (50.0) 4 (25.0) 
 
Abbreviations: FEV1=Forced expiratory volume in 1 second; BMI=Body Mass Index; 





Table 4.2.3: Participant level data for Day 1 clinical variables across exacerbation 




Absolute Drop in % 
predicted FEV1 
from best in  
previous 6-months  












Study ID Exac. 1 Exac. 2 Exac. 1 Exac. 2 Exac. 1 Exac. 2 Exac. 1 Exac. 2 
1 -19 -28 39 47 12.9 17.8 38.89 44.44 
2 -20 -16 9 4 11.6 12.6 33.33 44.44 
3 -21 -30 4 6 7.4 13.9 55.56 55.56 
4 -20 -17 4 5 4.5 4.9 61.11 55.56 
5 -13 -13 21 69 12.6 15.3 11.11 44.44 
6 -13 -22 26 68 10.8 10.6 27.78 22.22 
7 -46 -41 4 4 5.1 13.3 50.00 61.11 
8 -5 -4 4 7 12 11.3 61.11 44.44 
9 -8 -17 4 4 13.1 7.4 27.78 38.89 
10 -6  4  5.9  66.67  
11 -13 -9 40 7 22.3 13.9 72.22 83.33 
12 -11 -5 8 25 11.9 14.8 55.56 22.22 
13 -3  95  31.0  33.33  
14 -6  34  14.4  22.22  
15 -11 8 9 4 11.5 8.3 61.11 66.67 
16 -11  4  7.6  27.78  





4.3.1 Adjunct therapies  
Other routine CF treatments that might influence clinical response during an 
exacerbation (adjunct therapies) are presented in Table 4.3.1 & Table 4.3.2. 
Comparison of these adjunct therapies confirmed no intrinsic differences between 
treatment arms, see Table 4.3.3. 
 
4.3.2 No evidence of carry-over effect between exacerbations 
A “carry-over” effect can bias estimation of treatment effects in cross-over studies. 
To assess for any such effect, the average sum of day 14 improvements were 
compared between participants randomised to AZLI+IV followed by IV+IV (Group AB) 
and those randomised to IV+IV followed by AZLI+IV (Group BA) as previously 
described. [288] The null hypothesis tested here is that carry-over effects are equal 
between groups and results are presented in Table 4.3.4. No significant differences 
were observed between allocation groups for any of the outcomes of interest, 






Table 4.3.1: Adjunct therapies - AZLI+IV Arm 








Abbreviation: HTS=Hypertonic saline; SCTI=Subcutaneous terbutaline infusion 
  
Table 4.3.2: Adjunct therapies - IV+IV Arm 
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Table 4.3.3 Comparison of acute adjunct and chronic therapies prescribed during 
each exacerbation. 




 AZLI+IV IV+IV 
n 12 16 
Acute adjuncts   
Nebulised bronchodilators 12 (100%) 16 (100%) 
Oral corticosteroid 11 (91.7) 15 (93.8) 
Dose, mg 30.0 [27.5, 30.0] 30.0 [30.0, 30.0] 
Aminophylline infusion 2 (16.7) 3 (18.8) 
Subcutaneous terbutaline  
infusion 10 (83.3) 12 (75.0) 
Chronic therapies   
Azithromycin 12 (100.0) 16 (100.0) 
 
Hypertonic saline 8 (66.7) 11 (68.8) 
Dornase alfa 11 (91.7) 15 (93.8) 
Initiated during 
admission 0 (0.0) 2 (12.5) 
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Table 4.3.4  Mean differences between sums of Day 14 measurements between 
groups AB (AZLI+IV followed by IV+IV) and BA (IV+IV followed by AZLI+IV) 





Day 14 outcome Differences 95% CI p-value 
Systemic inflammatory markers    
White blood cell count 2.45 -12.6 to 17.5 0.68 
Neutrophils 2 -12.7 to 16.7 0.74 
Platelets 20 -147 to 187 0.78 
C-Reactive Protein 5.375 -1.58 to 12.33 0.11 
Change in White blood cell count 0.85 -10.4 to 12.1 0.86 
Change in neutrophils 0.91 -6.54 to 8.36 0.78 
Change in platelets -21.85 -125.6 to 81.9 0.63 
Change in C-reactive protein 20.75 -26.3 to 67.8 0.32 
    
Lung function    
FEV1 (% predicted) -11.5 -46.8 to 23.8 0.46 
Change in FEV1 (% predicted) -10.875 -28.6 to 6.85 0.18 
Change in Fev1 (litres) -0.501 -1.237 to 0.235 0.14 
    
Quality of life    
CFQ-R Respiratory 
Domain 0.7 -52.5 to 53.9 0.98 
Change in CFQ-R Respiratory 
Domain -6.95 -45.8 to 31.9 0.69 
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4.3.4 AZLI+IV and IV+IV are both associated with improved lung function 
over 14 days 
On day 1, lung function was similar between AZLI+IV (mean ± SD % predicted FEV1 
50.4%   ± 12.5) and IV+IV (53.1% ± 17.4), mean [95% CI] difference between groups -
2.6 [-15.0 to 9.0], p=0.46. Equally, on day 1, decline in % predicted FEV1 from 
previous 6-month best was similar between groups (-18.4% for AZLI+IV and -14.4% 
for IV+IV, mean [95% CI] difference 4.0 [-5.2 to 13.2], p=0.37). After 7 days treatment 
with AZLI+IV, lung function had significantly increased (mean [95% CI] absolute 
improvement in % predicted FEV1: +9.6% [3.2 to 16.2], p=0.007).  After 14 days of 
treatment, lung function had improved +13.5% [6.5 to 20.5], p=0.001, see Figure 
4.3.1A. In the IV+IV group, significant improvements from baseline were also 
observed such that by day 7, FEV1 had improved +7.9% [1.6 to 14.3], p=0.02 and by 
day 14 mean improvement was +8.3% [3.2 to 13.4], p=0.003, see Figure 4.3.1B. 
 
4.3.5 Primary outcome: 
4.3.5.1  AZLI+IV is associated with greater lung function improvement than IV+IV 
at day 14 
Participants whom completed both treatment arms were next included in a paired 
analysis for the primary outcome. After 14 days of treatment, AZLI+IV was associated 
with significantly greater lung function improvement from baseline than IV+IV 
(+13.5% ± 11.0 vs. +8.8% ± 10.1, mean [95% CI] paired treatment difference +4.6% 







Figure 4.3.1: Absolute change in % predicted FEV1 for AZLI+IV (A) and IV+IV (B) 
and paired between-treatment comparison at day 14 (C).  
Data are presented as box and whisker plots with lines linking individual study 









































































































4.3.6 Secondary outcomes 
4.3.6.1 Similar time to next exacerbation for each treatment 
 
Time to next exacerbation was similar between treatments. For the IV+IV treatment 
median (95% confidence interval) time to next exacerbation was 152 days [64-300] 
and for the AZLI+IV treatment 140 days [89-318], log-rank p= 0.93, see Figure 4.3.2 
  
Figure 4.3.2: Kaplan-Meier plot for time to next exacerbation after IV+IV (Blue) 
and AZLI+IV (Orange).  
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4.3.6.2 No difference between treatments for changes in systemic inflammatory 
markers 
White blood cells 
Median [IQR] serum white blood cell counts were similar between groups at 
treatment initiation (AZLI+IV arm: 12.3 [11.3, 13.0] x 109/ml, IV+IV arm: 11.8 [7.6, 
14.5] x 109/ml, p=0.98) and leucocytosis was present in 9/16 (56.3%) and 9/12 
(75.0%) participants receiving IV+IV and IV+AZLI respectively (p=0.34). Neither 
treatment was associated with significant differences in white blood cell count 
between day 1 and day 14 and there was no significant difference between 
treatments (median [95% CI] paired difference at day 14: 0.4 [-3.1, 4.5] x 109/ml, 
p=0.73), see Figure 4.3.3. Of those participants with leucocytosis on day 1, two 
participants in each arm had a normal white blood cell count at day 14, (p>0.99)  
 
C-reactive protein 
On day 1, median [IQR] CRP was equal between groups (AZLI+IV: 7.0 mg/L [<5.0, 
22.3] vs. IV+IV: 7.0 mg/L [<5.0, 40.5], p=0.6) and an elevated CRP was present in 7/12 
(58.3%) and 9/16 (50.0%) participants in the AZLI+IV and IV+IV groups respectively. 
Paired samples were available for 10/12 participants completing both treatments. Of 
those with an elevated CRP on Day 1, 4/7 (57.1%) in the AZLI+IV group had normal 
CRP at Day 14 compared to 7/9 (77.8%) in the IV+IV group, p=0.44. There were no 
significant differences in changes in CRP at day 7 or day 14 overall (median [95% CI] 
difference 4.0 [-9 to 26], p=0.40), see Figure 4.3.4. 
 
When only those with a raised CRP on day 1 were considered, median [IQR] day 1 
CRP was 34 mg/L [9 to 68] for the IV+IV group and 21 mg/L [8 to 39] for the AZLI+IV 
group. After 7 days of treatment, CRP had fallen to 15 mg/L and 10 mg/L respectively, 
median [95% CI] differences between groups 17 mg/L [-6 to 45], p=0.15. After 14 
days of treatment, median CRP in both groups was <5 mg/L and although reductions 
in CRP at day 14 were numerically greater in the IV+IV, there were no statistically 










































Figure 4.3.4: Paired changes in CRP (mg/L) after 14 days treatment with IV+IV 






























Figure 4.3.3: Paired changes in white blood cell count (109/ml) after 14 days 
treatment with IV+IV (blue) and AZLI+IV (orange).  
Comparison by Wilcoxon signed-rank test 
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4.3.6.3 Relevant improvements in quality of life achieved more often with AZLI+IV 
 
The Cystic Fibrosis Questionnaire-Revised (CFQ-R) score is a health-related quality of 
life tool validated in the CF setting. During pulmonary exacerbations, a minimum 
clinically important difference (MCID) has been validated as 8.5 points for the CFQ-R 
Respiratory domain. [291] AZLI+IV was associated with median [IQR] improvement 
in CFQ-R Respiratory domain scores of +11.1 [11.1, 18.1]. This change was not 
significantly different from that seen in the IV+IV arm where a median improvement 
of +8.3 [-1.4, 18.1] was observed, median paired differences 8.3 [-22.2 to 33.3], 
p=0.73 see Figure 4.3.5. However, the validated MCID was achieved more frequently 
with AZLI+IV where 10/12 (83.3%) participants achieved an improvement in CFQ-R 
Respiratory Domain of ≥8.5 points, compared with 7/16 (43.8%) in the IV+IV arm, 
Fisher’s exact test p=0.04. 
4.3.6.4 Similar safety profiles between treatments 
 
Adverse events were reported during the study in 10/16 (62.5%) participants. The 
proportion of participants experiencing an adverse event was identical between 
AZLI+IV and IV+IV treatment periods respectively: 6/12 (50%) vs. 8/16 (50%), p>0.99. 
All adverse events are presented in Table 4.3.5. The most common adverse event 
was the need for prolonged antibiotics beyond 14 days of trial treatment which 
occurred in 7/28 (25%) admissions and was seen similarly in the AZLI+IV and the 
IV+IV treatment periods: 3/12 (25.0%) and 4/16 (25.0%) respectively. Other 
treatment-emergent adverse events seen similarly across both treatment groups 
included rise in serum C-reactive protein (AZLI+IV: 1/12 (8.3%) vs. IV+IV: 2/16 
(12.5%), p=0.39) and pyrexia (AZLI+IV: 2/12 (16.7%) vs. IV+IV:  1/16 (6.3%), p=0.22). 
Aggravated cough was reported by 2/12 (16.7%) participants during the AZLI+IV 
treatment but by 0/16 (0%) during the IV+IV arm (p=0.16), whereas headache was 
reported in 2/16 (12.5%) participants during the IV+IV arm and 0/16 (0%) during the 































Figure 4.3.5: Paired changes in CFQ-R Respiratory Domain for IV+IV (blue) and 
AZLI+IV (orange).  













Total patients reporting an  
adverse event 6 50.0% 8 50.0% 
0.70 
Adverse event      
>14 days antibiotic therapy required 3 25.0% 4 25.0% >0.99 
Drop in lung function 1 8.3% 0 0.0% 0.23 
Pyrexia 2 16.7% 1 6.3% 0.38 
Raised inflammatory markers 1 8.3% 2 12.5% 0.72 
Headache 0 0.0% 2 12.5% 0.20 
Cough 2 16.7% 0 0.0% 0.10 
Nausea 0 0.0% 1 6.3% 0.38 
Bloating 1 8.3% 0 0.0% 0.23 
Musculoskeletal pain 0 0.0% 1 6.3% 0.38 
Comparison by Fisher’s exact test. Not significant (NS)= p>0.05 
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4.3.7 Exploratory baseline characteristic subgroup analysis 
 
A number of exploratory subgroup analyses were undertaken in order to assess 
whether any baseline characteristics were associated with different treatment 
outcomes. Caution must be taken when interpreting these findings due to low 
numbers included in these analyses. 
 
A two-way analysis of variance tested the interaction between LES status and change 
in lung function for each treatment. No significant interaction for LES on treatment 
responses observed, see Figure 4.3.6 and Table 4.3.6. The influence of co-colonising 
species on treatment outcomes was examined by testing the effect of recognised CF 
pathogens S. aureus, Aspergillus spp. and NTM on changes in lung function at day 14. 
For the purposes of this analysis co-colonisation was considered as at least one 
growth of that organism within the previous 12 months. Additionally, further analysis 
including the presence of ABPA was also undertaken.  No effects on treatment 
outcomes were observed for either the co-colonising pathogens or a diagnosis of 






Table 4.3.6 Two-way analysis of variance between lung function changes at day 
14, treatment arm and Liverpool epidemic strain 
  
  Df Sum Squares Mean Squares F p 
Treatment 1 178 178 1.7 0.21 
LES 1 45 45 0.4 0.52 
Interaction 1 4 4 0.03 0.86 
Figure 4.3.6:  Comparison of changes in lung function between treatment groups 




























LES−   LES+
Comparison by Wilcoxon signed-rank test 
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4.3.7.1 Elevated systemic inflammatory markers at admission 
 
This subgroup analysis focussed on whether different treatment efficacy was seen 
between those participants with and without raised inflammatory markers at 
admission. Overall, an elevated C-reactive protein at admission was associated with 
poorer improvement in lung function at day 14 (mean difference 9.0% predicted 
FEV1 [0.0 to 17.0], p=0.05). However this pattern was seen in both treatment groups, 
see Figure 4.3.8, and two-way analysis of variance showed no evidence of an 
interaction between C-reactive protein and Treatment group, see Table 4.3.8. 
Similarly, an elevated white blood cell count at admission was associated with poorer 
lung function improvements at day 14 (mean difference 9.9% [0.1 to 17.1], p=0.05) 
and this effect was similar across groups, Figure 4.3.8 and Table 4.3.9. Taken together 
these results suggest participants with raised systemic inflammatory markers on Day 




Table 4.3.7: Two-way analysis of variance between lung function changes at day 




























Abbreviations: ABPA=Allergic bronchopulmonary aspergillosis. NTM=Non-tuberculous 
mycobacteria
 Df Sum Squares 
Mean 
Squares F p 
Treatment 1 178 178 1.8 0.19 
S. aureus 1 262 262 2.7 0.12 
Interaction 1 16 16 0.2 0.69 
      
  Df Sum Squares 
Mean 
Squares F P 
Treatment 1 178 178 1.6 0.22 
ABPA 1 0.1 0.1 0.1 0.97 
Interaction 1 3.6 3.6 0.03 0.86 
      
  Df Sum Squares 
Mean 
Squares F p 
Treatment 1 178 178 1.8 0.20 
Aspergillus 
spp. 1 241.3 241.3 2.4 0.13 
Interaction 1 1.4 1.4 0.01 0.91 
      
  Df Sum Squares 
Mean 
Squares F P 
Treatment 1 178 178 1.6 0.21 
NTM 1 41.6 41.6 0.4 0.54 




























































































































NTM −   NTM +
D
Figure 4.3.7: Comparison of change in lung function based on history of positive sputum 
culture for S. aureus (A), Aspergillus spp. (C) and NTM (D), or history of ABPA (B).  







Table 4.3.8: Two-way analysis of variance between lung function changes at day 
14, treatment arm and elevated C-reactive protein (CRP) 
 
 
 Df Sum Squares Mean Squares F p 
Treatment 1 178 178 2.0 0.17 
Elevated CRP 1 474 474 5.3 0.03 




Table 4.3.9: Two-way analysis of variance between lung function changes at day 




 Df Sum Squares Mean Squares F p 
Treatment 1 178 178 2.2 0.15 
Elevated WCC 1 566 566 7.0 0.01 






CRP=C-reactive protein; WCC=White blood cell count 
 
Figure 4.3.8: Comparison of changes in lung function between treatment groups 
based on C-reactive protein (A) and white blood cell count (B) at treatment 





























































4.3.8 Primary outcome sensitivity analyses 
4.3.8.1 Primary outcome is robust regardless of FEV1 reporting method 
Potential bias exists in the reporting of lung function improvements in terms of 
absolute changes of % predicted FEV1. Whilst reporting in this manner is common, 
and easily interpretable for clinicians and people with CF alike, a 10% absolute 
improvement in FEV1 is less clinically significant for those with a baseline FEV1 of 
80% predicted than those with a baseline FEV1 of 40% predicted, where it would 
represent a proportional increase of 12.5% and 25% respectively. In order to 
establish whether differences in day 1 FEV1 measurements could have biased 
results, three further analyses were undertaken. [292,293] 
 
Firstly, a day 1, between-treatment comparison was undertaken for FEV1 expressed 
in terms of volume and also % of predicted.  No significant differences were observed 
at baseline between AZLI+IV and IV+IV for FEV1 expressed in litres (2.6 ± 0.7 vs. 2.6 
± 0.91, p=0.69) or as percentage of predicted FEV1 (63.9% ± 16.0 vs. 63.3% ± 21.7, 
p=0.82), see Figure 4.3.9A and Figure 4.3.9B. Secondly, a two-way analysis of 
covariance (ANCOVA) was performed to assess for an interaction between absolute 
changes in % predicted FEV1 at day 14 and day 1 FEV1. No significant effect for 
baseline FEV1 on change in FEV1 at day 14 was seen once controlled for treatment 
arm (F-statistic 0.63 on 3 and 23 degrees of freedom, p=0.60).  
 
Finally, changes in FEV1 at day 14 were expressed as a proportion of FEV1 on day 1, 
such that a comparison of relative, rather than absolute improvements in lung 
function could be performed. At day 14, IV+IV was associated with a relative 19.8 % 
± 22.9 improvement in FEV1 from day 1, compared to 29.3 % ± 25.1 improvement 
for AZLI+IV (mean differences 9.5 % [1.3 to 17.7], p=0.03), see Figure 4.3.9C.  Taken 
together, the results of these analyses confirm the superior absolute FEV1 (% 
predicted) improvements associated with AZLI+IV in the primary analyses are not as 
a result of differing baseline lung function and are robust when considered as both 




4.3.8.2 Primary outcome analysis is robust in a per-protocol analysis 
 
There was a need for further antibiotic treatment beyond 14 days for 3 participants 
after the AZLI+IV treatment and 4 participants after the IV+IV treatment. To test 
whether the primary analysis was robust when these participants were excluded, a 
per-protocol analysis, rather than intention to treat analysis was performed.  
 
The 7 exacerbations requiring prolonged antibiotic therapy occurred in 6 
participants. Of those, 4 completed both arms and were included in the primary ITT 
analysis. With these participants excluded, 8 participants who had completed both 
arms remained for inclusion in a per-protocol analysis group. In this group after 14 
days treatment with AZLI+IV, the mean ± SD improvement in % predicted FEV1 was 
+18.5% ± 11.0 in comparison to +13.5% ± 8.3 for the IV+IV treatment (mean [95% CI] 
treatment differences +5.0% [0.9 to 9.1], p=0.02). 
 
4.3.9 Decline from baseline and subsequent recovery of lung function 
 
To evaluate the decline from baseline on day 1 for each treatment the difference 
between day 1 FEV1 (% predicted) and best FEV1 (% predicted) in the preceding 6 
months was calculated. The overall median day 1 drop from preceding best was -
14.5% [10.5 to 20.3]. There were no significant differences between AZLI+IV and 
IV+IV in terms of day 1 drop from preceding best (median difference [95% CI] +1.4% 
[-6.0 to 17.0], p=0.69]. Recovery of lung function (defined as achieving >90% of the 
best FEV1 from the preceding 6 months, as previously described [294,295], was 
















Figure 4.3.9: Pairwise comparison of lung function on day 1, expressed in volume 
(A) and as % predicted (B). Relative improvements in FEV1 (% predicted) at day 


























































   
   
   
   
   
   

















This is the first prospective study of the use of AZLI for the treatment of acute 
pulmonary exacerbations in people with CF and showed the combination of AZLI and 
intravenous colistimethate was associated with significant improvement in lung 
function after 14 days. Furthermore, the cross-over study design allowed a paired 
analysis, which confirmed the improvements after 14 days of the AZLI treatment arm 
were significantly greater than those seen for standard dual intravenous antibiotic 
therapy.  In addition to the superior lung function improvements seen in the AZLI 
treatment arm, more participants achieved the MCID for CFQ-R Respiratory domain 
following the AZLI treatment arm than after standard intravenous therapy. 
 
The superior improvements seen here for the AZLI+IV treatment equated to an extra 
4.6% predicted FEV1 at day 14 and were robust when considered as absolute 
improvements, relative improvement or when adjusted for baseline FEV1. For both 
treatments, the majority of lung function improvement was achieved in the first 
week and relative improvements were similar between groups at day 7 suggesting 
the difference between treatments was established in the second week. Indeed the 
IV+IV group saw limited lung function improvement in the second week in keeping 
with previous studies of CF exacerbations, where intravenous antibiotic treatment 
has been found to improve FEV1 dramatically in the first week of treatment but 
plateau in the second week and average time to peak FEV1 is approximately 8-9 days. 
[296–299] A poor FEV1 response during treatment for an exacerbation is associated 
with failure to recover pre-exacerbation lung function and occurs in up to 25% of 
exacerbations treated with dual intravenous antibiotics. [148,277,299,300] In that 
regard, the continued improvements observed in the second week of treatment with 
AZLI+IV and subsequent superiority over the current standard practice of dual 
intravenous antibiotics may therefore be of particular clinical significance.  
 
Inhaling antibiotics for the treatment of acute chest infections is not a novel 
approach given clinical trials were conducted as early as the 1980s. [247–249] Those 
early studies simply re-purposed intravenous preparations and administered them 
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via a nebuliser, a crude approach given some constituents of intravenous antibiotics 
are associated with lung irritation, early results were unsurprisingly mixed. 
 
Although a large observational study in the US in 2012 reported ~10% exacerbations 
were treated with inhaled antibiotics in combination with intravenous antibiotics, it 
is not clear whether this was the addition of a new inhaled antibiotic or simply 
continuation of long-term inhaled therapies.[225] Outcome data for the 
combination of inhaled and intravenous antibiotics were not reported, however it 
was observed that inhaled plus oral antibiotics were superior to oral antibiotics 
alone. [225] Only one other prospective clinical trial of an antibiotic optimised for 
inhalation in the acute setting has been reported. There, tobramycin nebuliser 
solution was found to hold superior clinical benefits over IV tobramycin, in terms of 
time to next exacerbation and also renal safety outcomes. [251] The recent 
expansion of available inhaled antibiotics should allow further investigation of 
inhaled antibiotics as a treatment strategy in CF pulmonary exacerbations.   
 
There are good reasons to expect inhaled antibiotics to be effective in the treatment 
of acute pulmonary exacerbations given the delivery of much greater antibiotic 
doses to the airways, with considerably less systemic exposure. The higher 
concentration of antibiotic in the lung could theoretically reduce development of 
antimicrobial resistance whilst also reducing the risk to the patient of drug toxicity.  
 
Whilst the reduced systemic exposure associated with AZLI may be considered a 
benefit in terms of reduced toxicity, it could also be perceived as a potential 
limitation. For example, some exacerbations are associated with significant systemic 
inflammation and the reduced systemic absorption of inhaled therapies may 
represent insufficient treatment in those circumstances. To investigate this, serum 
white cell counts and CRP were compared before and after each treatment. Neither 
standard dual intravenous therapy nor AZLI+IV were associated with changes in 
white blood cell counts at day 14, a surprising finding given reductions in white blood 
cell counts have been reported previously following intravenous antibiotic treatment 
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[301,302]. However, in contrast to those previous studies where concurrent 
corticosteroid use was 0% and 17% respectively, in the present study nearly all 
participants received systemic corticosteroids. Thus, any effect on white blood cell 
counts may have been masked by the prolonged neutrophil survival associated with 
corticosteroid therapy.  [303] 
 
CRP is well validated as a predictor of treatment outcomes in CF pulmonary 
exacerbations, where an elevated CRP at admission  is associated with reduced 
treatment response and shorter time until next exacerbation. [104,281,282] Here, in 
keeping with prior work, a raised CRP at treatment initiation was associated with 
poorer response to treatment. [238] This effect was similar across both treatment 
groups and overall reductions in CRP at day 14 were similar between the two 
treatment groups. Importantly, in those with raised CRP at day 1, rates of 
normalisation at day 14 were also similar between treatments. Taken together, there 
is no evidence to suggest IV+IV modulated systemic inflammation superiorly to 
AZLI+IV.  
 
In the survey of UK CF clinicians set out in Chapter 2, another concern was identified 
regarding low systemic concentrations of inhaled antibiotics during exacerbations. 
This concern related to the deposition of inhaled antibiotics at the site of infection, 
where airways may be plugged with mucus. Little is known about the fate of inhaled 
antibiotics beyond the central airways, but areas of infection may be associated with 
increased mucus production, plugging of the airways, subsequent localised 
ventilation defects and thus potentially reduced penetration and antimicrobial 
activity for an agent delivered via the inhaled route. In that scenario, high systemic 
concentrations of antibiotic may be required to deliver antibiotic via the pulmonary 
vasculature. Computational flow dynamics have been used in attempts to model AZLI 
deposition in the small airways and suggested that small airways in more diseased 
lobes received a lower dose of AZLI than other parts of the lung, yet even those 
airways with lower deposition were generally predicted to have concentrations 10-
fold greater than the MIC90. [245] This study is unable to answer questions regarding 
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deposition and penetration of AZLI within the lung, but the positive effects seen on 
lung function and quality of life are reassuring that antibiotic deposition is adequate 
when given by the inhaled route.  
 
The cross-over design used in this study allowed each participant to act as their own 
control and increased the statistical efficiency of the study. Cross-over studies have 
been used frequently in CF research over the years and the Cochrane Cystic Fibrosis 
and Genetic Disorders Group recently identified over 200 cross-over trials included 
in their reviews. [289] However, the use of this design has previously attracted 
controversy, mostly due to the risk of carryover effects. For example, in an early 
study of long-term macrolide therapy published in the Lancet it was later suggested 
that a carryover effect may have accounted for some of the observed treatment 
effect. [304] Subsequently, parallel studies have been suggested as preferable to 
cross-over studies where additional arguments against cross-over studies include 
increased length of study, treatment periods and risk of exacerbation requiring 
discontinuation of participation in the trial. [305] Concerns regarding washout 
periods and carry-through effect are largely negated in acute pulmonary 
exacerbations as any benefit from treatment of a previous exacerbation has, almost 
by definition, been lost at the time of the next exacerbation. Equally, concerns 
regarding discontinuations due to exacerbations are irrelevant in this setting, where 
exacerbations and their management are the focus of research. A further concern 
regarding the applicability of crossover studies to the acute exacerbation setting it 
the theoretical variety in exacerbation endotype. Aetiological variation between 
exacerbations are likely to exist but remains poorly understood and, as such, 
treatments remain largely empirical and standardised regardless of aetiology. The 
crossover design therefore remains valid. Reassuringly, day 1 clinical parameters 
such as drop in lung function and inflammatory were similar between exacerbations. 
An important advantage of the cross-over design in acute exacerbation is the 
possibility of paired analysis, which not only increases statistical efficiency meaning 
fewer participants are required, but also reduces the inter-personal variation that 
exists between CF exacerbations. This study confirms that cross-over studies are 
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feasible in the CF exacerbation setting and may serve as a useful model for future 
studies in this area.  
 
There are a number of limitations to consider for this study. The study sample-size 
was small and conducted in a single-centre, hence the generalisability is uncertain. 
The cross-over design increased the statistical power sufficiently to discern the 
positive effect of AZLI+IV on lung function, however the study was likely 
underpowered to find statistical differences in the sub-group analyses, which should 
be considered exploratory. Future larger studies would allow more certain 
conclusions to be drawn in terms of differences between treatments for 
inflammation, quality of life and safety outcomes. Future studies will be informed by 
the findings in this study, both in terms of power calculations, but also in terms of 
feasibility and recruitment. The despite similar numbers of women and men being 
screened, recruitment of only one female participant in this study is an important 
limitation and will need to be considered in future studies to ensure generalisability 
of results. 
 
In terms of inflammation, only systemic inflammation was measured and hence no 
assessment of the effect of AZLI+IV on airway inflammation was made. Intravenous 
antibiotic treatment of exacerbations effectively resolves systemic inflammation but 
has less impact on airway inflammation, further studies are required to examine 
whether an inhaled antibiotic approach could modulate airway inflammation in 
exacerbations. [283,306] 
 
Participants were not blinded to treatment and hence there exists an intrinsic source 
of bias in that regard. Blinding of two different treatment modalities is practically 
challenging in this setting and would result in considerably increased treatment 
burden for the study participants. Fourth, allowing clinician discretion as regards the 
second IV antibiotic in the IV+IV arm restricts some of the conclusions that can be 
drawn from this data. Consideration of mandating aztreonam as the second 
intravenous agent in the IV+IV treatment group was given but opted against given IV 
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aztreonam is not used routinely as a first line anti-pseudomonal during acute 
exacerbations. It would thereby not serve as a relevant comparator, particularly 
when considering the relevance of this study to future larger studies.  A pragmatic 
decision was therefore taken to allow clinician discretion regarding the second IV 
antibiotic, such that the IV+IV group was a “real-world” comparator group. 
 
A further limitation lies in the pre-specified decision to limit study treatment to 14 
days. A quarter of patients required prolongation of treatment beyond 14 days, 
however we did not record reasons for need of >14 days treatment and are therefore 
unable to evaluate possible trends in the requirement for treatment prolongation   
[224]  
 
The strengths of this study lie in the successful completion of nearly 90% treatment 
periods, the use of a cross-over design to demonstrate the efficacy of the AZLI+IV 
approach and rigorous documentation of adjunctive therapies to allow comparison 
between groups. Importantly, the findings of this study are relevant to the CF 
community and addresses a number of the top ten research priorities recently 
established by a James Lind Alliance, namely the need to identify which antibiotic 
combinations are effective in exacerbations and the need to reduce negative adverse 
effects of antibiotics. [285] [219]  Furthermore, the use of inhaled antibiotics during 
exacerbation has been highlighted by systematic reviews from Cochrane and others 
as an area in need of more evidence.  [252,284] 
 
In conclusion, this study demonstrates AZLI in combination with intravenous 
colistimethate, safely improves lung function and quality of life in acute pulmonary 
exacerbations of CF. Taken together with previous studies, these results support the 
notion inhaled antibiotics can represent a viable treatment approach for some acute 
pulmonary exacerbations and larger studies are warranted to confirm these findings 





Chapter 5: Changes in Bacterial Load and Aztreonam 
Resistance in the AZTEC-CF study 
 Introduction 
The AZTEC-CF study, described in detail in Chapter 3 & 4, tested the use of AZLI+IV 
against IV+IV for the treatment of acute pulmonary exacerbations of CF. The aims of 
this Chapter were firstly, to compare the effect of each treatment on bacterial load 
and aztreonam resistance, and secondly, to explore how any changes were 
associated with clinical outcomes. 
 Methods 
5.2.1 AZTEC-CF Study 
The AZTEC-CF study methods are set out in detail in Chapter 3. Briefly, AZLI plus 
intravenous colistimethate (AZLI+IV) was tested against standard care dual 
intravenous antibiotics (IV+IV) for the treatment of acute pulmonary exacerbations 
of CF. Each treatment course was 14 days with sputum sampling performed on Day 
1, prior to first antibiotic dose, and Day 14, after last dose of antibiotic.  
5.2.2 Sample collection 
Sputum samples were collected in sterile containers and immediately refrigerated at 
4oC for up to 24 h before being flash frozen in liquid nitrogen and stored at -80oC. 
Once defrosted, an equal volume of diethiothreitol 1.4% w/v (Sputasol, Oxoid, UK) 
was added before 30 min incubation at 37oC on a shaker at 300 rpm. Where sputum 
samples were of low volume, they were prioritised for culture independent analyses. 
5.2.3 Media preparation 
Four different media were prepared to facilitate calculation of total bacterial load, 
total P. aeruginosa load, aztreonam-resistant bacterial load and aztreonam-resistant 
P. aeruginosa load respectively. For total bacterial load a non-selective nutrient rich 
agar (Luria-Bertani Agar, Oxoid, UK) and for total P. aeruginosa load a Pseudomonas-
selective agar (Pseudomonas (CN) Selective Agar, Oxoid, UK) were prepared. To 
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evaluate the respective aztreonam-resistant loads, 16 µg/ml aztreonam, the 
reference minimum inhibitory breakpoint (MIC), dissolved in dimethyl sulfoxide was 
added to each media. [307] NB: It is important to note that where “total bacterial 
load” is referred to herein, it represents the total culturable load in standard culture 
conditions. Extensive culture including anaerobic cultures were not performed. 
5.2.4 Dilution series 
A dilution series for each sputum sample was created in sterile phosphate buffered 
saline (PBS) at concentrations down to 10-11 by the addition of 20 µl of sputum to 
180 µl of sterile PBS, vortexing thoroughly, then adding 20 µl of the vortexed mixture 
to 180 µl of PBS into a second tube and sequentially repeating that process. 
5.2.5 Quantitative Culture 
10 µl of each dilution was plated onto four media in triplicate. After 48 h incubation 
at 37oC, colonies were counted at the dilution where 10-100 colonies were visible. 
Colony forming units per millilitre (CFU/ml) were subsequently calculated as follows: 
 
CFU/ml =No. of colonies counted in plate segment x dilution factor x 2 x 100 
 
5.2.6 Quantitative polymerase chain reaction 
Determination of sputum bacterial load by quantitative polymerase chain reaction 
(qPCR) was undertaken by targeted amplification of the 16S rRNA gene as previously 
described. [308] Standards were generated by conventional PCR using the Promega 
GoTaq kit (Promega, UK) and the following cycling conditions: 2 min 95oC, 30 cycles 
of 30 secs 95oC, 1 min 60oC, 1 min 72oC, and a final extension step of 72oC for 5 mins. 
A dilution series of the amplified DNA of known copy number was made and five 
dilutions analysed in order to generate a standard curve.  
 
The Qiagen Rotorgene SybrGreen qPCR kit (Qiagen, UK) was used for qPCR. The 25 
µl reaction mix included: 12.5 µl SYBR green PCR master mix, 1 µl of forward (5’-
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TCCTACGGGAGGCAGCAGT-3’) and reverse (5’ GGACTACCAGGGTATCTAATCCTGTT-
3’) primer, 8.5 µl water and 2 µl DNA. Controls of RNase and DNase free water were 
also analysed in duplication. qPCR was carried out using a Qiagen rotor-gene, using 
a three step with melt method. Results were analysed using the two standard curves 
method. 
5.2.7 Electronic health record 
Metadata were collected from the local electronic health record (EHR) at Liverpool 
Heart and Chest Hospital with a focus on anthropomorphic data and prior antibiotic 
usage. The EHR (Allscripts®, Manchester, UK) has been in place since 2013 and 
routinely collects all intravenous antibiotic prescriptions made at LHCH into a 
structured database, allowing retrieval of total and individual intravenous antibiotic 
use from 2013 to 2017. 
5.2.8 Statistical analysis 
Statistical analyses were conducted in RStudio (v1.0.136, R Studio Inc). All CFU/ml 
data was log-transformed. Between-group comparisons were made using Mann-
Whitney or Wilcoxon’s signed-rank tests for unpaired and paired data respectively. 
Associations between continuous variables were tested using Pearson’s correlation 
coefficient. Unadjusted p-values are presented throughout and a significance level 





5.3.1 Study population 
Participants from the AZTEC-CF study with available pre and post sputum samples 
for at least one treatment arm were included. All participants in the AZTEC-CF study 
were AZLI naïve. The IV+IV arm was completed by 16 participants, of whom 13/16 
(88%) had paired sputum samples available for culture. The AZLI+IV arm was 
completed by 12 participants of whom 11/12 (92%) had suitable paired samples 
available.  The excluded participant provided two samples, but one was consistently 
overgrown with fungus, making interpretation of bacterial loads and AMR impossible 
and was thus excluded from analysis.  
 
On day 1, median [IQR] cultured total bacterial load was 6.4 log10CFU/ml [5.8 to 7.0] 
and total bacterial load detected by qPCR was 8.1 log10 16S copies/ml [7.7 to 8.6].  P. 
aeruginosa was detected in culture in all day 1 samples with a median [IQR] cultured 
load of 4.5 log10CFU/ml [3.2 to 4.5]. On day 14, P. aeruginosa was not cultured in 
2/11 (18.2%) and 1/13 (7.7%) for AZLI+IV and IV+IV respectively. 
 
5.3.2 Quantitative PCR correlates with cultured bacterial load 
Cultured bacterial load was consistently lower (median [IQR] difference -1.6 log10 
counts [-1.9 to -1.3], p<0.0001) than that measured by qPCR, but there was a 
moderate correlation between both measures (r= 0.54, p<0.001), see Figure 5.3.1. A 
Bland-Altman plot was drawn to compare agreement between the two 
measurement modalities and showed the difference between the two 
measurements was generally consistent across the range of observed bacterial 




Figure 5.3.1: Relationship between total bacterial load as measured by qPCR and 
quantitative culture (A). Bland-Altman plot (with mean and 95% CI represented 
by dotted lines) and marginal histogram demonstrating the degree of agreement 
and distribution between bacterial load measured by qPCR and quantitative 
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5.3.3 Changes in sputum bacterial load do not differ between treatments 
Changes in total bacterial and P. aeruginosa sputum load are presented in Table 5.3.1  
Overall, neither culturable total bacterial load nor P. aeruginosa load had 
significantly changed following either treatment (p=0.69-0.99); see Figure 5.3.1 & 
Figure 5.3.2. On an individual level, after 14 days AZLI+IV 5/11 (45%) participants had 
reductions ≥1 Log in sputum P. aeruginosa load in comparison to 3/13 (23%) in the 
IV+IV group (Fisher’s exact p=0.36). There was wide variation in changes ranging 
from -2.0 log10CFU/ml to +2.6 log10CFU/ml for total bacterial load, and -3.3 
log10CFU/ml to +3.6 log10CFU/ml for P. aeruginosa, see Figure 5.3.3. 
 
A similar pattern was seen when bacterial load was measured by qPCR, for example 
no change in total 16S copies was observed after 14 days treatment with AZLI+IV 
(median [IQR] day 1 vs. day 14: 8.1 log10CFU/ml [7.5 to 8.6] vs. 7.9 log10CFU/ml [7.2 
to 8.0], p=0.43) or IV+IV (median [IQR] day 1 vs. day 14: 8.1 log10CFU/ml [7.9 to 8.6] 
vs. 8.2 log10CFU/ml [7.5 to 8.5], p=0.19), and individual differences ranged from -2.5 
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Figure 5.3.2: Comparison of cultured bacterial loads pre and post treatment 
with AZLI+IV (orange): Total bacterial load (A) and P. aeruginosa load (C) and 
IV+IV (blue): Total bacterial load (B) and P. aeruginosa load (D) 






Figure 5.3.3: Waterfall plot of individual changes in cultured total bacterial load 
and P. aeruginosa load for AZLI+IV (orange) and IV+IV (blue) 
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5.3.4 Changes in bacterial load are associated with quality of life, but not 
lung function. 
Next the relationship between changes in bacterial load and clinical outcomes was 
examined. On day 1 there were no relationships observed for bacterial load with 
either lung function or quality of life (CFQ-R Respiratory Domain), see Figure 5.3.4 
and Figure 5.3.5. After 14 days treatment, no significant relationship was found 
between change in bacterial load and lung function (r= 0.24, p=0.27) or P. aeruginosa 
load and lung function (r= -0.33, p=0.14). However significant moderate inverse 
relationships were observed between respiratory symptoms on day 14, as measured 
by the CFQ-R Respiratory domain, and changes in both total bacterial load (r= -0.41, 
p=0.05) and P. aeruginosa load (r= -0.49, p=0.01), see Figure 5.3.4 and Figure 5.3.5.  
 
5.3.5 Aztreonam resistance is prevalent regardless of previous aztreonam 
exposure 
At study entry i.e. first day of first admission, aztreonam-resistant P. aeruginosa CFUs 
were observed in 8/16 (50%) study participants. EHR interrogation confirmed no 
record of previous aztreonam exposure in any participant. We therefore tested the 
hypothesis that those with aztreonam resistance would be different in terms of 
clinical characteristics and prior antibiotic exposure and found that although patients 
harbouring aztreonam-resistant isolates were similar in terms of age, lung function 
and LES status, aztreonam resistance was associated with increased intravenous 
meropenem use in years prior to study entry (median days [IQR] 43.5 days [13.8 to 
56.8] vs. 9 [0 to 18], p=0.05), see Table 5.3.2.  Baseline aztreonam resistance did not 
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Figure 5.3.4: Pearson’s correlation coefficients between sputum bacterial load 
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Figure 5.3.5: Pearson’s correlation coefficient between sputum bacterial load and 
quality of life   
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5.3.6 Aztreonam resistance increased following treatment with IV+IV but 
not AZLI+IV 
At initiation of AZLI+IV, 5/11 participants (45%) harboured aztreonam-resistant P. 
aeruginosa  and after 14 days treatment there was no difference in aztreonam-
resistant pseudomonal load, see Table 5.3.1 & Figure 5.3.6. At initiation of the IV+IV 
treatment, 8/13 (62%) participants harboured aztreonam-resistant isolates and after 
14 days treatment aztreonam-resistant increased (median difference [95% 
confidence interval] +0.9 log10 CFU/ml [0.3 to 1.9], p=0.01). The increased aztreonam 
resistance seen after 14 days treatment with IV+IV appeared to be driven exclusively 
by those 8 participants with resistance at baseline given the 5 participants without 
aztreonam resistance at baseline were all still susceptible at day 14, whereas the 8 
participants with aztreonam resistance at baseline all saw increased resistance at 




Data are presented as median [IQR] or count (%). Statistical comparison by Mann-
Whitney U test or Fisher’s Exact test, unadjusted p-values. 
 
Table 5.3.2: Comparison of clinical characteristics and prior antibiotic by 
aztreonam resistance at study entry. 
 
BMI=Body Mass Index; FEV1=Forced expiratory volume in 1 second 
 Aztreonam susceptible Aztreonam resistant p 
n 8 8  
Age 30.4 [22.8, 31.7] 28.34 [25.4, 30.4] 0.60 
Male 7 (87.5) 8 (100.0) 0.99 
DF508 homozygous 3 (37.5) 8 (100.0) 0.03 
BMI 18.9 [17.8, 23.8] 22.3 [21.6, 23.3] 0.25 
FEV1, % predicted 46.0 [38.8, 62.0] 60.0 [54.8, 66.3] 0.19 
P. aeruginosa 8 (100.0) 8 (100.0) 0.99 
LES 4 (50.0) 6 (75.0) 0.61 
S. aureus 2 (25.0) 2 (25.0) 0.99 
Long-term antibiotics    
Oral macrolide 8 (100.0) 7 (87.5) 0.99 
Colistimethate 8 (100.0) 6 (75.0) 0.45 
Tobramycin 4 (50.0) 2 (25.0) 0.61 
Annual IV days 28.0 [10.5, 45.8] 23.0 [13.8, 37.5] 0.96 
 
Prior IV exposure 2013-2017, days   
Fosfomycin 0.0 [0.00, 3.3] 8.0 [0.0, 27.8] 0.13 
Tobramycin 18.0 [3.8, 22.8] 18.5 [0.0, 81.8] 0.63 
Colistimethate 43.0 [17.8, 57.0] 54.5 [16.8, 61.5] 0.75 
Meropenem 9.0 [0.0, 18.0] 43.5 [13.8, 56.8] 0.05 
Ceftazidime 33.0 [24.0, 96.5] 28.0 [7.8, 46.8] 0.29 
Co-trimoxazole 0.0 [0.0, 0.0] 0.0 [0.0, 0.0]  
Aztreonam 0.0 [0.0, 0.0] 0.0 [0.0, 0.0]  
Piperacillin/Tazobactam 0.0 [0.0, 16.3] 6.0 [0.0, 22.8] 0.60 
Teicoplanin 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.93 
Temocillin 0.0 [0.0, 0.0] 0.0 [0.0, 0.0]  
Total 165.0 [63.3, 228.3] 134.0 [94.3, 332.5] 0.75 
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Data are presented as median change with comparison by Wilcoxon Signed-rank 
test 
 
Table 5.3.3: Comparison of key clinical outcomes in participants with and without 
baseline aztreonam resistance. 
 
 
  Aztreonam Resistance at baseline   
 Yes  No  p 
AZLI+IV      
n 5  6   
Change after 14 days      
FEV1, % predicted +10.5  +11  0.84 
CFQ-R Respiratory domain +13.9  +11.1  0.76 
White cell count +1.7  +0.1  0.33 
C-reactive protein -3.5  0.0  0.64 
Total Bacteria +0.1  -0.6  0.13 
P. aeruginosa -1.5  +1.5  0.25 
      
IV+IV      
n 8  5   
Change after 14 days      
FEV1, % predicted +9  +8  0.67 
CFQ-R Respiratory domain +16.6  +5.6  0.50 
White cell count -0.7  -0.9  0.99 
C-reactive protein -24  -21  0.99 
Total Bacteria -1.1  +0.4  0.23 




Figure 5.3.6: Comparison of aztreonam-resistant sputum bacterial load pre and post 
treatment with AZLI+IV (orange): Total aztreonam-resistant load (A) and aztreonam-
resistant P. aeruginosa load (C) and IV+IV (blue): Total aztreonam-resistant load (B) 
and aztreonam-resistant P. aeruginosa load (D)  




This study compared the impact of AZLI+IV and IV+IV on sputum-culture bacterial 
load and aztreonam resistance. Overall, there was considerable variability in 
treatment responses and neither treatment consistently reduced total bacteria or P. 
aeruginosa counts.  On an individual level, large reductions were observed for some 
participants and the degree of reduction in P. aeruginosa load was found to be 
significantly associated with improved subjective response to treatment. After 14 
days treatment, no overall differences in aztreonam resistance were found for 
AZLI+IV, however a surprising finding was increased aztreonam resistance after IV+IV 
treatment, despite those treatment regimens not including aztreonam. 
 
The lack of overall change in total bacterial or P. aeruginosa load seen here is at odds 
with early studies of CF exacerbations. For example, in 1988 Smith et al. reported 
hospitalisation and treatment with intravenous antibiotics was associated with 
reductions from 7.8 to 4.6 locus/ml. [309] Similarly in 1990, Regelmann et al. found 
antibiotic treatment of exacerbations was associated with >2-Log reductions in P. 
aeruginosa CFUs. [310] However, these studies were performed prior to the routine 
use of long-term inhaled antibiotics targeted towards P. aeruginosa and the day 1 
sputum loads reported in those early studies (~8 LogCFU/ml) are greater than the 
baseline P. aeruginosa densities seen here. The results seen here are similar to a 
recent study which found IV antibiotic treatment of acute pulmonary exacerbations 
resulted in reduced P. aeruginosa counts only 60% of the time, and confirm the 
findings of other studies from the last decade where no consistent changes in 
sputum bacterial load were observed during treatment of exacerbations. [149,311–
314]  
 
Although neither treatment was associated with overall changes in P. aeruginosa 
load, changes were evident on an individual basis where some participants had 
substantial reductions in sputum counts. A significant relationship between changes 
in bacterial load and quality of life was observed, such that greater reductions in 
bacterial load were associated with improved patient-reported quality of life. In 
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contrast, there was no relationship between changes in sputum load and lung 
function, in keeping with prior work where lung function and quality of life metrics 
have previously been found to be incongruent in the acute exacerbation setting. 
[277,315,316] It is plausible that lung function and patient reported quality of life 
outcomes measure different aspects of disease. For example, FEV1 (the primary 
outcome measure in the AZTEC-CF study) is notoriously insensitive to changes in 
small airways, and a reduced bacterial load could theoretically accompany 
unplugging of obstructed small airways, resulting in improved symptoms but no 
change in FEV1. [317] 
 
Surprisingly, aztreonam-resistant P. aeruginosa was present in half of participants 
despite all being AZLI-naïve. Interrogation of the local electronic health record 
confirmed no prescription of intravenous aztreonam in the previous five years 
although historical exposure at this centre, or in paediatrics cannot be entirely ruled 
out. Interestingly, those with evidence of aztreonam resistance at baseline had 
significantly greater resistance after fourteen days of IV+IV despite those regimens 
consisting of colistimethate with meropenem or ceftazidime rather than aztreonam, 
see Table 4.3.2. These findings may be explained by the shared mechanisms of 
resistance between aztreonam and other commonly used anti-pseudomonals. For 
example, meropenem and ceftazidime are both also known substrates for β-
lactamases and the MexAB-OprM efflux system, which are antimicrobial resistance 
mechanisms naturally encoded within the P. aeruginosa chromosome, but not 
always expressed at high levels. [318–320] Antibiotic exposure can select for 
populations with mutations in key regulatory genes where overexpression of B-
lactamases increase the ability of P. aeruginosa to enzymatically inactivate 
antibiotics and de-repression of the MexAB-OprM efflux system allows removal of 
the antibiotic from the cell entirely. [75] 
 
Increased prior exposure to meropenem was noted in participants with baseline 
aztreonam resistance, in keeping with previous work which identified meropenem 
as a key driver of multi-drug resistance in clinical P. aeruginosa strains. [321] 
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Collateral resistance refers to an antimicrobial agent inducing resistance to another 
agent and we hypothesise that historical up-regulation of resistance mechanisms, in 
response to exposure to other anti-pseudomonals such as meropenem, resulted in 
collateral baseline resistance to aztreonam despite no aztreonam exposure.   
 
Overall, no increased aztreonam resistance after treatment with AZLI+IV was 
observed and this finding is relevant to the clinical utility of AZLI in the acute setting 
where it remains an important chronic suppressive agent against P. aeruginosa. 
Although the relationship between susceptibility testing and clinical response is not 
well established in CF, had AZLI+IV been associated with increased aztreonam 
resistance clinicians may be more wary of adopting AZLI+IV as a treatment in the 
acute setting for fear of reducing efficacy when needed in the chronic setting in the 
future.  
 
Our finding of increased aztreonam-resistant pseudomonal load in the IV+IV group, 
but not AZLI+IV group is in keeping with findings from studies in ventilator-acquired 
pneumonia where nebulised antibiotic delivery has been associated with reduced 
antimicrobial resistance compared to intravenous antibiotics. [267,322] As described 
previously, aztreonam is a substrate for similar resistance mechanisms to other anti-
pseudomonal antibiotics, which may explain the increased resistance seen in the 
IV+IV group, however this does not explain the lack of a similar pattern in the AZLI+IV 
group. It is important to recognise increases in MIC below the reference breakpoint 
cannot be ruled out  but an explanation for these findings may lie in the high dose of 
antibiotic delivered to the lung with nebulised treatments (up to 100-fold greater 
with AZLI than IV aztreonam). [206] Such high doses may exceed the mutant 
prevention concentration (MPC) more often than systemically delivered antibiotics. 
[323] Alternatively, evolutionary theory suggests higher doses of antibiotic may lead 
to mutations that result in higher resistance, but also associated  higher fitness costs, 





There are a number of limitations to consider for this study. First, although 16 
participants were recruited to the AZTEC-CF study, quantitative culture of paired 
samples was only possible for 11 and 13 participants for the AZLI+IV and IV+IV 
treatments respectively. The AZTEC-CF study was not powered toward 
microbiological end-points and hence findings here should be considered hypothesis 
generating. For example, although no overall increased resistance to aztreonam was 
seen with AZLI+IV, there were considerable changes on an individual level and a 
better powered study would allow firmer conclusions on the reproducibility and 
relevance of these findings. Second, sputum was sampled at beginning and end of 
treatment only and cannot exclude a transient treatment effect as reported 
previously by Deschaght et al., where P. aeruginosa counts had reduced after 8 days 
treatment with intravenous antibiotics, but by day 15 had increased back towards 
day 1 values. [325] Third, given aztreonam was the investigational agent of interest 
in the AZTEC-CF study, only aztreonam resistance was measured and therefore no 
assessment on whether AZLI+IV also induced collateral resistance could be made. 
Fourth, aztreonam resistance was assessed based upon the reference MIC 
breakpoint rather than determining individual MICs for each sputum sample. As a 
consequence, it is not known whether individual MICs increased towards the 
reference breakpoint during treatment. 
 Conclusion 
Neither IV+IV nor AZLI+IV consistently reduced sputum bacterial load but where 
bacterial load was reduced, it was associated with improved respiratory symptoms. 
Overall, AZLI+IV was not associated with increased aztreonam resistance, whereas 
the IV+IV group did see increased aztreonam resistance, perhaps suggestive of 




Chapter 6: Lung Microbiota Dynamics during the AZTEC-CF 
Study 
 Introduction 
The premise and evidence base for culture-independent identification of microbial 
communities in the lungs of people with cystic fibrosis (CF) are set out in Chapter 1. 
As discussed therein, the CF lung microbiota has been extensively investigated in 
cross-sectional and longitudinal studies yet relatively little work has been performed 
in an interventional trial setting.[153,326–328]  Instead, studies to date have been 
largely limited to comparing changes in the CF lung microbiota across different 
clinical states e.g. stability and exacerbation, rather than comparing treatment 
effects.  
 
This chapter explores the lung microbiota of AZTEC-CF study participants with 
attention paid to how an individual’s clinical characteristics relate to the bacterial 
community found within their lungs, whether each study treatment exerted 
different effects on the microbiota and how those changes relate to clinical 
outcomes. 
 Methods 
6.2.1 AZTEC-CF Study 
The AZTEC-CF study methods are set out in detail in chapter 3. Briefly, AZLI plus 
intravenous colistimethate (AZLI+IV) was tested against standard care dual 
intravenous antibiotics (IV+IV) for the treatment of acute pulmonary exacerbations 
of CF in a cross-over study. Each treatment course was 14 days with sputum sampling 
performed on Day 1, prior to first antibiotic dose, and Day 14, after last dose of 
antibiotic. After collection, sputum samples were immediately refrigerated at 4oC 




6.2.2 DNA extraction 
For DNA extraction, samples were defrosted and extractions undertaken in batches. 
Freeze-time was standardised such that each participant’s pre-treatment and post 
treatment samples were defrosted in the same batch. Once defrosted, an equal 
volume of diethiothreitol 1.4% w/v (Sputasol, Oxoid, UK) was added before 30 min 
incubation at 37oC on a shaker at 300 rpm. DNA extraction was performed using the 
ZymoBIOMICSTM DNA Miniprep Kit (ZymoBIOMICS, USA) in conjunction with the 
manufacturers protocol. This method consists of the addition of 200µl sputum to 
tubes containing ultra-high-density beads and lysis solution. Mechanical cell lysis was 
then performed by bead beating in a high-speed cell disrupter (TissueLyser II Qiagen, 
Manchester, UK) for 5 minutes at 25 Hz. Centrifugation allowed removal of lysate 
which then underwent washing and purification stages in spin-columns 
(ZymoBIOMICS, USA). Finally, PCR inhibitors e.g. polyphenolics, humic/fulvic acid and 
melanin were removed before the DNA elution in 100µl of DNAse/RNase free water. 
Eluted DNA was stored at -80oC until sequencing. 
 Control samples 
 
A number of control samples were included in the study design: 
1. Negative kit control: A “blank” DNA extraction, where 200 µl of Invitrogen™ 
DEPC- Treated Water (ThermoFisher, UK) was used in place of sputum to 
allow assessment and identification of potential kit/reagent contamination. 
2. Negative sequencing control: A “blank” sample, 1µl of PCR grade DNA-free 
water, was included alongside study samples at the PCR stage to allow 
assessment of de-novo contamination or cross-contamination introduced 
during amplification sequencing. 
3. Positive kit control:  75 µl of a mock community (ZymoBIOMICS™ Microbial 
Community Standard) underwent DNA extraction and sequencing alongside 
all other study samples. A mock community of known composition acts as a 
well-defined input to the DNA extraction and sequencing process. 
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Comparing sequencing output to the known input allows assessment of bias 
and contamination associated with the extraction process. 
4. Positive sequencing control: A defined mixture of genomic DNA isolated 
from pure cultures (ZymoBIOMICS™ Microbial Community DNA Standard) 
was included at the PCR stage to allow assessment of bias introduced by the 
amplification and sequencing process. 
 
6.3.1 DNA quantification 
To confirm the presence and purity of extracted DNA, eluted samples underwent 
quantification by microvolume spectrophotometry (NanoDrop 1000, Thermo 
Scientific) and fluorometry (Qubit 4, Invitrogen).  Quantitative polymerase chain 
reaction (qPCR) was performed as set out in Chapter 5.  
6.3.2 16S rRNA gene sequencing 
Amplification and sequencing of the V4 hypervariable region of 16S followed a 
standardised and optimised protocol at NU-OMICS sequencing facility. The protocol 
is set out in depth by Kozich et al. [329] Briefly, 1µl of template DNA was added to 
17µl of AccuPrime™ Pfx Supermix in a 96 well plate and 2µl of the index primers (515 
(GTGCCAGCMGCCGCGGTAA) and 806 (GGACTACHVGGGTWTCTAAT). After PCR, 
library clean-up was performed with Invitrogen SequalPrep Plate Normalisation kit. 
Samples from all plates were pooled and quantified using a KAPA Biosystems Q-PCR 
kit.  The library was sequenced in in the Illumina MiSeq System (Illumina Inc., USA), 
including 5.0% PhiX as internal control. 
6.3.3 Amplicon bioinformatics 
The QIIME2 pipeline was used for quality control, sequence inference and 
taxonomical assignment. [330] First, low-quality reads were removed, and reads 
were trimmed to a 250bp length. Next, unique sequences and their read counts were 
computed using a parameterised model of substitution errors to distinguish 
sequencing errors from real biological variation. Chimeras (artefact sequences 
incorrectly joined in the PCR process) were removed and the remaining unique 
amplicon sequence variants (ASVs) were taxonomically assigned using the 
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Greengenes 16S rRNA database version 13.5.[331] ASVs are annotated throughout 
with the highest taxonomic rank achieved, for example ASVs resolved to the genus 
level are preceded by “g_” and those resolved to species level are preceded by “s_”. 
6.3.4 Data, samples and statistical analyses 
ASV table and taxonomic assignment were exported for analyses performed in 
RStudio (Version 1.0.136 – © 2009-2016 RStudio, Inc). Sequencing outputs were 
combined with meta-data and initial inspection of data was conducted in the 
“phyloseq” package.[332] Other subsequent packages used for analysis included 
“vegan”, “factoExtra” and “microbiome”.[333–335]  Plots were created within 
“ggplot2” or “ggpubr” packages.[336,337] 
 
To avoid repeated measures bias, only each participant’s first study sample was used 
(n=16) for assessments of the relationship between clinical characteristics and the 
lung microbiota. For between-treatment comparisons, only those participants who 
provided valid study samples for day 1 and 14 of each treatment (n=10, 40 samples 
in total) were included for analysis.  
 
Data is presented throughout as median [IQR] or where specified for paired 
differences, median [95% confidence interval]. Between-treatment comparisons for 
continuous data were made using a paired Wilcoxon test and comparisons across 
study period were made using a Kruskal-Wallis test. Correlations were tested using 
Pearson’s Correlation Coefficient. Where multiple comparisons were being made 
simultaneously, e.g. associations between the microbiota and clinical characteristics, 




6.3.5 Microbiota analyses 
6.3.5.1 Alpha diversity 
 
Alpha diversity is an ecological measure of community structure. The simplest 
measure of alpha diversity is “richness” i.e. the observed number of different species 
within a sample. Other frequently used measures include the Shannon Diversity 
Index (also known as the Shannon-Wiener or Shannon-Weaver index) which takes 
into account the number of species but also their relative proportion within the 
community. [338] A sample made up of only a few species with an uneven 
distribution of abundance would yield a low Shannon Diversity Index, whereas a 
sample with many species, all of equal abundance would achieve a high Shannon 
Diversity Index. Given sample Richness and Shannon’s index are prone to bias from 
sampling depth, Fisher’s alpha index, which describes the relationship between the 
number of species and abundance of that species in a logarithmic series model, was 
also included. Fisher’s index is less prone to bias from sequencing depth, and is 
robust in the face of incomplete sampling. [339] 
6.3.5.2 Core and satellite microbiota partitioning 
Partitioning CF microbiota into “core” and “satellite” taxa has previously been shown 
to be important for revealing changes that would be neglected without such a 
distinction. [340] Challenges in identifying a “core” microbiota from sequencing data 
include many zeros in datasets and large variance in distribution patterns with 
certain samples dominated by particular taxa which may be completely absent in 
other samples. Previously, sequencing datasets have been arbitrarily filtered to 
remove low abundance taxa, however novel methods such as the Prevalence Interval 
for Microbiome (PIME) tool  can be used to partition a “core” microbiota in a 
standardised manner. [341] PIME improves “core” partitioning by using a Random 
Forests analysis to determine the level of prevalence that provides the best model 
to predict differences in the communities while still including as many taxa as 
possible in the analysis. Using the PIME package, a prevalence interval of 60% was 
identified as an optimal threshold. Taxa prevalent in >60% of study participants were 
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therefore included in the “core” microbiota for Beta diversity and individual taxa 
analyses. 
6.3.5.3 Beta Diversity 
Beta diversity describes the variation between two or more samples. Permutational 
multivariate analysis of variance (PERMANOVA) models were constructed to test the 
effect of each treatment on Beta diversity. Unweighted Bray-Curtis dissimilarity was 
computed to quantify the compositional differences between groups. The inter-
relatedness of samples was visualised by principle components analysis (PCA), where 
samples with similar compositions cluster together closely. 
6.3.5.4 Total abundance calculations 
To allow a robust assessment of treatment effect on individual ASV abundance, total 
abundance was calculated by multiplying relative abundance of each ASV within a 
sample by the total 16S copies in that sample, as previously described.[153,342] An 
important methodological consideration is that some taxa have more than one copy 
of the 16S rRNA gene, with some species harbouring as many as 8 copies within their 
genome.[343] This clearly has potential to bias total abundance calculations. To 
account for this, the bioinformatics package PICRUSt2 (phylogenetic investigation of 
communities by reconstruction of unobserved states) was utilised to predict 16S 
rRNA gene count for each individual ASV. [344,345]   ASV reads were then normalised 
to gene count before estimating relative abundance and multiplying by total sample 







6.4.1 Sequence counts 
Sequencing was performed for 63 samples (56 study samples, 3 negative kit controls, 
2 positive kit controls, 1 negative sequencing control and 1 positive sequencing 
control) resulting in 1,115,862 reads. After filtering, denoising and merging, 909,633 
sequences remained of which 16,302 were chimeric and were removed. The 
remaining 893,331 sequences were then taxonomically assigned to 847 individual 
ASVs. 
 
Figure 6.4.1 illustrates the number of sequence reads for each study sample and also 
for the controls. The study sample with the most sequence reads had 23,352, whilst 
the sample with the least sequences reads had 273.  There was a positive association 
(r= 0.50, p<0.001) between sequence reads and the sputum bacterial load as 
measured by qPCR (Log10 16S copies/ml), Figure 6.4.2. 
 
Samples with less than 500 reads were excluded from further analyses meaning 
paired samples were available for 10 and 15 participants for the AZLI+IV and IV+IV 
treatment periods respectively. For between-treatment comparisons, 10 
participants had a pair of samples for each treatment available for analysis (40 
samples in total). 2/40 (5%) had <1000 reads and were therefore scrutinised for 
consideration of removal from further analysis. Visual inspection of these samples 
(sample ID: 6A2 and 4B2) confirmed similar community structures to those 
participants’ other study samples and rarefaction curves showed they had 
approached asymptote sufficiently to be considered an accurate representation and 






























































































































































































Figure 6.4.2: Positive association between sequencing reads per sample and the 
bacterial load  
Figure 6.4.1: Distribution of sequencing reads per sample for all study samples and 
controls 
NUNEG3=Sequencing negative control. NegControl1,2,3 =Negative kit controls. 
PosControl&PosControl3=Positive kit controls. NUPOS3=Sequencing positive control 
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  Figure 6.4.3: Rarefaction curve for all samples (A) showing asymptote was 
reached by ~1000 reads for the vast majority of samples. Two samples with 
<1000 reads were included for analysis after confirming asymptote was 
approached despite low reads (B). 
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6.4.2 Comparison of controls and clinical specimens 
Significantly fewer reads were obtained in the negative controls than study 
specimens (median reads [IQR] 121 [97 to 358] vs. 15279 [9939 to 17166], p<0.001). 
The sequencing negative control was dominated by Escherichia coli, see Figure 6.4.4, 
a pattern not seen in the clinical samples suggesting no major sequencing 
contamination of the clinical samples. The negative kit controls mainly consisted of 
ASVs resolved to the genera Pseudomonas, Prevotella and Veillonella, which in 
keeping with prior literature were the most common taxa in the clinical samples. 
[146,150,153,346] Given the negative kit controls had low overall reads and 
consisted mainly of taxa known to be prevalent in the CF lung microbiota with no 
evidence of known kit contaminants, it is likely that the reads represent carryover 
from clinical samples rather than significant kit contamination. [169] To assess for 
inherent bias within our extraction or sequencing methods, positive kit controls and 
a positive sequence control, all consisting of the same known ‘mock community’ 
were included. Figure 6.4.5 demonstrates all three positive controls clustered tightly 
and separately from negative controls. Figure 6.4.4 shows the positive controls all 
closely resembled each other, confirming consistency across both DNA extraction 
and sequencing. Bacillus subtilis only represents 12% of the mock community but 
represented ~25% of the sequenced microbiota, suggesting an extraction bias in 
favour of Bacillus spp. Reassuringly, Bacillus spp. were not found frequently in either 
negative controls or the core microbiota of study samples and hence any extraction 
bias is unlikely to have impacted results. 
 
6.4.3 The CF lung microbiota is individualised with few clinical factors 
associated with community structure and diversity. 
To test the hypothesis that clinical factors were associated with the CF lung 
microbiota, clinical characteristics and community structure/composition for each 
participant at study entry (n=16) were computed. Variables of interest were those 
considered to have biologic plausibility and/or those previously reported to be of 
significance in this setting. Table 6.4.1 shows differences in Richness and Shannon 























































Figure 6.4.4: Relative abundance of the top ten taxa in Positive Controls (Top 
Panel) and Negative Controls (Bottom Panel) used in the AZTEC-CF Study. All 



























Figure 6.4.5: Principle com
ponents analysis of the inter-relatedness of negative and positive controls. Positive controls all closely 
resem
bled one another and clustered distinctly from




ilar to one another. 
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Overall, the CF sputum community structure was highly individualised with few 
consistent associations between community structure and clinical chracteristics. No 
relationships between baseline clinical characteristics and richness were found, see 
Table 6.4.1 & Table 6.4.2. The presence of the Liverpool epidemic strain was 
associated with reduced Shannon diversity and the use of nebulised tobramycin was 
associated with increased Shannon diversity, see Table 6.4.2. No relationship was 
observed between age or lung function with richness or Shannon diversity, however 
this study is likely underpowered in that regard. When all study samples (n=56) were 
considered, both age (r= -0.55, p<0.001) and bacterial load, i.e. total 16S copies (r= -
0.37, p=0.004) were inversely associated with Shannon diversity. A relationship was 
for allergic broncho-pulmonary aspergillosis (ABPA) whereby those participants with 
a previous diagnosis of ABPA (n=4) had greater Shannon diversity, indicated a more 
rich and even community. 
6.4.4 At study entry the core microbiota was dominated by an ASV resolved 
to the Pseudomonas genus 
The Prevalence Interval for Microbiome Evaluation (PIME) tool was used to identify 
a “core” microbiota. [341] The core microbiota consisted of 11 ASVs, which are 
presented in Table 6.4.3. The most abundant ASV was 
“ff9d93d7b7e46787568f2d241caeaf3b” which was resolved to the Pseudomonas 
genus (g_Pseudomonas_ASV001). Of the remaining 10 core constituents, 6 ASVs 











Two were resolved to the Streptococcus genus (g_Streptoccous_ASV021 and 
g_Streptococcus_ASV023), one each to the Granulicatella genus and Actinomyces 
genus (g_Granulicatella_ASV033 and g_Actinomyces_ASV032 respectively). 
 
The relative abundance of the core taxa for all participants at study-entry are 
presented in Figure 6.4.6. g_Pseudomonas_ASV001 was the most dominant taxa 
with >75% abundance in 11/16 (68.8%). g_Pseudomonas_ASV001 was more 
dominant in samples from participants known to harbour the Liverpool Epidemic 
Strain (median McNaughtey’s Dominance index [95% CI]: 0.79 [0.62 to 0.92] vs. 0.69 
[0.39 to 0.84], p=0.0003). For the 10 participants included in the comparative 





Table 6.4.1: Comparison of Shannon Diversity and Richness (i.e. number of 
species observed) across a number of clinical characteristics 
Data are presented as median (interquartile range) with unadjusted and Bonferroni 




Abbreviations: GORD=Gastro-oesophageal reflux disease; CFRD=Cystic fibrosis related diabetes; 
ABPA=Allergic bronchopulmonary aspergillosis; LES=Liverpool Epidemic Strain of P. aeruginosa; 
MSSA=Methicillin sensitive S. aureus; PPI=Proton pump inhibitor; Tobi=Nebulised Tobramycin; 
Coli=Nebulised Colistimethate  
Shannon Diversity 
  Condition Present Condition Absent p Bonferroni 
GORD 1.48 (0.569 to 2.13) 1.23 (1 to 1.67) 0.690 NS 
CFRD 1.48 (0.59 to 1.76) 1.23 (0.569 to 1.9) 0.308 NS 
ABPA 1.98 (1.19 to 2.45) 1.24 (0.59 to 1.67) 0.005 ** 
LES 1.36 (0.58 to 1.76) 1.68 (1.05 to 2.2) 0.001 ** 
MSSA 1.43 (0.904 to 2.04) 1.36 (0.59 to 1.9) 0.950 NS 
PPI 1.57 (0.597 to 1.95) 1.24 (1 to 1.98) 0.633 NS 
Tobi 1.69 (1.07 to 2.2) 1.34 (0.58 to 1.76) 0.001 ** 
Coli 1.46 (0.892 to 1.98) 1.19 (0.904 to 1.19) 0.954 NS 




      
Richness 
  Condition Present Condition Absent p Bonferroni 
GORD 48 (13 to 58) 38 (23 to 48) 0.780 NS 
CFRD 37 (36 to 37) 48 (13 to 49) 0.900 NS 
ABPA 43 (36 to 53) 36 (13 to 59) 0.900 NS 
LES 42.5 (12 to 53) 43 (35.5 to 58) 0.703 NS 
MSSA 43 (36 to 48.5) 38 (12 to 66) 0.900 NS 
PPI 43 (37 to 58.5) 42.5 (23 to 53) 0.503 NS 
Tobi 42.5 (29 to 58) 43 (12 to 49) 0.870 NS 
Coli 30 (12 to 30) 43 (36 to 53.5) 0.384 NS 
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Table 6.4.2: Correlations of clinical characteristics with alpha diversity measures  
 





Abbreviations: BMI=Body Mass index; IV=Intravenous antibiotic; FEV1=Forced expiratory 







    r p Bonferroni 
Age   -0.45 0.080 NS 
Log16S   -0.21 0.430 NS 
BMI   0.03 0.920 NS 
Annualised IV days   0.29 0.280 NS 
Blood white blood count   0.42 0.110 NS 
Blood C-reactive protein   0.21 0.440 NS 





    r p Bonferroni 
Age   -0.05 0.865 NS 
Log16S   -0.05 0.845 NS 
BMI   0.30 0.258 NS 
Annualised IV days   -0.34 0.200 NS 
Blood white blood count   0.03 0.909 NS 
Blood C-reactive protein   -0.25 0.357 NS 





ic classification of the core bacterial constituents of the CF m
icrobiota identified in the AZTEC-CF study. 
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  Figure 6.4.6: The relative abundance of the core taxa at baseline for all AZTEC-CF study participants. Each bar represents the baseline 
sam
ple for each participant w
ith Study ID
 denoted above the respective bar. The relative abundance of all core taxa in each sam
ple are 
represented by the proportion their respective colour occupies w










































  Figure 6.4.7: Relative abundance of core taxa before and after each treatm
ent. Each bar represents a sputum
 sam
ple for each participant 
w
ith Study ID
 denoted above the respective bar. Sam
ples from
 exacerbations treated w
ith IV+IV are in the top row




n the x-axis D
ay 1 or D
ay 14 is denoted. The relative abundance of all core taxa in each sam
ple are represented by the 
proportion their respective colour occupies w














































































































































6.4.5 The CF lung microbiota is highly resilient to exacerbation and 
treatment 
Richness, Shannon Index and Fisher’s alpha index were calculated for all 53 included 
samples. Overall, all measures of alpha diversity were preserved across the study 
period suggesting the CF microbiota community structure is resilient to perturbation 
at the time of exacerbation and also with treatment, see Figure 6.4.8. Similarly, when 
each treatment was considered separately, neither IV+IV, nor AZLI+IV were 
associated with any significant changes in alpha diversity measures, see Figure 6.4.8 
 
6.4.6 IV+IV but not AZLI+IV exert significant changes on CF sputum 
community composition 
At day 1 i.e. pre-treatment, there was no significant difference between the two 
treatment groups, (Bray-Curtis r2=0.08, p=0.21, see Figure 6.4.9). After 14 days 
treatment, there were significant differences between treatments (Bray-Curtis 
r2=0.18, p=0.001, see Figure 6.4.9). These findings were supported by comparing 
beta diversity at day 1 and day 14 for each treatment, where no change was seen for 
the AZLI+IV arm (Bray-Curtis r2=0.03, p=0.64) but was observed in IV+IV treatment 
group (Bray-Curtis r2=0.14, p=0.02). 
 
6.4.7 AZLI+IV and IV+IV exert different effects on individual ASVs 
To investigate the effect of each treatment at the individual ASV level, the total 
abundance of individual constituents of the core microbiota were calculated on day 
1 and day 14 for each treatment. The IV+IV treatment was associated with significant 
reductions in total abundance of s_Veillonella_parvula_ASV017 (Day 1 median [IQR] 
abundance 6.8 [6.3 to 7.3] vs Day 14 0.0 [0.0 to 6.1] Log10 copies/ml, paired Wilcoxon 
p=0.01), s_Veillonella_dispar_ASV002 (5.8 [5.2 to 6.4] vs. 0.0 [0.0 to 3.2] Log10 
copies/ml, paired Wilcoxon p=0.009), g_Granulicatella_ASV033 (4.8 [2.0 to 7.7] vs. 
0.0 [0.0 to 5.5] Log10copies/ml, paired Wilcoxon =0.04) and 
 s_Prevotella_melaninogenica_ASV010 (6.2 [3.9 to 8.9] vs. 0.0 [0.0 to 0.0], paired 




AZLI+IV was associated with an increase in the total abundance 
g_Streptococcus_ASV023 (median abundance [IQR] 4.4 [1.9 to 7.0] to 5.1 [4.9 to 5.4] 
Log10 copies/ml, paired-Wilcoxon p=0.018), but no other significant differences. 
Neither IV+IV, nor AZLI+IV (7.5 [6.1 to 8.3] vs. 7.3 [6.1 to 7.9] Log10 copies/ml, paired 
Wilcoxon p=0.18) was associated with any overall difference in 
g_Pseudomonas_ASV001. 
 
Between-treatment differences at day 14 were most pronounced for 
s_Prevotella_melaninogenica_ASV010 and s_Veillonella_dispar_ASV002. Median 
[IQR] change in total abundance of s_Prevotella_melaninogenica_ASV010 for 
AZLI+IV was +0.1 [-3.5 to 1.3] Log10 copies/ml vs. -5.7 [-6.7 to 0.0] Log10 copies/ml for 
IV+IV, paired Wilcoxon p=0.049. For s_Veillonella_dispar_ASV002, change in total 
abundance for AZLI+IV was +0.28 [-0.15 to +0.73] Log10 copies/ml vs. -6.1 [-7.5 to 0.0] 
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Figure 6.4.8 Top panel: Alpha diversity measures (Richness, Shannon Index and 
Fisher’s Alpha Diversity index) across the AZTEC-CF Study period. . Bottom two 
panels: Alpha diversity measures before and after AZLI+IV (orange) and IV+IV 
(blue) .  
Timepoint 1=Exacerbation 1 Day 1, Timepoint 2: Exacerbation 1 Day 14, Timepoint 






















































































Figure 6.4.9: Principle component analysis comparing inter-relatedness of 
samples before and after each treatment.  
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Figure 6.4.10: Boxplots of total abundance of each core ASV on Day and Day14 
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Figure 6.4.11: Boxplots of betw
een-treatm
ent differences for change in total abundance of each core 
ASV at day 14 
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6.4.8 Changes in individual ASVs analysed by relative abundance alone can 
be misleading 
 
To investigate whether the analysis of total abundance rather than relative 
abundance of individual ASVs provides extra insight or leads to substantially different 
conclusions, the analyses performed in section 6.4.7 were repeated using relative 
abundance data rather than total abundance. 
 
When analysis was performed using relative abundance only, the abundance of 
g_Pseudomonas_ASV001 was seen to increase with IV+IV (median [IQR] day 1 vs. day 
14: 85.6% [61.5 to 100] vs. 98.6% [93.5 to 100], p=0.006), whereas decreases were 
observed for AZLI+IV (median [IQR] day 1 vs. day 14: 85.1% [77.3 to 92.8] vs. 66.0% 
[30.0 to 100], p=0.05), see Figure 6.4.12. In each case, the total abundance of 
g_Pseudomonas_ASV001 was static, see section 6.4.7, and the relative changes were 
therefore actually as a result of absolute changes in other ASVs, for example reduced 
s_Prevotella_melaninogenica_ASV010 and s_Veillonella_dispar_ASV002 with IV+IV 
treatment, and increased g_Streptococcus_ASV023 with AZLI+IV. These findings 





Comparison by Wilcoxon Signed-Rank test 
  








































Figure 6.4.12: Boxplots of relative abundance of g_Pseudomonas_ASV001 at day 
1 and day 14 for IV+IV (Dark blue) and AZLI+IV (Orange).  
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6.4.9 Changes in Pseudomonas abundance within the lung microbiota are 
associated with quality of life outcomes 
 
To explore whether changes in particular elements of the lung microbiota were 
associated with different clinical outcomes, the relationship between the lung 
microbiota and changes in lung function, quality of life and time to next exacerbation 
was compared.  
 
First, the relationship between changes in individual ASVs and clinical outcomes was 
explored. A moderate positive correlation was observed for change in 
g_Granulicatella_ASV033 abundance and change in lung function, r= 0.53, p=0.02, 
however this was not significant when Bonferroni correction was applied and no 
other relationship between ASVs and changes in lung function were observed, see  
Figure 6.4.13. 
 
Associations between changes in ASV abundance and quality of life (CFQ-R 
Respiratory domain) are presented in Figure 6.4.14. A moderate negative correlation 
was observed between change in total g_Pseudomonas_ASV001 abundance and 
changes in quality of life (r=-0.61, p=0.004, remains significant with Bonferroni 
correction) but no associations were found for other taxa.  This pattern was similar 
for both IV+IV and AZLI+IV treatments, see Figure 6.4.14B and also when changes 
were considered in terms of relative abundance as well as total abundance, Figure 
6.4.14C. 
 
To explore if changes in the abundance of ASVs were related to time to next 
exacerbation, a Cox proportional hazard model was constructed for each ASV and 
the results are presented in Table 6.4.4. Changes in ASV abundance over the course 
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Figure 6.4.13: Correlation between changes in total abundance of core ASVs and 
change in lung function at day 14 
Raw p-values are presented. A Bonferroni adjusted value of p<0.0045 







Figure 6.4.14: Correlation between changes in total abundance of core ASVs and 
CFQ-R respiratory domain (A). A negative correlation was seen for 
g_Pseudomonas_ASV001, which was consistent for both total abundance (B) and 
relative abundance (C). 
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Raw p-values are presented. A Bonferroni adjusted value of p<0.0045 
was considered statistically significant for panel A. 
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Table 6.4.4: Cox proportional hazards models constructed for the relationship 
between change in individual ASV abundance from day 1 to day 14, and time to 
next exacerbations.  
 
ID 
Hazard Ratio  
(95% Confidence Interval) p 
Bonferroni 
corrected 
g_Pseudomonas_ASV001 1.2 (0.65 to 2.21) 0.56 NS 
s_Streptococcus_infantis_ASV018 0.88 (0.77 to 1) 0.05 NS 
g_Granulicatella_ASV033 0.99 (0.89 to 1.09) 0.82 NS 
s_Veillonella_dispar_ ASV002 0.94 (0.83 to 1.06) 0.31 NS 
s_Prevotella_melaninogenica_ASV010 0.9 (0.8 to 1.01) 0.07 NS 
s_Veillonella_parvula_ASV017 0.94 (0.82 to 1.08) 0.38 NS 
s_Escherichia_coli_ASV007 1.08 (0.89 to 1.31) 0.42 NS 
s_Rothia_dentocariosa_ASV039 0.97 (0.83 to 1.14) 0.69 NS 
g_Actinomyces_ASV032 0.96 (0.86 to 1.07) 0.49 NS 
g_Streptococcus_ASV023 0.87 (0.75 to 1.01) 0.07 NS 
g_Streptococcus_ASV021 0.86 (0.7 to 1.07) 0.17 NS 
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Next, the relationships between bacterial loads/abundances on day 1 of treatment, 
and treatment outcomes were examined. Overall, no relationship was seen between 
day 1 total bacterial load and change in lung function (r= 0.23, p=0.33) or change in 
the CFQ-R Respiratory domain (r= -0.08, p=0.72). Similarly, no relationships were 
observed when each treatment was considered separately. 
 
The associations between the abundance of individual core ASVs on day 1 and 
subsequent changes in lung function are presented in Figure 6.4.16. 
s_Prevotella_melaninogenica was the only ASV with a statistically significant 
association (r= -0.52, p=0.018), however the association was no longer significant 
when bonferroni adjustment was applied.  When each treatment was considered 
separately, baseline s_Prevotella_melaninogenica abundance appeared to be more 
important to outcomes of  IV+IV (r= -0.7, p=0.025) than AZLI+IV (r= -0.33, p=0.36), 
see Figure 6.4.17. To determine whether s_Prevotella_melaninogenica abundance is 
important for time to next exacerbation, day 14 samples were reviewed and assigned 
into a “High” or “Low” abundance group. The “Low” abundance group consisted of 
all those day 14 samples with <1 Log10 16S copies/ml (12/20 in total). The “High” 
abundance group was the remaining 8 samples. The median time to next 
exacerbation was 96 days in the “Low” abundance group, compared to 188 days in 
the “High” abundance group. Despite the clinically significant numerical difference, 
this was not statistically significant (p=0.12), see Figure 6.4.17. 
 
Finally, the relationships between baseline abundance of ASVs and subsequent 
changes in quality of life are presented in Figure 6.4.18. No significant relationships 
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Figure 6.4.15: Correlation between qPCR derived total bacterial load on day 1 and 
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Figure 6.4.16: Correlation between total abundance of individual ASVs on Day 1 
and subsequent changes in lung function 
Raw p-values are presented. A Bonferroni adjusted value of p<0.0045 
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Figure 6.4.17: Correlation between the abundance of Prevotella 
melaninogenica on Day 1 and subsequent changes in lung function after 
treatment with 14 days of AZLI+IV and IV+IV. Below is a Kaplan-Meier plot for 
time to next exacerbation between those with high and low Prevotella 
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Figure 6.4.18: Correlation between abundance of individual ASVs on day 1 and 
subsequent change in quality of life 
Raw p-values are presented. A Bonferroni adjusted value of p<0.0045 





This aim of this study was to explore the lung microbiota of AZTEC-CF study 
participants and investigate differences in the effect of AZLI+IV and IV+IV treatment 
approaches. Unsurprisingly, given the AZTEC-CF study was limited to adults with CF 
and known P. aeruginosa infection, the microbiota of study participants tended to 
be dominated by an ASV resolved to the Pseudomonas genus, and this was 
particularly the case in those known to be infected with the Liverpool Epidemic Strain 
(LES). A more diverse microbiota was observed in those without LES and also in those 
with a prior diagnosis of ABPA.  
 
In keeping with prior literature, the core microbiota was enriched with taxa 
belonging to the Prevotella, Veillonella and Streptococcus genera. 
[127,146,150,153,347] These taxa are not considered classical CF pathogens, yet all 
are well documented as common constituents of the CF microbiota and associated 
with variable clinical outcomes. [151,340,348–350] In contrast to some prior studies, 
Staphylococcus was not found to be a constituent of the core lung microbiota in this 
study. This was surprising given S. aureus is a well-recognised CF pathogen and  
Staphylococccus OTUs have previously been reported in North American studies to 
be important for outcomes to inhaled aztreonam and inhaled tobramycin in the 
stable disease setting . [146,351] However, in keeping with the findings in this study, 
other studies in the UK utilising similar core partitioning techniques did not find 
Staphylococcus to be constituents of the core microbiota. [150,340,352] A potential 
explanation for this lies in the historical usage of anti-staphylococcal antibiotics in 
the UK as compared to North America, although demographic differences between 
study cohorts cannot be ruled out.  
 
When IV+IV and AZLI+IV were compared, the two treatments exerted different 
effects on the lung microbiota. For example, although alpha diversity was maintained 
throughout the study, the beta-diversity of sputum samples differed after each 
treatment, despite samples coming from the same patients.  The most striking 
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differences were reductions in the abundance of the anaerobes Prevotella 
melaninogenica and Veillonella dispar seen with IV+IV but not AZLI+IV. Interestingly, 
neither treatment had any discernible consistent effect on Pseudomonas 
abundance, despite this classically being the target of treatment in CF exacerbations.  
 
This is the first study of the impact of an inhaled antibiotic on the CF lung microbiota 
in a controlled clinical trial setting. Of the currently available inhaled antibiotics, AZLI 
has received the most attention in terms of prior microbiome studies with previous 
work including a retrospective analysis using biobanked samples, [147] and also a 
prospective observational study. [146] Our study confirms the findings of those 
earlier studies in that AZLI was not consistently associated with perturbations of 
alpha diversity or changes in Pseudomonas abundance. The results here did differ in 
that changes in Pseudomonas abundance were associated with improved quality of 
life at day 14, a pattern not seen previously. Instead, the earlier studies suggested 
species belonging to the Prevotella and Streptococcus genera were more important 
when it came to changes in quality of life. The differences here may be related to the 
different study setting (i.e. acute exacerbation vs. clinically stable) or methodological 
differences discussed later. 
 
The relative lack of impact of  AZLI+IV on anaerobes may potentially be explained by 
the limited anaerobic cover provided by aztreonam and colistin (the two antibiotics 
in the AZLI+IV treatment), whereas the second IV antibiotic in the IV+IV arm was 
commonly a beta-lactam such as meropenem or piperacillin/tazobactam, which do 
convey greater anaerobic coverage. [353] However, AZLI use in clinically stable 
patients has previously been reported to result in reduced Prevotella abundance, 
suggesting some in-vivo activity may exist. [147] An alternative explanation is that 
nebulised antibiotics can only penetrate areas of the lung where there is good 
ventilation. If anaerobes were found more frequently in areas with poorer 
ventilation, AZLI would have less chance to act against them.  Increased mucus 
plugging and subsequent reduced ventilation to some areas of the lung during an 
exacerbation could therefore explain the relative lack of impact against anaerobes 
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compared to IV+IV, which would reach poorly ventilated areas via the pulmonary 
vasculature.  
 
The clinical relevance of the between-treatment differences as regards these 
anaerobic species is not entirely clear. For example, Prevotella identified in prior CF 
microbiome studies were associated with milder lung disease and reduced 
inflammation and was put forward as a marker of a more diverse and “healthy” 
microbiota. [127] Reductions could, on that basis, be considered undesirable yet 
elsewhere increases in Prevotella abundances have been reported at the time of 
exacerbation and subsequent reductions in Prevotella with treatment were 
associated with lung function improvement. [354–356] Part of the difficulty in 
making comparisons between studies relates to the poor ability of conventional 16S 
rRNA gene sequencing to taxonomically resolve beyond the genus level. Thus, the 
conflicting findings reported previously may be due to the sequences in question 
representing different Prevotella species within a heterogenous genus. [357]   
 
More recently, both Prevotella melaninogenica and Veillonella dispar were noted to 
have increased prevalence in milder CF lung disease.  [352] The authors speculated 
that interventions promoting the growth of those taxa might mitigate the effects of 
resident pathogens on lung function. The lack of effect on AZLI+IV on these species 
could therefore be considered advantageous. However, results here showed a trend 
towards greatest improvements in lung function in those with lower abundance of 
Prevotella melaninogenica at treatment initiation. Interestingly, after treatment, 
those with low Prevotella melaninogenica abundance showed a trend toward 
reduced time to exacerbation, although the small numbers in this study limit the 
interpretation of this observation. These results may suggest that community 
dynamics and pathogenicity differ between clinical stability and periods of acute 
exacerbation. The association between Prevotella melaninogenica and clinical 




In this study, amplicon sequence variants rather than operational taxonomic unit 
clustering were employed to assign taxonomy and we were therefore able to identify 
Prevotella melaninogenica as the Prevotella genus member within the core 
microbiota. The greater resolution provided by ASV techniques offer self-evident 
benefit in this context given the variable outcomes associated with the genus 
Prevotella mentioned previously. ASVs also offer two further benefits over a 
clustered OTU-based approach: firstly, ASVs can be reproducible across studies 
making cross-study comparisons or even meta-analyses more consistent, and 
secondly, they allow improved identification of contaminants, particularly in variable 
biomass settings. [120,358] 
 
A further important methodological consideration of this study is the use of 
estimated total abundance rather than relative abundance. Relative abundance has 
previously been shown to be well correlated to qPCR estimated load, [149,161] and 
indeed a positive correlation between overall reads and qPCR measured bacterial 
load were observed here. However, using relative abundance as an outcome 
measure in longitudinal studies or treatment-effect comparison is problematic given 
increases in relative abundance of one ASV must result in decreased relative 
abundance of other ASVs, regardless of whether the true abundance has changed. 
Here, total abundance was estimated by multiplying the relative abundance of each 
ASV by the total 16S copies (determined by 16S rRNA gene qPCR) in its respective 
sample, as previously described. [342,354] Given the number of 16S copies within a 
bacterial genome can vary from one to fifteen, abundance was also normalised to 
16S copy count prior to this calculation. [359] The advantage of this approach was 
apparent when considering the effect of each treatment on 
g_Pseudomonas_ASV001, where AZLI+IV was associated with reduced relative 
abundance and IV+IV was associated with increased relative abundance. Total 
abundance analysis revealed both treatment effects were overstated and 
abundances were instead quite stable, with the apparent relative changes likely 
related to changes on total abundance of other taxa. Without estimating total 




Recently, it has been suggested by Hahn and colleagues that clinical outcomes and 
changes in lung microbiota are related to antibiotic serum concentration, which can 
vary considerably between patients, and given antibiotic serum or sputum 
concentrations were not measured we cannot rule out sub-therapeutic antibiotic 
concentrations as a confounder. [360,361] Although sputum or serum 
concentrations of antimicrobials were not measured in this study, inhaled antibiotics 
are known to result in higher airway concentrations than their intravenous 
equivalents  [204–206] and given the favourable clinical outcomes associated with 
AZLI+IV, this study would support Hahn and colleagues’ main finding that higher 
antibiotic concentrations are important for clinical outcomes of CF exacerbations. 
[361] However, our finding of more pronounced changes in the IV+IV arm differ from 
Hahn’s analyses. The difference in results may be partially explained by the 
paediatric cohort used in Hahn’s studies, where alpha diversity was higher at 
baseline than seen in our cohort. However, perhaps more importantly, the two 
groups in Hahn’s study (therapeutic antibiotic concentration group and sub-
therapeutic antibiotic concentration group) were actually significantly different at 
baseline in terms of age, lung function, alpha and beta-diversity, making it difficult 
to attribute the differing antimicrobial effects solely to antibiotic concentration. The 
cross-over design employed here, negates some of those issues and strengthens the 
veracity of the findings.  
 
Our finding that total g_Pseudomonas_ASV001 abundance was not reduced in either 
treatment arm is interesting since both arms targeted P. aeruginosa with aggressive 
doses of two anti-pseudomonal antibiotics, an approach that is considered standard 
practice in this setting. This finding is at odds with some previous microbiome studies 
where Pseudomonas relative abundance was reported to increase, [160,356] or in 
some cases decrease, [161,356] in response to treatment of an acute pulmonary 
exacerbation. These studies often relied solely on relative abundance and hence the 
limitations described earlier are applicable in that regard. Studies with rigorously 
quantified P. aeruginosa before and after treatment of an acute exacerbation have 
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reported no consistent effects [312,313,362,363], in keeping with the results seen 
here and in other microbiome studies. [130,150,354] 
 
The lack of effect on Pseudomonas abundance raises questions as to the purpose of 
high-dose antipseudomonal antimicrobials. However, interestingly where 
Pseudomonas abundance was reduced, it was associated with better quality of life. 
This was not true for any other taxa, reaffirming the importance of P. aeruginosa in 
outcomes of exacerbations of CF. The methodological limitations of the sequencing 
approach employed here must also be considered. Firstly, despite using an ASV-
based approach, sequencing of the 16S rRNA gene here was only able to resolve the 
dominant taxon to the genus Pseudomonas level at best, limiting conclusions that 
can be drawn without species level resolution. Second, even with species level 
resolution, amplicon sequencing would be unable to detect the within-species 
changes in phenotype and genotype previously reported during treatment of acute 
pulmonary exacerbations. [314] That is to say that acute, intense antipseudomonal 
antimicrobial therapy may impact the genotypic and phenotypic make-up of P. 
aeruginosa infection in the lung, without affecting the overall load. Such changes are 
not detectable by the methods used here. Metagenomic or “multi-omics” 
approaches, which are now becoming more widely available, will be important for 
investigating this possibility in the future. Finally, no attempt was made to 
discriminate between DNA from alive and dead bacteria. Some previous studies have 
utilised agents such as propidium monoazide (PMA) to bind DNA in cells with 
damaged external membranes (presumed to be dead), excluding that DNA from PCR 
amplification, sequencing and downstream analyses. [150,170,171] The decision not 
to use PMA was made on a number of grounds. Firstly, due to the lack of 24-hour 
laboratory availability at Liverpool Heart & Chest Hospital, standardising time from 
sample collection to PMA treatment would have been impossible.  This may have 
introduced bias, for example cells that were viable at the time of sputum collection 
becoming non-viable by the time of PMA treatment. Secondly, it is not known how 
long DNA from dead cells persists in the lung, it is likely to vary between patients and 
even within patients based on their mucociliary clearance and hence adding PMA 
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may introduce further bias in longitudinal sampling studies such as this. Reassuringly, 
PMA has recently been shown to have a greater impact on the community analysis 
of rarer (<1% abundance) taxa rather than the core microbiota, suggesting findings 
here are unlikely significantly biased by the possible inclusion of non-viable DNA. 
[170] No difference was found between treatments in terms of  changes in viable 
(culturable) bacterial load or total bacterial load measured by qPCR, see Chapter 5, 
which suggests that if non-viable DNA did mask a treatment effect in this study it 
would have been limited to non-culturable bacteria, for example anaerobes or 
dormant aerobes. 
 
The AZTEC-CF study excluded people with CF who were not infected with P. 
aeruginosa and the results seen here, both in terms of community composition and 
treatment effects may therefore not be generalisable to the wider CF population. 
Other limitations to this study include the small sample size of only 16 participants 
from a single centre, which further limit the generalisability of these findings. The 
sample size for all comparative analyses was limited to 10 participants, such that all 
participants had a Day 1 and Day 14 samples available for analysis for both 
treatments. Despite this reduction in size, the inclusion of 40 samples for 
comparative analysis make this study one of the largest analyses of the CF lung 
microbiota in a controlled clinical trial to date. Finally, to safely conduct the AZTEC-
CF study, all participants were given a test dose of AZLI during the enrolment process. 
The impact of a single dose, temporally dissociated from the study time-period, on 
the lung microbiota is unclear, but we cannot completely rule out an impact on the 
treatment effects we observed. 
 
The strengths of this study lie in the cross-over design, which allowed inclusion of 
matched samples before and after each treatment. This approach facilitated a 
rigorous evaluation of longitudinal treatment effects, with each person acting as 
their own control, thereby minimising bias from high inter-individual variability seen 
here and previously reported in the wider CF microbiome literature. Other important 
methodological strengths include the use of estimated total abundance rather than 
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relative abundance to robustly assess treatment effect and ASV-based approached 
to allow better taxonomic resolution. 
 
In conclusion, AZLI+IV and IV+IV exerted different effects of the lung microbiota.  
which appeared to be driven by reductions in total abundance of the anaerobes 
Prevotella melaninogenica and Veillonella dispar seen with IV+IV but not AZLI+IV. 
Although neither treatment consistently changed the abundance of Pseudomonas, 






Chapter 7: General Discussion 
 
The purpose of this thesis was to investigate the clinical and microbiological 
outcomes of AZLI in the treatment of acute pulmonary exacerbations of CF and the 
AZTEC-CF study was designed to evaluate these in a prospective clinical trial.  The 
main findings are discussed and contextualised below, alongside their limitations and 
wider implications. 
 AZLI can be effective and safe in the treatment of acute 
pulmonary exacerbations of cystic fibrosis 
Inhaled antibiotics deliver a high dose of antibiotic directly to the lung with minimal 
systemic exposure but as yet have been relatively untested in the acute setting. The 
AZTEC-CF study showed AZLI+IV may be superior to the current standard treatment 
IV+IV, in terms of improved lung function and quality of life, with a similar safety 
profile. There was no difference in the modulation of systemic inflammatory markers 
or time to next exacerbation, although the small study size may limit interpretation 
of these secondary outcomes. Overall these findings show that substituting AZLI for 
an intravenous antibiotic can be a safe and effective strategy in the treatment of 
acute pulmonary exacerbations of CF.  
 
In the only other clinical trial in this setting, Al-Aloul et al. reported that nebulised 
tobramycin (TNS) was associated with a 3.6% improvement in lung function 
compared to IV tobramycin which, although not statistically significant, was not 
dissimilar to the +4.6% improvement seen here for AZLI+IV over IV+IV. [251]  Al-Aloul 
et al did report a significantly longer time to next exacerbation for TNS, an effect not 
seen with AZLI. Participants in the TNS study were of similar demographics to the 
AZTEC-CF study and time to next exacerbation in the IV arms of each study is almost 
identical, suggesting that the difference between studies might be agent-specific 
rather than a class effect. For example, the sputum half-life of TNS is approximately 





Despite the absence of any improvement in time to next exacerbation in for AZI+IV, 
the 4.6% improvement in lung function over IV+IV may be clinically important for 
two reasons. Firstly, a major concern for CF clinicians and people with CF alike is that 
failure to recover lung function after acute pulmonary exacerbations treated with IV 
antibiotics is associated with a poorer long-term prognosis. [299,300] Thus, any lung 
function improvement above and beyond that achieved with standard care is 
important. Secondly, the successful recovery of lung function means there exists 
potential to reduce treatment burden and systemic complications with the inhaled 
route.[364]   
 
The main limitations of the AZTEC-CF study relate to the small sample size at a single 
centre and the unblinded nature of the interventions. The findings are therefore 
unlikely to instigate widespread change of practice in themselves but will inform 
future studies in this area. The results of the nationwide survey reported in chapter 
2 showed that some UK clinicians are already adopting this approach and its use is 
likely to increase with time. In that regard the AZTEC-CF study taken together with 
the earlier TNS study provides reassurance that an inhalational approach is safe and 
can be effective, but also highlights the need for more research in this area.  
 Neither AZLI+IV nor IV+IV reduced sputum P. aeruginosa load 
Chapter 5 and 6 addressed the microbiological outcomes of the AZTEC-CF study using 
both quantitative culture and culture-independent methods.  Despite both 
treatments consisting of high dose anti-pseudomonal antibiotics, neither had a 
consistent effect against either P. aeruginosa load (by culture) or sequenced 
abundance (culture-independent). Although this finding was similar across 
platforms, improving its validity, it must be interpreted with a degree of caution 
given AZTEC-CF was not specifically powered towards detecting differences in 
bacterial abundance. In the wider literature, some studies have previously reported 
differences in bacterial load at exacerbations, [309,310] yet in keeping with the 
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findings here many recent studies, often using more robust quantification 
techniques, have found no consistent changes in bacterial load. [130,311,313,314] 
 
Although no overall reductions in P. aeruginosa were found, there were reductions 
of >1 Log in nearly half of study participants, in keeping with the study by Lam and 
colleagues. [311] That study also demonstrated that changes in P. aeruginosa load 
did not relate to recovery of lung function during exacerbations, a finding replicated 
in this study.  
 
Together, these findings could support the notion that within-population shifts in the 
phenotypic make-up of a P. aeruginosa population might be more important than 
overall abundance/load alone in the pathophysiology and resolution of acute 
exacerbations. [365] The absence of a consistent effect of either treatment on P. 
aeruginosa load despite clear clinical improvements highlights its inadequacy as an 
outcome measure in future clinical trials in the acute exacerbation setting. 
 Quantitative changes in Pseudomonas aeruginosa correlate with 
changes in quality of life 
The apparent lack of a consistent effect for either treatment against P. aeruginosa, 
coupled with a lack of an obvious relationship between changes in pseudomonal load 
and lung function, challenges the conventional wisdom of using high dose anti-
pseudomonal agents to treat acute pulmonary exacerbations. However, the finding 
that reductions in P. aeruginosa abundance alone were associated with improved 
quality of life reinforces the relevance of P. aeruginosa and reaffirms the rationale 
of the conventional approach to some extent. Importantly, this finding was 
consistent across sequencing and culture-derived quantification methods. 
 
Baseline Prevotella melaninogenica abundance appeared to be associated with 
subsequent changes in lung function outcome and interestingly was one of the only 
taxa found to be differentially affected by IV+IV and AZLI+IV. A recent international 
collaborative sequencing study identified Prevotella melaninogenica as being 
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associated with improved lung function in the clinically stable CF setting and 
interestingly a potential trend towards shorter time to next exacerbation in those 
with a reduced post-treatment abundance was observed here. [352] The lack of 
relationship between any other taxa and clinical outcomes may also be an indication 
that the wider microbiota composition is unlikely to act as a useful biomarker by 
which to predict treatment response and/or allow a more targeted approach. This 
supports the findings of the CFMATTERS study, which remains unpublished at the 
time of writing but has reported no benefit for adding microbiome targeted therapy 
to standard exacerbation treatments. [366]  
 
 Aztreonam resistance increased with IV+IV but not AZLI+IV 
Prior exposure to AZLI was an exclusion criterion of the AZTEC-CF study, and no 
participants had received IV aztreonam in at least five years prior to study entry. It 
was therefore surprising to find that half the study participants had in-vitro 
resistance to aztreonam at enrolment. Analysis of prior antibiotic exposure showed 
that baseline resistance to aztreonam was associated with increased meropenem 
exposure, but not overall antibiotic exposure, in the previous five years. This finding 
suggests that collateral resistance may be a driver of aztreonam-resistance in this 
study population. 
 
In keeping with prior work, in-vitro resistance did not appear to relate to clinical 
outcomes but interestingly aztreonam resistance increased in the IV+IV treatment 
arm but not in the AZLI+IV arm. [194,204] This unexpected finding further supports 
the notion that collateral resistance contributes to in-vitro aztreonam resistance, 
speculatively through mutations impacting on the MexAB-OprM efflux pump or the 
AmpC beta-lactamase. [367] Interestingly, increased aztreonam resistance after 
IV+IV was seen exclusively in those with prior aztreonam resistance, while those with 
no resistance at baseline remained sensitive. Taken together these results suggest 
intravenous antibiotic use is not the most likely primary mode of acquisition of 
collateral resistance but does contribute to increased collateral resistance where 
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standing levels of genetic variation in the P. aeruginosa population mean that it is 
already present.  
 
The main limitation of this aspect of the study is that resistance testing was 
performed for aztreonam only and measured relatively simplistically as cultured load 
in the presence of the reference MIC. Aztreonam-resistance was originally included 
as an exploratory safety outcome and more sophisticated techniques were therefore 
not included a priori. The finding of no increased aztreonam-resistance is reassuring 
in that regard, but the findings in the IV+IV arm mean more work is required to 
understand the mechanisms of collateral resistance to aztreonam, to determine 
whether collateral resistance to other even unrelated antibiotics occurs, and to 
determine if there are any clinical implications.  
 AZLI+IV and IV+IV exert different effects on the lung microbiota 
In concordance with most prior microbiome work in adults with CF, the lung 
microbiota seen here was dominated by Pseudomonas but frequently enriched with 
anaerobes from the Prevotella and Veillonella genera. [130,146,147,150] Alpha 
diversity was reduced in those participants harbouring the Liverpool Epidemic Strain 
of P. aeruginosa but, contrary to a number of earlier studies, there was no 
relationship between alpha diversity and age or lung function. [130,133,147,153] 
The small sample-size of only sixteen samples for these calculations, limited to one 
patient per sample to avoid repeated measures bias, may have limited the ability to 
detect a relationship in that regard. Further studies may elucidate whether the 
Liverpool Epidemic Strain is an independent driver of reduced diversity, putatively 
by out-competing other taxa, or whether the changes seen here relate to the 
increased antibiotic usage and generally older age-group seen in that cohort. [286] 
 
When comparing treatment effects, alpha diversity measures were stable across the 
study with no treatment-effect seen, supporting previous work suggesting alpha 
diversity is resilient to perturbation at both time of exacerbation and in response to 
treatment. [149,150] Comparing beta-diversity before and after each treatment did 
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reveal treatment-specific changes and the most striking changes to individual taxa 
were an effect against Prevotella melaninogenica and Veillonella dispar for IV+IV but 
not AZLI+IV. Neither treatment exerted an effect on Pseudomonas abundance. 
Speculatively, the differences in effect against the anaerobes Prevotella 
melaninogenica and Veillonella dispar may relate to poor penetration of AZLI into 
unventilated, mucus-plugged airways where anaerobes may be localised. Such areas 
would still receive systemic blood supply and IV antibiotics could therefore have an 
effect. Alternatively, colistimethate could have had a synergistic action against 
anaerobes in the IV+IV but not AZLI+IV treatment. No studies have been performed 
investigating the effect of colistimethate on the human CF lung microbiota, but a 
study in a sheep model found that daily IV colistimethate did not significantly 
influence the lung microbiota, making IV+IV synergism an unlikely explanation for 
these findings. [287] 
 
This is the first prospective clinical trial to assess the impact of antibiotics on the lung 
microbiota and it included a number of methodological strengths, allowing a robust 
estimation of treatment effects. Firstly, the cross-over design allowed each patient 
to act as their own control thereby minimising inter-individual variation as a 
confounder. In addition, the use of positive and negative controls allowed a rigorous 
assessment of contamination or bias introduced in laboratory or sequencing 
processes. Finally, the study showed that relative abundance is inherently flawed as 
an outcome measure. Based upon these findings, calculation of total abundance in 
all microbiome studies attempting to estimate a causal treatment effect is 
recommended. 
 Future directions: 
7.6.1 Optimising and expanding the use of inhaled antibiotics in acute 
exacerbations 
 
There are a number of further research avenues indicated by the results in this thesis. 
Firstly, although the results of AZTEC-CF demonstrate that inhaled antibiotics can be 
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effective in the acute setting, all participants were mandated to remain inpatients 
for the treatment of their exacerbations. For the largest improvements in treatment 
burden to be realised, inhaled antibiotics could be used in the home setting, negating 
the need for inpatient admission. This will require further studies testing the efficacy 
of this approach, but also including assessments of treatment burden and patient 
preference, which were not included in this study.  
 
There has been a recent expansion in available inhalational antibiotics, with 
levofloxacin inhalation solution (LIS) now licenced in the UK and nebulised liposomal 
amikacin having also passed through phase 3 clinical trials. [242,368] Additionally a 
fosfomycin/tobramycin combination is in development for CF and an 
amikacin/fosfomycin combination product was developed for ventilator associated 
pneumonia. [244,268] Elsewhere, inhaled liposomal ciprofloxacin was found to be 
safe and effective in non-CF bronchiectasis. [256,369] None of these preparations 
have been tested in the acute setting, and they may represent potential new 
therapeutic agents for acute exacerbations of CF and other suppurative lung 
diseases.  
 
In the era of highly effective CFTR modulator therapy, exacerbation frequencies are 
likely to reduce and people with CF will attend hospital less frequently. Nevertheless, 
a residual exacerbation rate will persist and optimising the outcomes of these 
exacerbations while minimising treatment burden will become even more important 
as people with CF live with a greater degree of normalcy. Inhaled antibiotics may be 
one approach that allows a more ambulatory approach to future exacerbation in 
people receiving CFTR modulator therapy.  
7.6.2 Application of AZTEC-CF results to the design of larger clinical trials 
 
Given the pilot nature of this study, results from the AZTEC-CF study will inform 
design of larger clinical trials. Sample size estimations for a number of possible study 
designs are presented below. For all calculations an alpha of 0.05, beta of 0.2 were 
utilised. Based on AZTEC-CF study results, a population SD of 8.4 was included in 
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calculations and pre-randomisation attrition was considered as 15% for all studies. 
For cross-over studies between-treatment retention was considered as 75%. 
 
Trial A: Cross-over study powered to superiority in absolute change in % predicted 
FEV1 between AZLI+IV and IV+IV 
 
To detect a 2.1% difference in absolute change in % predicted FEV1 (a conservative 
estimate, i.e. the lower 95% confidence interval of the treatment effect seen in the 
AZTEC-CF study) with a power of 80%, 128 participants would be required to 
complete the study. Allowing for attrition and retention rates, 180 participants 
would be an appropriate recruitment target. 
 
Trial B: Parallel study powered to superiority in absolute change in FEV1 between 
AZLI+IV and IV+IV 
 
To detect a 2.1% difference in absolute change in % predicted FEV1 (a conservative 
estimate, i.e. the lower 95% confidence interval of the treatment effect seen in the 
AZTEC-CF study) with a power of 80%, 502 participants would be required to 
complete the study. Allowing for attrition, 581 participants would be an appropriate 
recruitment target. 
 
Trial D: Parallel study powered to non-inferiority in absolute change in FEV1 
between AZLI+IV and IV+IV 
 
If there is truly no difference between AZLI+IV and IV+IV treatments, then 620 
patients would provide the trial with 80% power to detect the lower limit of a one-
sided 95% confidence interval above the non-inferiority limit of -2% absolute change 
in % predicted FEV1. With a 15% attrition rate accounted for 713 participants would 





7.6.3 Multi-omics approach   
 
The biobanking of paired samples across two complete exacerbation/treatment 
cycles in a controlled clinical trial with associated clinical outcome data will allow 
further studies to explore changes related to treatment and exacerbations in 
general. Metagenomic analyses would address some of the limitations of the 16S 
rRNA gene sequencing analysis undertaken, e.g. improved taxonomic resolution, 
whilst also providing information regarding antimicrobial resistance genes or 
mutations. Metabolomics could integrate understanding of the downstream 
implications of changes within the metagenome. Both are technically feasible on the 
banked study samples. The costs of these approaches at the time of study design 
were prohibitively expensive but have reduced significantly and will continue to 
reduce in the coming years. Combining species-level resolution, and in some cases 
strain-level resolution, with functional information about gene expression related to 
metabolism and antimicrobial resistance may detect changes that this study was 
unable to elucidate.  
 
7.6.4 Investigating the underlying mechanisms and clinical relevance of 
collateral resistance 
 
A surprising result in this study was the finding of increased aztreonam resistance 
induced by the IV+IV treatment but not AZLI+IV. Understanding mechanisms for this 
finding could be addressed by further antimicrobial susceptibility testing combined 
with target gene analysis, e.g. qPCR of mutations/genes associated with known 
resistance mechanisms.  Similarly, although no increased aztreonam resistance was 
observed for the AZLI+IV treatment, it is important to establish whether AZLI 
conferred collateral resistance to other antibiotics and via which mechanisms. Given 
the overall relationship between in-vitro antibiotic susceptibility and clinical 
outcomes in CF is not strong, exploring the relationship between the presence of 
specific antimicrobial resistance genes or mutations and outcomes of acute 





The current project investigated the use of AZLI for treatment of acute pulmonary 
exacerbations. The AZTEC-CF study showed AZLI+IV was effective, safe, and superior 
to the current standard care (IV+IV) for important clinical outcomes. Whilst the small 
sample size is a limitation to the study, a major strength of this study lies in its 
relevance to the CF community, indeed AZTEC-CF is the only currently registered 
clinical trial which meets the recently identified James Lind Alliance research 
priorities relating to acute exacerbation (Priority 8) and antibiotic related adverse 
events (Priority 9) [285,370]. The cross-over design allowed a robust assessment of 
the microbiological effect of each treatment and showed the two treatments exert 
different effects on the lung microbiota but there was generally little relationship 
between the microbiota and clinical outcomes. Instead, despite neither treatment 
consistently changing the abundance or sputum load of the classical CF pathogen P. 
aeruginosa, it was still found to be associated with important clinical outcomes. 
These findings hint at the complexity of chronic airway infection in CF and also the 
limitations of 16S rRNA sequencing for identifying clinically relevant changes within 
CF airways. Future studies, described above, will require significant sequencing and 
bioinformatics capacity but it is likely technological advances will improve the 
feasibility of such studies in the near future. Overall, inhaled antibiotic use in the 
acute setting is likely to increase and the results of this project will reassure clinicians 
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